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1.1. Obesity and eating-related disorders 
Obesity and overweight, defined as abnormal or excessive fat accumulation, are 
currently considered as major worldwide public health issues 1. According to the World 
Health Organization (WHO), obesity is recognized as a global epidemic that has been 
spreading all over the world contributing to the higher incidence of major health 
problems, thus increasing mortality. The high levels of intra-abdominal or visceral fat 
that are associated with this clinical condition are the most responsible for the 
development of the main obesity comorbidities such as hypertension, dyslipidemia, type 
2 diabetes, osteoarthritis, and changes in the reproductive system 2. 
Obesity is a multifactorial disease and among the several conditions that predispose to 
the weight gain and consequently to obesity, it is well known that genetic, 
environmental and physiologic factors play a key role 3.  
Moreover, some medications can contribute to the development of this complex disease 
by increasing appetite, reducing the basal metabolic rate and by stimulating adipose 
cells proliferation as well. Among the pharmacological classes that might be more 
commonly involved in this process there are antidepressants and corticosteroids 4,5. 
More rarely obesity is the consequence of other medical conditions including Prader 
Willi 6 and Cushing syndrome 7, hypothyroidism or hypothalamic dysfunctions 8.  
The current most commonly used method for classifying obesity is the body mass index  
(BMI), calculated as weight (kg) divided by the square of the height (m2), which ranges 
between 25 and 29.9 in overweight individuals whereas it is equal to or more than 30 in 
obese-classified patients 9,10. Furthermore, waist circumference, another marker of 
excess body fat, has becoming discriminating as a measure of overweight/obesity 11.  
The WHO estimated that in 2016 more than 1.9 billion adults, over the age of 18 years 
old, were overweight, of these over 650 million were obese 12.  
Since over the past 40 years it has been registered a huge increase in the percentage of 
overweight and obese individuals worldwide, it has been estimated that by 2030 the 
38% of the world’s adult population will be overweight and another 20% will be obese 
13. 
Moreover, changes in body weight are frequently accompanied by psychological and 
psychosocial problems thus leading to persistent disrupted eating behaviours, which are 
defined as eating disorders (EDs).  
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EDs are currently considered, likewise obesity, major health problems worldwide and 
they are characterized by altered dietary habits and impaired physical health. The 5th 
edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) 
recognizes three different EDs: anorexia nervosa (AN), bulimia nervosa (BN), and 
binge eating disorder (BED) 14. The latter will be abundantly discussed in the following 
paragraph since it is one of the main topic of this experimental dissertation.  
Although EDs can occur in adults or young individuals indiscriminately, adolescence 
represents the most vulnerable period for the onset of these diseases 15.  
The main criteria for classifying an individual affected by AN are represented by: a 
persistent caloric restriction followed by a considerable body weight loss with a BMI of 
17.5 or even less 16; a strong fear to gain weight along with a distorted body image 
perception 14.   
AN occurs more commonly among women than men (80-90% of patients with AN are 
female) and it reaches a peak incidence in adolescents between 14 and 17 years 15. 
Moreover, AN is often linked with depressive disorder 17, obsessive compulsive 
disorder and autism spectrum disorder 18, counting the highest mortality of any 
psychiatric disease 19.  
BN is primarily characterized by recurrent overeating episodes followed by 
compensatory purging behaviours such as vomiting, use of laxative or excessive 
physical activity whose purpose is avoiding body weight gain 17. Likewise the AN, BN 
is also more common in females than males occurring in 1-2% of women mainly 
between 20 and 30 years 20. BN can also take place along with other psychological 
problems such as affective disorders, impulse control disorders, attention 
deficit/hyperactivity disorder (ADHD), drug dependence, anxiety and dissociative 
disorders 17.  
1.1.1. The binge eating disorder (BED) 
BED is the most frequent eating-related maladaptive disorder, characterized by 
compulsive and distressing overeating of high palatable food (HPF), a food with high 
fat or sugar content and consequently rich in kilocalories.  
The above-delineated situation is called “binge eating episode”, which is defined, 
following the description of the DSM-V, by two main features: 1) the individual 
consumes a huge quantity of food in a short period of time, 2) along with a strong sense 
of loss of control, feeling of shame, guilt, disgust and anxiety 15.  
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Binge eating episodes occur at least once a week for three months. BED is classified as 
moderate when the weekly binge eating episodes are 1-3, while it is considered as 
severe when they become more frequent rising to 14 or even more 14.  
It is possible to distinguish three different feeding behaviours, which can be at the bases 
of binge eating episodes:  
- Restrictive eating: food consumption is predominantly driven by the appearance, 
smell and brand of the food; this particular behaviour causes loss of control and 
overeating episodes more frequently;  
- Emotional eating: feeding as an escape strategy to fight negative emotions such as 
anxiety, sadness and stress;  
- External eating: the feeding behaviour is mainly triggered by external stimuli 
including the sight and smell of the food 21. 
Due to its critical features, BED leads to reduced social and emotional functioning, 
health impairments and worsens the quality of life 15. 
BED differs from the other eating disorders, since it is not characterized by extreme 
compensatory strategies such as vomiting, use of laxative or increased physical activity 
14,22. 
It has been observed that the excessive intake of certain foods under specified 
conditions is able to alter not only eating behaviour but also it induces changes in the 
brain that resemble an addiction-like state. In particular, growing evidence found that 
one of the central mechanisms disrupted in BED conditions is represented by the 
dopamine (DA) rewarding circuitry.  
BED is not only linked with the DA system, on the contrary it has been also 
demonstrated that an impairment in brain serotonin or 5-hydroxytryptamine (5-HT) 
signalling might play a role in the pathophysiology of BED in humans 23–26.  
1.2. Neurobiological mechanisms regulating energy homeostasis 
Overweight and obesity derive by an imbalance of the energetic metabolic rate. Our 
body, in fact, uses the food ingested-derived energy to manage the complete functioning 
of the main physiological systems at basal or active conditions, process that is called 
energetic balance. The excess energy quantity is normally stored and it is the primary 
responsible for fat accumulation leading to obesity development.  
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Several mechanisms partake in the control of energy balance by sending pro-satiety or 
pro-appetite signals to the brain in order to regulate energy consumption. Among these, 
white adipose tissue and liver play a key role in storing energy in the form of fat (energy 
storing) and in regulating the energy storage and consumption cycle, respectively 27.  
The central nervous system (CNS) exerts the most crucial role in controlling feeding 
behaviour and energy homeostasis by interacting with several other systems. Most of 
the individuals, in fact, are able to maintain a stable body weight 28 thanks to a 
homeostatic regulation involving hypothalamic nuclei which integrate orexiant and 
anorexiant signals coming from other brain regions or from the periphery 29. The 
hypothalamus (HYPO) is a structure of the CNS located on the sides of the third 
ventricle 30 that regulates the energy metabolism by producing several neuropeptides 29. 
Moreover, it also partakes in neuronal networks that consist of non-peptidergic 
neurotransmitters including noradrenaline (NA), DA, 5-HT, histamine and 
endocannabinoids 29. The hypothalamic system is also connected with extra-
hypothalamic areas primarily located in the brainstem such as the dorsal motor nucleus 
of the vagus (DMV), the nucleus of solitary tract (NST), the area postrema (AP) and the 
parabrachial nucleus (PB) 31. In this regard, it has been demonstrated that hindbrain 
neurons from the NST and the AP project to the HYPO by sending signals and building 
integrative networks 29. 
Among the several nuclei of the HYPO, the arcuate (ARC), paraventricular (PVN), 
supraoptic (SON), and tuberomamillary (TMN) nuclei are the most studied nuclei for 
their pivotal role in integrating appetite-regulating signals.   
The ARC is situated in close contact with the median eminence (ME), a 
circumventricular organ with fenestered capillaries and a weak blood brain barrier 
(BBB) 32. Therefore, the ARC, via the ME, can represent a receptive region for 
circulating signals regulating energy balance such as leptin and insulin 33. It consists of 
two distinct neuronal populations which are called “first order” neurons and exert 
opposite effects in regulating energy homeostasis: 1) the agouti-related protein 
(AgRP)/neuropeptide Y (NPY) neurons that are responsible for stimulating food intake, 
and 2) those co-expressing the pro-opiomelanocortin (POMC) and cocaine-and 
amphetamine regulated transcript (CART) exerting anorexigenic effects 34 (Fig. 1.1). 
Both the two neuronal populations, POMC/CART and NPY/AgRP neurons, project to a 
variety of hypothalamic nuclei such as PVN, the lateral hypothalamic area (LHA) and 
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the perifornical area (PFA), each containing ‘‘second-order’’ neurons that integrate the 
information (Fig. 1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.1: schematic representation of the neuropeptidergic hypothalamic networks involved in the 
homeostatic control of food intake. Abbreviations: CRH, corticotropin-releasing hormone; MCH, 
melanin-concentrating hormone; NPY/AgRP, neuropeptide Y/agouti-related protein; ORX, neurons 
producing orexigenic peptides orexin; OT, oxytocin; POMC/CART, pro-opiomelanocortin/cocaine-and 
amphetamine regulated transcript; TRH, thyrotropin-releasing hormone 42.  
 
The PVN represents a crucial hypothalamic nucleus involved in the control of feeding 
behaviour 35–37. It is composed of magnocellular and parvocellular divisions. The 
magnocellular neurons are oxytocinergic and vasopressinergic neurons, which release 
oxytocin (OXY) and vasopressin (AVP) in the neurohypophysis 38. On the other hand, 
the medial parvocellular neurons contain corticotropin-releasing hormone (CRH) and 
thyrotropin-releasing hormone (TRH) which are secreted into the hypophysial portal 
vessels in the ME 39, whereas the dorsal, ventral and lateral subdivisions of 
parvocellular neurons mainly project to the periaqueductal grey matter, PB and NST 38–
41. The SON neurons, likewise those located in the PVN, have been demonstrated to 
produce either OXY or AVP and they all project to the neurohypophysis. Furthermore, 
these neurons can also co-release a variety of other peptides such as cholecystokinin 
(CCK) and CRH, among others.  
Several lines of evidence suggest that the TMN is the main histaminergic cell group in 
the rat brain which projects to a number of brain regions such as the nucleus accumbens 
(Acb), the prefrontal cortex (PFC) and other hypothalamic nuclei 43. Thanks to its 
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widespread innervation, the TMN exerts a control in many physiological functions by 
regulating the daily food consumption, the glucose absorption as well as emotional and 
memory processes 44,45.  
The above-described complex neuronal network is responsible for the long-term 
regulation of energy balance and is primarily involved in the maintaining of a stable 
body weight.  
On the other hand, a short-term regulation modulates the daily consumption of food, the 
number and duration of meals and it is modulated by the physico-chemical signals that 
are generated in the gastrointestinal tract upon the meal ingestion 46. Therefore, the 
short-term regulation of feeding behaviour occurs at the level of mesencephalic nuclei 
such as DMV and NST, that project to the PB, that, in turn, sends innervation to the 
PVN 46 (Fig. 1.2).  
The NST is considered as an entry point for a variety of peripheral signals that are 
responsible for lowering the quantity of food consumed upon a meal 47. As already 
mentioned in the text, projections from the NST, in particular noradrenergic neurons 
deriving from the A2 region, reach the hypothalamic neurons in the PVN 47. Moreover, 
growing evidence showed that the ablation of these noradrenergic projections prevents 
the anorexigenic effects of many pro-satiety endogenous signals, such as the CCK. The 
NST consisted of distinct neuronal populations that, depending on their specific 
localization within different NST subnuclei, react in different ways to the central and 
visceral stimuli 48. These subnuclei are innervated in a selective and specific manner by 
afferents fibres arising from specific segments of the gastrointestinal tract 48. For 
instance, the gustatory nerves end in the most rostral portion of the NST 49, whereas the 
vagal afferents mainly project to the caudal part of the nucleus 50. Furthermore, the 
neurons of the dorsomedial subnucleus (SolDM) of the NST are particularly sensitive to 
gastric distention 51, on the contrary the neurons of the commissural part (SolC) mostly 
respond to the duodenal signals and those located in the medial portion (SolM) are 
responsive to both gastric and duodenal signals 51.  
Moreover, it has been demonstrated that the SolM responds to leptin that acts directly 
on SolM neurons to reduce food intake 52. In 1986, Edwards et al., demonstrated that the 
lesions that extensively damage both medial and commissural subnuclei of NST 
markedly attenuate CCK-suppression of food intake 53.   
An additional brain region crucially involved in food intake regulation is the AP, a 
circumventricular organ highly vascularized that displays a weak BBB by virtue of its 
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lack of tight junctions and the presence of fenestrated capillaries 54, features that give to 
the AP the appearance of a sponge.  
The AP is the most caudal of the sensory circumventricular organs 54, located at the 
apex of the calamus scriptorius in the dorso-medial medulla oblongata, at the base of the 
fourth ventricle and it appears as a hump of tissue surrounded by the NST 31. 
The AP consists of specialized ependymal cells that make up a unique capillary 
architecture in the ventricles and central canal 55 and it can be subdivided into several 
zones depending on cell type location and projection patterns 54. The central and mantle 
zones predominantly contain neuronal cell bodies and axons which are in close contact 
with the ependymal cells, while in the ventral zone mainly reside glia 56.  
Although the AP has been considered, for many years, for its function as the 
“chemoreceptor trigger zone” 57,58, it is now well recognized also its role in the 
regulation of cardiovascular system, metabolism, immune function as well as in the 
control of cerebrospinal fluid (CSF) balance 54. In this context, recent studies have 
suggested that the AP expresses a variety of receptors for many hormones involved in 
the control of feeding behaviour including amylin, glucagon-like peptide-1 (GLP-1), 
ghrelin, CCK, NPY, AVP, substance P and insulin 59–68. Moreover, through its efferent 
projections, the AP can in turn signal to important autonomic control centres behind the 
BBB and regulate the autonomic nervous system 54. Studies conducted in rats in which 
the AP has been lesioned, recognise the important role of this hindbrain region in the 
homeostatic control of food intake and body weight as well as in the modulation of 
peripheral signals 69. The AP is therefore considered as an entry and integration point in 
the CNS for a variety of blood-borne substances 54.  
Because of its anatomical location, the AP is in close contact with the NST, mostly at -
13,80 mm from the bregma where it reaches the maximum extent 31. Several evidence 
70,71 suggests that AP sends major and minor efferents to several nuclei in both the 
brainstem and the HYPO.  
AP primarily projects to the lateral parabrachial nucleus (LPBN) and to the subnuclei of 
the NST, among which the most innervated is the SolM 70–76 (Fig. 1.2). Furthermore, 
minor projections innervate the nucleus ambiguus, DMV, dorsal regions of the 
tegmental nucleus, cerebellar vermis, paratrigeminal nucleus, ventrolateral 
catecholaminergic column in the medulla, and the spinal trigeminal 70,71 (Fig. 1.2). 
Moreover, the AP also receives afferents from the NST and LPBN but also from 
functionally distinct regions of the brain such as the hypothalamic PVN and 
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dorsomedial nucleus (DMH) 70,71,77. Additionally to this central input, the AP receives 
also afferents from the periphery, in particular from the vagus nerve 70,71 (Fig. 1.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.2: Neuronal projections to and from the area postrema in the central nervous system 
(afferents (blue) and efferents (red)). 4V = 4th ventricle; AP = area postrema; DMH = dorsomedial 
hypothalamus; DMV = dorsal motor nucleus of the vagus; DTN = dorsal tegmental nucleus; NA = 
nucleus ambiguus; NST = nucleus of the solitary tract; PB = parabrachial nucleus; PVN = paraventricular 
nucleus of the hypothalamus; SON = supraoptic nucleus. Adapted from 54. 
 
In addition to catecholaminergic and serotonergic neurons 78,79, AP has been shown to 
abundantly express also noradrenergic fibres 76 as well as neurons containing GABA, 
substance P, encephalin, neurotensin, and CCK 78,80–83. Moreover, catecholaminergic 
and CCK neurons, which are located in the central zone of the AP, have been found to 
project to the NST and to modulate arousal and the emetic reflex 84,85. While A2 
neurons project to oxytocinergic hypothalamic neurons of the SON and have been 
shown to play a role during experimental fear conditioning 86.  
1.2.1. Hormonal signals  
A variety of circulating hormones, mainly originating from fat cells, gastrointestinal 
tract, and endocrine pancreas, partake in the control of energy homeostasis through their 
actions on the HYPO, brainstem, or afferent autonomic nerves 87 (Fig. 1.3).  
Leptin is a 146 amino acids peptidic hormone, produced by adipocytes 88 and involved 
in the regulation of energy homeostasis, neuroendocrine and immune functions 89. It has 
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also been found in several other tissues including placenta, mammary gland, ovary, 
skeletal muscle, stomach, pituitary gland, and lymphoid tissue 90. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.3: Role of circulating hormones in the central control of energy homeostasis. Gastrointestinal 
and fat-derived hormones modulate food intake through stimulating specific brain areas such as the 
arcuate nucleus (ARC) in the hypothalamus and the hindbrain nucleus of solitary tract (NST) and dorsal 
motor nucleus of the vagus (DMV) 104. 
 
Leptin is transported across the BBB by a saturable transport system 91 and exerts its 
anorexigenic effect in the ARC by activating POMC/CART 92,93, and inhibiting 
NPY/AgRP neurons 92,93, thereby reducing food consumption.  
Moreover, Leptin is also implicated in stimulating the secretion of neuropeptides that 
play a role in energy homeostasis such as CRH, TRH and the brain-derived 
neurotrophic factor (BDNF) 91,94–96. Beyond interacting with these central neuronal 
processes it became evident an interplay between leptin and CCK 97. In particular, leptin 
appeared to increase the CCK-induced pro-satiety effect 98. 
Interestingly, hematic leptin concentration changes in respect to the body fat mass 99.  
Leptin is also able to signal rapid negative variations of energetic balance, although they 
occur independently of body weight fluctuations; during fasting, for example, 
circulating leptin drastically decreases while body weight does not significantly change 
100. Leptin effects on energy homeostasis regulation are mediated by binding its specific 
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membrane receptor (Ob-R) that has a single transmembrane domain and is a member of 
cytokine receptor family 101. 
Finally, it has been demonstrated that the direct leptin administration in the ARC 
inhibits feeding 102; moreover, ARC lesions dampen the hypophagic effect of 
peripherally administered leptin 103, thus suggesting the ARC crucial role in mediating 
leptin effects on energy homeostasis. The gastrointestinal tract also produces other 
hormones that are involved in the short-term regulation of appetite by predominantly 
interacting with the HYPO. 
In this context, although ghrelin has been originally identified as the main responsible 
for growth hormone secretion 105, it is now recognised as one of the peripheral 
orexigenic factor implicated in sending to the CNS short-term modifications of energy 
balance.  
Ghrelin is a peptide hormone of 28 amino acids secreted by stomach and duodenum 105, 
which exerts, compared to leptin, opposite effects at hypothalamic level. In fact, it 
activates the anabolic pathway increasing dietary intake and reducing energy 
expenditure. Moreover, it has been shown that circulating ghrelin levels increase 
immediately before eating thus promoting food intake 99,100. By contrast, in a post-
prandial phase, hematic ghrelin levels significantly decrease 99,100.  
In the HYPO ghrelin-containing neurons are mainly located in the ARC, which is also a 
leptin target 106. From here, ghrelin neurons project to NPY/AgRP expressing fibres in 
order to prevent leptin-induced inhibition of food intake and stimulate orexigenic 
peptides release; whereas by contacting POMC neurons, ghrelin fibres suppress 
anorexigenic peptides production 107.  
Among other intestinal hormones that play a role in feeding behaviour regulation, the 
most studied are the CCK and peptide tyrosine-tyrosine (PYY) 108. CCK is considered 
as a physiological pro-satiety factor that is produced at both peripheral (intestine) and 
central level upon food consumption 109. It is normally released in response to long-
chain fatty acids, amino acids and small peptides deriving by proteins ingestion 110,111.  
CCK binds two different receptors: CCK receptor type 1 (CCK1) and 2 (CCK2). The 
former has been identified in peripheral tissues including pancreas, gall bladder, vagal 
afferents innervating intestine 112 as well as in CNS areas involved in food intake 
regulation such as NST, AP, and DMH 63. While the latter has a different distribution, 
being mostly located in the cortex, HYPO, vagal afferents and gastric mucosa. 
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Intravenous injection of physiological CCK doses in humans has been demonstrated to 
increase appetite sensation and reduce food consumption 113.  
PYY is a 36 amino acids peptide mostly containing tyrosine, produced by 
enteroendocrine L-cells of the distal gastrointestinal tract, whose plasmatic levels 
increase within 30 minutes after a meal consumption 114. PYY consists of 2 different 
isoforms: a 36 amino acids isoform (PYY1-36) and another who misses the first two 
amino acids (PYY3-36). A line of evidence showed that circulating PYY3-36 levels are 
particularly high after meal consumption 114 thus suggesting the anorexic effect of this 
hormone peptide. The hypophagic effects of PYY3-36 appeared to be mediated by the 
ARC. Moreover, both the two isoforms exert their action by binding NPY receptors 
family 115; in particular, PYY1-36 shows the same affinity for all the receptor subtypes, 
while PYY3-36 displays a higher selective affinity for Y2 receptor 
116.  
Finally, other two peripheral hormones regulating energy homeostasis are represented 
by insulin and amylin.  
Insulin is a metabolic hormone produced by the β-cells of the pancreatic islets of 
Langerhans and  consists of two polypeptide chains which are linked together by two 
disulfide bonds: an A chain of 21 amino acids and a B chain of 30 amino acids.  
Insulin is known to act on hypothalamic neurons located in the ARC, where insulin 
receptors are abundantly expressed, thus exerting a pivotal role in regulating glucose 
homeostasis and reducing energy intake 117. It has been observed that insulin 
intracerebroventricular (i.c.v.) infusion or systemic injection induce a dose-dependent 
reduction of food intake 118 through NPY inhibition and POMC stimulation 119. 
Both insulin and leptin are able to activate POMC neurons, however they appeared to 
differently regulate AgRP, since leptin is responsible for its inhibition while insulin is 
important for its stimulation 120.  
Amylin is a polypeptide of 37 amino acids which is co-secreted, along with insulin, 
from pancreatic mammalian β-cells in response to food consumption, in a ratio of 1:100 
amylin:insulin 121. Likewise insulin, amylin displays a role in glucose metabolism 
regulation; moreover, it also appears to lessen digestion through reducing digestive 
secretions (bile, enteric and pancreatic fluids) and to inhibit plasmatic glucagon 
production 121. 
Amylin represents a pro-satiety physiological signal 122; in fact, it has been 
demonstrated to exert an anorexic effect even during fasting conditions 27, through both 
central and peripheral mechanisms. Amylin inhibitory effect on food intake seems to be 
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mediated by the activation of hindbrain regions including the AP 123, as well as the NST 
and LPB 124.  
A large body of evidence demonstrated amylin ability to exert its hypophagic effect also 
through serotonergic, histaminergic, and dopaminergic systems 124. Moreover, amylin 
appeared to communicate, at the level of brainstem, with other signals involved in short-
term control of food intake such as CCK, GLP-1 and PYY 121. 
1.2.2. Neuropeptidergic system 
A major player in energy homeostasis regulation in the CNS is represented by the 
hypothalamic neuropeptidergic system that consists of a variety of orexigenic and 
anorexigenic peptides, which are released at both synaptic and soma-dendritic level and 
modulate the neuronal networks by binding specific receptor targets 125. As already 
mentioned in the text, the neurons populating the HYPO are classified in “first-order” 
and “second-order” neurons. The former are represented by the neurons co-expressing 
POMC/CART and those co-expressing NPY/AgRP both located in the ARC, while the 
latter consist of the PVN neurons releasing TRH, CRH and OXY (Fig. 1.1).  
Among the neuropeptides stimulating appetite NPY, AgRP, orexins and the melanin-
concentrating hormone (MCH) are the most studied.  
Although the NPY displays different actions in the control of feeding behaviour, its 
most evident effect is the stimulation of food intake after its central administration 126.  
Furthermore, it has been observed that acute food deprivation 127 or chronic food 
restriction 128,129 induced the increase of hypothalamic NPY mRNA levels, which 
returned to normal levels after refeeding 130. 
NPY synthesis in the ARC and its release at the level of PVN are regulated by 
inhibitory afferent signals including leptin and insulin, and by stimulatory signals such 
as ghrelin 126.  
5 different G protein-coupled receptors (GPCRs) for NPY have been identified: Y1, Y2, 
Y4, Y5 and Y6 131,132 and they are widely distributed throughout the brain, including 
cortex, hippocampus (Hipp), amygdala (AMY), and HYPO.  
Likewise NPY, AgRP is another orexigenic peptide of 132 amino acids which induces a 
sensation of appetite when i.c.v. injected in the PVN or in the DMH 133.  
In vitro and in vivo studies have demonstrated that both POMC and AgRP neurons 
express leptin and insulin receptors and are targeted by the respective hormones to 
increase POMC mRNA expression and decrease NPY and AgRP mRNA levels 134,135. 
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Orexin-A and orexin-B are appetite stimulant neuropeptides which are produced in the 
PFA, DMH and LHA 136,137 and bind two distinct GPCRs: orexin receptor 1 (OxR1), 
mainly expressed in the ventromedial region of the HYPO (VMH), and orexin receptor 
2 (OxR2) mostly present in the PVN 138. Evidence showed that after being i.c.v. 
administered, orexin-A and orexin-B caused increased food intake in rats, while fasting 
led to upregulation of prepro-orexin mRNA 137. Orexin secreting neurons project their 
axons broadly throughout the brain and, particularly, to the NPY neurons of the ARC, 
which express OxR1 139.  
The MCH is an orexigenic neuropeptide of 19 amino acids abundantly expressed in the 
LHA 140 and targeting two central receptors: MCHR1 and 2 141,142. The crucial role of 
MCH in controlling feeding is demonstrated by the observation that its injection into the 
rat lateral ventricle induces increased food intake 143.  
Besides the orexigenic signals, growing interest is given to a number of anorexigenic 
peptides.  
CART is a pro-satiety neuropeptide located in several regions of the HYPO including 
the DMH, PFA, PVN, and the ARC 94 as well as in the periphery. It has been observed 
that CART mRNA co-localizes with AVP and CRH containing neurons 94 in the PVN 
and with POMC in the ARC 144. 
Several evidence supported the anorexic effect of CART, for instance its i.c.v. 
administration showed to inhibit food intake in rats 145, result that has been further 
sustained by the injection of an antibody against CART peptide 82–103 which has been 
demonstrated to stimulate feeding 145. 
Melanocortins are bioactive lipids deriving from the tissue-specific post-
translational cleavage of the precursor molecule POMC 95. The POMC coding gene is 
physiologically expressed in several tissues including pituitary gland, skin, immune 
system, and hypothalamic neurons 96. 
The long-term regulation of energy homeostasis mediated by POMC is a consequent of 
α­melanocyte­stimulating hormone (α-MSH) release, which occurs after POMC 
neurons stimulation 34. α-MSH, in turn, induces satiety by binding to downstream 
melanocortin-3 and melanocortin-4 receptors (MC3 and MC4) in the PVN 34. 
Consistently, it has been found that the ability of POMC neurons to suppress feeding is 
consecutive to melanocortin receptors activity 146. 
On the contrary, it has been found that AgRP is a MC3/4-R competitive antagonist of α 
– MSH and lowers food intake by reducing α –MSH signaling 147. 
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CRH is the main physiological regulator of the adrenocorticotropic hormone (ACTH) 
secretion by pituitary gland, and growing evidence suggests its involvement in energy 
balance regulation 148. It is a 41-amino acid neuropeptide largely expressed in PVN 
neurons and, in mammalian brain, it is also abundantly present in extrahypothalamic 
regions, including the olfactory bulb, bed nucleus of the stria terminalis (BNST), medial 
preoptic area, PVN, LHA, and central amygdala (CeA). 
Moreover, when centrally injected, CRH inhibits food consumption and reduces body 
weight in rats through stimulating POMC-related peptides synthesis and secretion in the 
hypophysis 149. It has been observed that, when peripherally administered in human, 
CRH significantly increases energetic expenditure and fat oxidation 118. Furthermore, 
leptin infusion appeared to stimulate CRH expression, whereas the pre-treatment with a 
CRH antagonist dampens leptin-induced food intake and body weight reduction 118. 
1.2.2.1. Oxytocinergic system 
Among the satiety stimulating neuropeptides, a great deal of attention has been attracted 
by OXY, a 9-amino acid peptide crucially involved in feeding behaviour and energy 
homeostasis regulation 119–121. OXY is synthesized as a part of a precursor protein, 
preprohormone, which is cleaved with the consequent release of a nonapeptide, the 
neurophysin 150. Neurophysin appeared to be non-biologically active, however it seems 
to protect OXY against enzymatic damage and to mediate OXY inclusion into 
neurosecretory vesicles 151,152.  
The major OXY neurosecretory system is represented by the hypothalamic-
neurohypophysial system whose neurons, having the cell body in the PVN and SON, 
project their axons to the posterior lobe of the pituitary gland (neurohypophysis) as well 
as to the ARC, ME, lateral septum (LS), and medial amygdala nucleus (MeA) 153. 
Different observations suggest that OXY is primarily synthesized into the magnocellular 
neuronal population of the PVN and SON 154 that, once activated, are responsible of 
OXY release in the neurohypophysis. OXY is then secreted from the posterior lobe of 
the pituitary gland into the blood circulation where it can exert its effects by binding 
OXY receptors (OXTR), which are located throughout the body 155. Furthermore, it has 
been observed that after being secreted into the blood stream, or after its peripheral 
stimulation (during milk suckling or vaginal dilatation), cerebral OXY levels do not 
change, thus suggesting that OXY does not readily permeate the BBB 156.  
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Several evidence suggests that in the PVN and SON OXY can be released at both 
axonal and dendritic level 157. 
The observation that hypothalamic oxytocinergic neurons project, among other 
destinations, also to the anterior part of the pituitary gland 158, suggested OXY ability to 
act as a hypothalamic regulation factor able to physiologically modulate the 
adenohypophysial hormones including prolactin adrenocorticotropic hormone 159, and 
gonadotropins 160.  
OXTR, is a GPCR coupled to a Gq/11α protein that has been identified not only in the 
CNS but also in the periphery 156. Interestingly, its distribution changes according to the 
species. For instance in the rat brain, in addition to PVN and SON, OXTR is also widely 
expressed in the olfactory system, cortex, thalamus, basal ganglia, VMH, BNST, CeA, 
ventral subiculum (vSUB), Hipp, Acb, brainstem, and spinal cord 155; while in human 
brain it is abundantly distributed in pars compacta of substantia nigra (SN), globus 
pallidus, anterior cingulate and medial insula 155.  
Interestingly in the periphery OXTR is present in a variety of organs including uterus, 
mammary gland, ovary, kidney, heart, bone, and endothelial cells 155. 
Thanks to its wide distribution in the body, the oxytocinergic system plays a crucial role 
in many physiological functions. For instance, it has an uterotonic action and therefore 
it is involved in the induction of labor 161,162. Growing evidence suggests an 
involvement of OXY in the regulation of social behaviour 163,164 that is dependent on the 
context: when the social cues are considered as “safe” OXY is able to improve sociality; 
whereas if they are interpreted as “unsafe” OXY induces defensive behaviour 165,166. 
A large body of evidence indicates that OXY is also released during stressful conditions 
including conditioned fear, pain, electric footshock, exposure to novel environments, 
and restraint stress 156. Moreover, concerning OXY capability to dampen the stress-
induced hypothalamic-pituitary-adrenal (HPA) axis activation 167, it has been shown an 
interplay between the hypothalamic oxytocinergic system and the corticotrophin-
releasing factor (CRF) system 168.  
Furthermore, OXY has been shown to participate in the control of autonomic and 
somatic effects, such as sexual behaviour in both rodents 163 and humans 163,169, the 
cardiovascular system 170 and analgesia 171,172.  
Interestingly, due to its effects in the control of social behaviour, OXY appeared to 
improve social cognition, functioning and repetitive behaviour in autism spectrum 
disorders 156. 
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A large body of evidence suggests the pivotal role of OXY in the regulation of feeding 
behaviour and energy homeostasis, being OXY particularly involved in stimulating 
appetite suppression 119–121. Intravenous infusion of both OXY and OXTR receptor 
agonists has been demonstrated to induce a dose-dependent reduction of food intake 
121,173,174. Subsequent studies revealed that OXY acts as “homeostatic” inhibitor of 
feeding behaviour. In fact, it plays a role in gastric motility and in the response of 
stomach distension, which occurs upon food consumption 175. Olszewski and 
collaborators found increased oxytocinergic neurons activity in concomitance with the 
meal termination 175, thus suggesting their function in mediating satiety.  
Moreover, studies conducted in rodents revealed that OXY plays a role in the 
conditioned taste aversion (CTA) mechanisms 156. 
Several studies have been conducted in order to investigate a possible interaction 
between OXY and other feeding related peptides. In this context, Olszewski 
demonstrated that α-MSH injection in the PVN, reduces food intake because of a 
concomitant increase of the percentage of neurons co-expressing c-Fos and OXY 176. 
Furthermore, CART 177 and CCK 178 injection determined increased oxytocinergic 
neuronal activity in PVN and SON and/or increased OXY release, while a cerebral 
injection of OXTR antagonists has been demonstrated to prevent CRH-induced 
hypophagic effect 179 and to attenuate the pro-satiety leptin action 180.  
OXY is not only involved in the control of energy homeostasis but it also regulates 
body weight and fat 181. Finally, McCann and Rogers found that oxytocinergic neurons 
modulate gastric motility by increasing the excitability of sensorial NST fibres and 
DMV motoneurons 182.  
1.2.3. Neurotransmitter systems 
It is now well recognised the existence of an interplay between the monoaminergic 
neurotransmitters (such as DA, 5-HT and NA) along with neuropeptidergic and 
hormonal signals in regulating eating behaviour. Also the neurotransmitter histamine 
participates in the regulation of feeding consumption and it is considered a neural 
satiety signal; in fact it has been demonstrated that pharmacological treatments that 
increase the brain histamine availability are able to suppress eating, whereas 
administration of histamine antagonists increases food consumption and body weight 
183.  
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- Dopaminergic system 
Knowledge accumulated during the last years investigated DA role in the control of 
food intake, particularly in the rewarding aspects of food 184–186. 
DA is the predominant catecholamine neurotransmitter, which is synthetized within the 
ventral tegmental area (VTA) and the SN of the midbrain, from here DA neuronal cell 
bodies project to various brain structures.  
We distinguish three different circuitries: 1) a nigrostriatal pathway originating in the 
SN and projecting to the dorsal part of the striatum such as the caudate putamen (CPu), 
involved in the regulation of movements; 2) a mesocorticolimbic pathway where 
dopaminergic cell bodies, residing in the VTA, project to both limbic (such as Acb and 
AMY) and cortical (such as PFC and medial prefrontal cortex (mPFC)) regions, thus 
controlling reward, and reinforcement behaviours as well as emotional and motivational 
responses; and 3) a tuberoinfundibular circuit which connects the ARC, where reside 
the cell bodies, and the ME 187 (Fig. 1.4).  
 
 
 
 
 
 
 
 
 
Fig. 1.4: Dopaminergic pathways in the rat brain. The mesocorticolimbic circuit connects the VTA 
and both limbic (Acb, black‐dotted line) and cortical (PFC, dark gray line) areas; the nigrostriatal circuit 
connects the SN to the CPu and others brain regions including the PFC, Acb and AMY (light gray line). 
The tuberoinfundibular pathway connects the ARC and the ME (dark gray dotted line).  
Acb, nucleus accumbens; AMY, amygdala; ARC, arcuate nucleus; CPu, caudato putamen; ME, median 
eminence; MPOA, medial preoptic nucleus; PFC, prefrontal cortex; PVN, paraventricular nucleus; SC, 
spinal cord; SON, supraoptic nucleus; VTA, ventral tegmental area; ZI, zona incerta. Adapted from 187. 
 
It has been demonstrated that DA effects in the regulation of feeding vary depending on 
the brain sites of action and on the variety of receptor subtypes 35. For instance, 
mesolimbic dopaminergic circuitry is responsible of the rewarding aspects of 
consuming HPF 188, whereas DA release in the HYPO suppresses food intake by 
reducing the duration of meal consumption 93,189.  
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Growing evidence showed that DA release is linked with both short-term and long-term 
control of feeding 189,190. Moreover, several findings suggested that a different 
expression in the HYPO of dopaminergic receptors in obese and lean phenotypes is 
directly involved in the regulation of meal size and meal number 189.  
Among the different neurotransmitters implicated in the rewarding effects of food, DA 
represents the best characterized, in fact several evidence revealed that the ingestion of 
HPF induces DA release in the striatum of both humans and rodents 191,192. In particular, 
the first exposure to HPF stimulates an increase in the firing of DA neurons, whose cell 
bodies are located in the VTA, with the consequent DA release in the Acb 193. On the 
other hand, DA response habituates following situations of repeated HPF exposures 194. 
The involvement of dopaminergic circuitry in regulating food reward is strictly 
correlated to the motivational aspects driving the desire for the food, referred to as 
“wanting” 195. The dopaminergic brain regions involved in this rewarding aspect of food 
are represented by the striatal nuclei such as CPu and Acb 196.  
This concept is opposed to the mechanism involved in the hedonic properties of food, 
referred as “liking” which are predominantly regulated by opioid and cannabinoid 
systems 195. Conversely, in the hedonic aspects of food are implicated the LHA, ventral 
pallidum (VP), orbitofrontal cortex (OFC), Acb 197–199 and insula 200.  
Brain-imaging studies revealed that the food cue-induced increase of DA release in 
humans is associated with the motivational salience of food (wanting) 201, while opioid 
or cannabinoid receptors activation enhances the liking of the food, thereby stimulating 
appetite.   
- Serotonergic system 
5-HT is a monoamine neurotransmitter derived from the amino acid tryptophan and it is 
synthesized both peripherally (in the gastrointestinal tract) and centrally 202–204.  
Among the variety of functions that 5-HT exerts including reproduction, mood, sleep, 
and cognition, a very important physiological role appeared to be the control of feeding 
behaviour 189.  
In this context, it has been demonstrated that peripheral administration of 5-HT inhibits 
food intake by reducing meal size in rats 205. This effect seems to be associated to the 
indirect activation of the CNS, which occurs through the recruitment of ascending vagal 
afferent fibres 206–208. 5-HT, in fact, does not cross the BBB.  
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Central 5-HT is released by the 5-HT-synthesizing neurons, whose cell bodies are 
located in the brainstem, particularly in the caudal and rostral raphe nuclei, and densely 
innervate many regions of the brain 189. 
More specifically, the 5-HT neurons of the caudal raphe project to the cerebellum, 
midbrain, pons, medulla, and most segments of the spinal cord, while 5-HT neurons 
whose cell bodies reside in the rostral raphe project in regions including cortex, Hipp, 
thalamus, HYPO, striatum, and AMY 209,210. 
In particular, it has been observed that 5-HT fibres synaptically contact POMC and 
AgRP ARC neurons thereby affecting melanocortin neuronal activity 211,212. 
The role of central 5-HT in eliciting satiety has been demonstrated by the observations 
that the administration of different compounds acting as direct or indirect agonists at 
central 5-HT synapses cause a significant  reduction of food intake 189. 
Moreover, it has been found that during feeding, 5-HT release increased in the HYPO 
213.  
A large body of evidence shows the existence of an interplay between 5-HT and DA, in 
particular it has been observed that DA release is partially regulated by 5-HT release 
214–216.  
To this regard, it is important to mention that meal size and meal number are 
independently regulated by distinct brain regions. In particular, several evidence 
demonstrated that the meal size is influenced by the intra-LHA DA and 5-HT, whereas 
the meal number is modulated by DA and 5-HT interaction within the VMH 217–219. 
Thanks to 5-HT properties in inducing satiety, a number of drugs enhancing 5-HT 
transmission have been used for obesity treatment. In this context, several evidence 
supported an important role for 5-HT2C receptors in the inhibitory control of eating.  
For example, mice lacking these receptors have been found to be hyperphagic thus 
developing obesity 220–222. Moreover, they showed a lower responsiveness to 
dexfenfluramine 223, GLP-1, and CCK 224. This aspect will be further discussed in the 
next sessions of the text.  
- Noradrenergic system 
NA is a catecholamine neurotransmitter synthesized in the dorsal vagal complex and in 
the locus coeruleus (LC) of the brainstem. In particular, Dalhström and Fuxe have 
recognised in mammalian brainstem several distinct groups of NA neurons from A1 to 
A7 225. 
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These regions contain the caudal ventrolateral medulla (A1), the NST (A2) the reticular 
regions around inferior olivary nuclei (A3) and the ependyma of the fourth ventricle 
(A4), the ventrolateral pons (A5), the LC (A6) and the rostral caudal pons (A7) 225,226.  
From these hindbrain regions, noradrenergic fibres have been found to project both 
caudally to the spinal cord and rostrally to the HYPO, thalamus and cortex 93. In 
particular, it has been shown that the NA neurons innervating the HYPO are those 
originating from A1, A2, and A6 regions 40,227. 
Several observations demonstrated the crucial involvement of the noradrenergic 
neurotransmission in controlling food intake 93. For instance, particularly in the 
noradrenergic neurons projecting to the PVN, NA has been found to co-localize with 
NPY 93. Moreover, likewise NPY, intra-PVN injection of NA in rats appeared to 
strongly increase feeding and body weight 228 through the activation of the α2-receptor 
229. Conversely, NA by binding to α1- and β2-receptors exert opposite effects on food 
intake 229.  
The observation that elevated NA signaling in the PVN or other hypothalamic areas 
produced an increase of leptin deficiency-induced hyperphagia, suggests that NA acts as 
an anabolic effector in the control of energy homeostasis of CNS 93.  
Further evidence confirming the role of noradrenergic tone in feeding behaviour 
regulation is represented by the observation that A2 neurons are activated when food 
intake is inhibited 230.  
Moreover, in order to investigate the role of noradrenergic neurons located in the NST 
in mediating anorexic responses to gastric stimulation and in conveying gastric sensory 
signals to the HYPO and AMY, these hindbrain noradrenergic fibres have been lesioned 
through the microinjection of saporin, a toxin conjugated to an antibody against the 
enzyme responsible for NA synthesis, dopamine-β-hydroxylase (DBH) 231. 
These experiments demonstrated the involvement of noradrenergic neurons of the NST 
in mediating CCK-anorexia and the hyphotalamic responses to gastric sensory 
stimulation 231. 
- Histaminergic system 
Histamine is an organic nitrogenous compound that is produced from the amino acid L-
histidine by the enzyme histidine decarboxylase (HDC) and it has been isolated for the 
first time by Sir Henry Dale and colleagues from ergot in 1910 232. The first evidence of 
histamine presence in the brain dates back to 1919 233, however its role as a 
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neurotransmitter became evident only several decades later with the morphologic 
characterization of histamine- synthesizing neurons 234.  
The central location of histaminergic neurons is represented by the above-mentioned 
TMN of the HYPO, from here these neurons project to the whole CNS through three 
major pathways: two ascending fibre groups reaching the forebrain structures and one 
ascending way that innervates the spinal cord 235–237 (Fig. 1.5).  
 
 
 
 
 
 
 
 
 
Fig. 1.5: The histaminergic pathways in the rat brain 234. 
 
Histamine is known to be involved in local immune responses and, as a 
neurotransmitter, it regulates many physiological functions 234 including arousal 238, 
sleep-wake cycle 239, seizure activity 239, release of hypothalamic hormones (AVP, 
OXY, prolactin, ACTH and β-endorphin) 240–243, thermoregulation 244, glucose and lipid 
metabolism 245, blood pressure 239 and food intake suppression 44,246.  
Although histamine is able to activate both G protein-coupled receptors 247 and ligand-
gated ion channels 239, its physiological functions are mainly mediated by the binding of 
the former referred to as H1R 
248, H2R 
249, H3R 
250, H4R 
251.  
Among histamine biological functions, a crucial role is represented by the regulation of 
eating behaviour. Histamine, in fact induces satiety being released during the appetitive 
phase of food intake 252. Moreover, the observation of increased hypothalamic histamine 
levels during the feeding state of rats that have been fasted for 24 hours demonstrated a 
role for histamine also in regulating the consummatory phase of eating behaviour 253,254.  
Preclinical data collected over the years concerning the administration of histamine 
within the brain of laboratory rats 255,256 or cats 257 revealed histamine ability to induce a 
long-term inhibition of food intake.  
 23 
 
Moreover, additional evidence of the pro-satiety action of histamine comes from the 
observation that both the activation of H1R within the PVN and VMH and the blockade 
of brain H3R autoreceptors (that increases histamine release) are able to suppress food 
consumption 258. These receptors have been recognized to regulate energy intake and 
expenditure and their activation has been demonstrated to modulate feeding circadian 
rhythms 44,259.  
Furthermore, there is consistent evidence indicating that a variety of regulatory peptides 
involved in the homeostatic control of food intake, including orexin, leptin, GLP-1, 
TRH, amylin and the emerging gut-derived pro-satiety compound oleoylethanolamide 
(OEA), require an intact histaminergic system to exert their orexigenic or anorexigenic 
effect 45,260.  
1.3. Neurobiological mechanisms regulating stress  
The way by which our body reacts to the exposure of stressful agents (physical, 
chemical or emotional stress) consists of an adaptation response whose objective is the 
homeostasis maintenance.  
The mechanisms accounting for this process consider both the catecholamines release 
from adrenal medulla and the activation of the HPA axis that is responsible for higher 
cortisol levels 261. As previously described in the text, medial parvocellular neurons of 
PVN containing CRF, project to the ME where they release this hormone into the 
hypophysial portal vessels 39. From here, CRF reaches corticotropic cells of anterior 
pituitary gland 261 where it binds to its receptor, thus leading to ACTH secretion within 
the systemic circulation (Fig. 1.6). ACTH, in turn, binds to specific receptors expressed 
by the adrenal cortex in order to stimulate synthesis and release of corticosterone 
(CORT) in the general circulation, a hormone crucially involved in the body adaptation 
mechanisms to the stress response 262. 
Among the stress factors characterizing the stressful conditions, both systemic and 
psychological factors result in HPA activation. 
In particular, systemic stress factors are also associated with an activation of brainstem 
and circumventricular organs that directly project to the PVN neurons. Moreover, it is 
also possible that HPA axis hyperactivation, occurring during stressful conditions, is 
dependent on catecholaminergic ascendant input 261.  
On the other hand, psychological stress factors evoke excitement conditions leading to 
the so-called “fight-or-flight” homeostatic stress response, which is linked to 
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glucocorticoids and neuro-hormones secretion and to the activation of the sympathetic 
part of the autonomic nervous system.  
Both systemic and emotional stress factors are elaborated in a variety of limbic 
structures, including AMY, Hipp, and PFC regions of the brain receiving projections 
from sub-cortical and cortical areas and involved in regulating emotional or memory 
processes and conditioned responses 263.  
The above-mentioned limbic regions also modulate HPA axis activation and collaborate 
in the autonomic stress responses 264.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.6: Regulation of the hypothalamic–pituitary–adrenal axis (HPA) 265. 
 
Limbic modulation of the stress responses is primary mediated by oligosynaptic inputs 
to the PVN and other preautonomic brain regions. In this context, the PVN is 
considered as the principal integrator of stress signals 264. 
In particular, the vSUB provides glutamatergic input to primarily inhibitory PVN relays, 
thus limiting psychogenic stress responses 264.  
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On the other hand, AMY, that is a structurally complex brain region, differently 
regulates systemic and psychogenic stressor responses. For instance, GABAergic 
projections from the CeA are involved in the regulation of responses to systemic 
stressors, while those from the MeA are responsible for the modulation of psychogenic 
stressor responses. Finally, the basolateral amygdala (BLA) via glutamatergic 
projections, within and outside the AMY, regulates both the acute and the chronic 
psychogenic stress response 264.  
As far as the cortex, the prelimbic cortex (PL) via glutamatergic projections directed to 
inhibitory PVN relays suppresses the responses to emotional stress, whereas the 
infralimbic cortex (IL) appeared to activate autonomic responses to psychogenic stress, 
via direct (NST) or indirect (CeA) projections.  
CRF effects on physiological and behavioural stress responses are mediated by binding 
to its receptors: CRF receptor type 1 (CRF1) and 2 (CRF2). Between the two receptors, 
the CRF1 represents the most abundant and it is predominantly expressed within 
HYPO, VTA, AMY, and cortical structures; while CRF2 distribution is restricted to the 
HYPO, dorsal raphe (DR), and LS 266–268.  
It has been reported that, CRF1 antagonists reduce stress-induce food-seeking in rats 269. 
Moreover, an interplay between CRF and the dopaminergic and oxytocinergic 
systems has been predominantly studied in the last years 270,271.  
For instance, the HPA stimulation leads to the activation of the mesolimbic 
dopaminergic pathway, which is associated to the reward circuitry. In fact, it has been 
demonstrated that the high CRF levels followed stressful events exert a role on DA 
neurons of the VTA, which projects to both limbic and prefrontal regions 272.  
Moreover, experiments conducted in rodents reported that a variety of stressful stimuli 
including pain, fear conditioning and the exposure to novel environments induce an 
increase of plasmatic OXY concentration 161, which leads to the decrease of the stress-
induced HPA axis activation 167. OXY represents, in fact, an important regulator of the 
anxiety disturbances related to the physiological stress response 164.  
1.4. Neurobiological mechanisms regulating food addiction 
Growing evidence considers obesity not only as a metabolic disease but also as the 
consequence of persistent disrupted eating behaviours thus affecting not only the 
physical but also the psychosocial health 273.  
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In this context, it is current knowledge that overeating is linked to neurobiological and 
psychological aspects, such as mood disturbances, altered reward perception and 
motivation, and addictive behaviour 274.  
From this point of view, it is now prevailing the tendency to consume certain foods, 
particularly those high in sugar or in fat and therefore highly palatable, for pleasure and 
not to maintain energy homeostasis. Due to its intrinsic features, the HPF has an 
important impact on mood regulation so that it is becoming frequent the activity to 
overconsume these nutrients to self-medicate from negative emotional conditions such 
as anxiety, depression, mental fatigue 275.  
Based on this background, it is now clear that there are many similarities between HPF 
consumption and reinforce behaviours related to the use of abuse drugs 276–279. In fact, 
HPF has been demonstrated to induce CNS modifications similarly to those evoked by 
drugs of abuse 276–279. In this context, it has been defined the concept of food addiction, 
suggested for the first time by Randolph in 1956 280.  
The first indirect evidence showing affinities between excessive food consumption and 
drugs of abuse comes from the pharmacological data, since common therapies that are 
known to influence the intake of abuse drugs have been also shown to attenuate 
compulsive overeating occurring, for example, during binge eating episodes. Among 
these drugs, we recognize naloxone 281, naltrexone, baclofen 282,283, topiramate 284, 
Rhodiola rosea and hypericum perforatum extracts 285,286, adenosine A2A receptor 
agonists 287, orexin 1 288 and CRF1 receptor antagonists 289.  
Moreover, additional molecular and neurochemical evidence suggests that 
uncontrollable HPF consumption stimulates reward dopaminergic and opioid systems 
273, which appear deeply readapted in people suffering from BED and obesity, thus 
leading to a reward hyposensitivity state 290–293. Moreover, this readaptation seems to be 
the consequence of disrupted striatal D2 receptors signalling 294–297. 
Interestingly, another evidence supporting the link between obesity and drug addiction 
comes from the observation that the disruption of the reward dopaminergic circuitry 
occurring during food overconsumption is similar to that observed after intravenous 
cocaine or heroin self-administration 298–300.  
Human brain imaging data showed an increase in DA levels in the brain of both 
addicted individuals and obese people with BED 301,302. This effect appeared to be 
parallel to a reduced expression of DA receptors observed during obesity and drug 
dependence conditions 290. 
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In particular, in BED patients the higher DA release, which occurs upon exposure to 
food cues, has been described as an index to classify the severity of the disorder 302.  
Moreover, the symptoms described during food withdrawal including headaches, 
sweats, irritability, and panic 303, are also similar to those found in drugs addicted 
individuals such as symptoms resembling tolerance, withdrawal, and craving 291.  
The aversive emotional state that triggers the negative reinforcement of addiction such 
as stress and negative moods (depression, anxiety), is also predominant in food 
addiction and can cause uncontrollable food consumption in humans through the 
involvement of a three-step cycle characterized by binge/intoxication, 
withdrawal/negative affect and preoccupation/anticipation 304–306. 
It is important to mention that obesity and BED are not synonyms of food addiction, 
which is neither necessary nor sufficient for obesity 277,307. 
To conclude, the inclusion of food addiction in the DSM-V suggests the similarities 
between people suffering from EDs and drug addicted individuals 308.  
This observation indicates that the neuronal circuitry engaged in the two pathological 
conditions are the same 273.  
1.5. Pharmacological treatment for obesity and BED 
- Obesity 
The growing prevalence of obesity highlights the need to deal with this public health 
issue by using specific anti-obesity treatments as an adjunct to a complete weight-loss 
program including diet and physical activity. Moreover, for patients with a BMI of 40 
kg/m2 or greater, who failed an adequate exercise and diet program (with or without 
therapy), the most effective anti-obesity approach is represented by a bariatric surgery, 
which reduces the size of the stomach 309.  
The European Medicines Agency (EMA) recommends that, in order to be considered 
efficient against obesity, a drug needs to induce a response that is more than 10% 
weight loss at the end of a 12-month period 310. 
The anorexiant drugs that have been used over the last years are numerous, however 
most of them has been withdrawn from the market due to their several side effects. 
Some examples are represented by d-fenfluramine, a 5-HT  reuptake inhibitor, that was 
withdrawn from the U.S. market in 1997 after reports of heart valve disease and 
pulmonary hypertension 311; rimonabant, a cannabinoid receptor type 1 (CB1) 
antagonist which is not more available since 2008 because of its effects in increasing 
 28 
 
the risk of psychiatric disorders such as depression and suicidal tendency 312; 
sibutramine, a NA and 5-HT reuptake inhibitor that displayed severe cardiovascular 
side effects when administered in patients who already showed cardiac disorders 313 and 
therefore withdrawn from the market in 2010.  
Over the last 20 years, the pharmacological research identified novel compounds for 
long-term obesity treatment and, in particular, three drugs have been approved both by 
EMA and Food and drug administration (FDA) and are currently on the market 
(Orlistat, Liraglutide and naltrexone/ bupropion combination therapy).  
Orlistat is a synthetic hydrogenated lipostatin derivative acting as a specific 
gastrointestinal lipase inhibitor, which reduces dietary fat absorption by the 30%, 
thereby consequently lowering body weight 314.  
Orlistat treatment is also associated with an important reduction of the cardiovascular 
risk factor by lowering total cholesterol, low-density lipoproteins, triglycerides and 
arterial blood pressure 315. Moreover, through decreasing body weight it also improves 
glycemic control and it has been shown to reduce the type 2 diabetes incidence to 6.3% 
after 4 years of treatment 315. However, Orlistat is associated with several adverse 
effects such as liquid and soft stools, abdominal discomfort, flatulence, faecal urgency, 
and/or incontinence 314. At least one of these effects, which are related to Orlistat 
pharmacologic mechanism of action, occurred in up to 95% of orlistat-treated patients 
during clinical trials 316. Nevertheless, they occurred during the first week of treatment 
and did not persist for more than 4 weeks 314.  
Liraglutide, an acylated form of the human GLP-1, represents another pharmacological 
target for obesity management. Thanks to its structural change, Liraglutide is able to 
spontaneously aggregate in the injection site and to bind circulating albumin therefore 
having a greatly prolonged half-life compared to native GLP-1 15. Although originally 
developed for type 2 diabetes mellitus treatment, Liraglutide was demonstrated to lower 
body weight and then approved by both the FDA (2014) and EMA (2015) for obesity 
therapy 317.  
The most commonly reported adverse events are gastrointestinal complaints such as 
nausea, diarrhoea and vomiting 317.  
In order to manage both homeostatic and hedonic aspects of eating, a combination 
therapy containing naltrexone and bupropion has been approved in 2014 in the US and 
in 2015 in Europe 318,319.  
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In particular, Naltrexone is a high-affinity μ-opioid receptor antagonist while bupropion 
is a NA and DA transporter inhibitor 320. It has been demonstrated that the reduced food 
intake followed by naltrexone/bupropion treatment is strictly related to an increase in 
POMC neuronal activity 318, an effect that is primarily stimulated by bupropion action 
and subsequently amplified by naltrexone-induced inhibitory effects on β-endorphin 321.  
Moreover, thanks to the effects of naltrexone in reducing dopamine levels in the Acb, 
this combination therapy decreases the reward value of food and the preference for the 
so-called HPF 322–324 thus addressing one of the goals of obesity management 
pharmacotherapy.  
Among the most common adverse effects of naltrexone/bupropion (nausea, vomiting, 
migraine, and dizziness), increased blood pressure and cardiac frequency appeared to be 
related to its mechanism of action, being bupropion a sympathomimetic substance.  
Other two pharmacological approaches, Lorcaserin and Phentermine/Topiramate 
combination, have been approved by FDA in 2012 and are currently available on the US 
market. Lorcaserin is a selective 5-HT2C receptor agonist, which inhibits appetite and 
reduces body weight, showing classical side effects such as constipation, fatigue, dry 
mouth, headache and dizziness 325.   
Phentermine/Topiramate is an extended-release formula designed for long-term obesity 
therapy and indicated for lowering body weight and increasing resting energy 
expenditure 320. Phentermine is a sympathomimetic compound, which inhibits appetite 
by increasing NA in the HYPO and consequently stimulating β2-adrenergic receptors 
326. On the other hand, Topiramate is a non-specific drug originally indicated as 
anticonvulsant and proposed to act at several cellular targets including voltage-gated 
sodium channels, high-voltage-activated calcium channels, gamma-aminobutyric acid 
(GABA-A) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA)/kainate (AMPA/KA) receptors, and carbonic anhydrase isoenzymes 327. The 
specific mechanism by which Topiramate reduces body weight is still debated, however 
it has been proposed that its effects in reducing compulsive or addictive food cravings 
are mediated by topiramate’s antagonism of AMPA/KA receptors 328. Furthermore, 
topiramate reduction of food intake seems to be mediated, at least in part, by the 
activation of GABA-A receptors 329.  
It is important to mention that initially topiramate was approved as a monotherapy for 
obesity but it was withdrawn because of its neuropsychiatric and cognitive side effects 
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330. As a combination formula, Phentermine/Topiramate therapy shows common 
adverse effects including constipation, dry mouth, paraesthesia, and insomnia 320.  
Moreover, an additional anti-obesity approach considers the supplementation of diet 
with naturally occurring nutritional ingredients such as the N-oleoyl-phosphatidyl-
ethanolamine (NOPE) conjugated with epigallocatechin gallate (EGCG) 331.  
NOPE is a phospholipid present in animal and vegetable foods and hydrolysed by the 
membrane phospholipase D into N-oleyl-ethanolamide (NOE) which is known to exert 
an anorexic effect through peroxisome proliferator activated receptor-alpha (PPAR-α) 
activation, when systemically administered in rat 331. Whereas EGCG is a standardized 
green tea extract and has been shown to promote lipolysis and, consequently, weight 
and fat loss 332 by inhibiting catechol-O-methyltransferase (COMT)-induced 
degradation of catecholamines 333. Several evidence showed that, when NOPE is orally 
administered, NOE is rapidly hydrolysed in the stomach in oleic acid and ethanolamine 
and therefore it is not able to reach the intestine and to exert its anorexic action. 
Moreover, the conjugation with EGCG prevents the rapid breakdown of NOPE 
improving its availability 331.  
- BED 
To date there are no efficacious therapies for the treatment of BED, especially because 
of the complexity of the pathology, but also because of their high relapse rates and a 
wide range of side effects 334,335. The main outcome criteria for BED treatment should 
represent a reduction of binge eating episodes and the improvement of the disrupted 
feeding behaviour, the control of the psychopathological aspects of the disease, and the 
reduction of the possible excessive body weight 21.  
BED seems to be sensitive to three classes of drugs: antidepressant drugs, central 
appetite suppressors, and antiepileptic agents.  
The possibility to use antidepressant therapies for the treatment of BED is related to the 
high correlation existing between BED and major depression 336. Moreover, the 
overeating occurring during binge eating episodes is similar to that observed in people 
suffering from BN, which is treated with antidepressant drugs.  
Furthermore, several evidence demonstrated that the impairment in brain 5-HT 
signalling is one of the mechanism underlying the pathophysiology of BED 23–26.  
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In keeping with this observation, it has been recently reported that fluoxetine and d-
fenfluramine, selective 5-HT reuptake inhibitors that increase 5-HT content, are able to 
suppress BED 337, by reducing the number of binge episodes in obese patients 338–340. 
However, d-fenfluramine, as already mentioned in the text, it was withdrawn from the 
market for its cardiopulmonary adverse effects 311.  
Interestingly, an important interplay of the serotonergic and dopaminergic pathways has 
been recently found in the regulation of BED, as suggested by Xu and collaborators, 
who showed that lorcaserin attenuates BED in mice fed with a high fat diet, by 
stimulating central dopaminergic neuronal activity 341. 
Anti-obesity agents may also be used for treating BED since there is a significant 
overlap between both diagnoses 342–347. In this context, naltrexone, which is used in 
combination with bupropion for obesity management, has been reported to regulate both 
the homeostatic and the hedonic aspect of food consumption. 
For example, naltrexone has been demonstrated to decrease DA levels in the Acb, 
leading to a decrease in food seeking and binge-like eating  322,348,349, thus reducing the 
preference for highly palatable, high-fat, and high-sugar foods 323,324,350.  
Among its several mechanisms of action, it has been observed that topiramate’s 
antagonism of AMPA/KA receptors seems to improve BED 351 and reduce other 
addictive behaviours 352 through reducing compulsive or addictive food cravings 328.  
The only FDA-approved (in 2015) medication for the treatment of moderate to severe 
BED in adults is the Lisdexamfetamine (LDX), a pro-drug of d-amphetamine 353, which 
primarily acts by enhancing dopaminergic and noradrenergic neurotransmission in the 
brain 353. Beyond influencing the hedonic system, it has been demonstrated that LDX 
also up-regulates CART expression in animal models 354,355. 
However, it has several limitations since it causes serious adverse effects in patients 
with cardiac damages (cardiomyopathy, heart arrhythmia, coronary artery disease), 
which, unfortunately are quite frequent comorbidities in the population affected by 
eating disorders 356,357.  
Less important side effects of LDX are insomnia, weight loss, and headache 358. 
Furthermore, being a psychostimulant there is a considerable risk of abuse. LDX is only 
approved in the US, its use in other countries is still off-label.  
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1.6. Oleoylethanolamide and N-acylethanolamides as lipid 
mediators  
Nowadays, the limited and poorly efficacious anti-obesity therapies highlight the 
urgency to find novel pharmacological targets for controlling aberrant feeding 
behaviour. In this context, a great deal of attention has been dedicated to N-
acylethanolamides (NAEs), a family of phospholipid-derived signalling molecules, 
which have been shown to participate in many physiological and pathological 
conditions 273,359–362.  
Even though NAEs have been isolated from animal and vegetal tissues more than 50 
years ago 363,364, they did not attract any attention until anandamide (AEA) discovery, a 
polyunsaturated NAE binding to cannabinoid receptors 365. Hence, the identification of 
AEA as an endogenous cannabinoid ligand 366 has raised the interest for the other 
members of NAEs family thus recognizing their role in many biological functions 
including the regulation of food intake 359. The first NAE to be discovered was 
palmitoylthanolamide (PEA), followed by OEA. 
Among NAEs, PEA, OEA, stearoylethanolamide (SEA) and linoleoylethanolamide 
(LEA) are the best characterized and, in addition to feeding, they have been shown to 
exert roles in conditions like inflammation, pain and memory consolidation 367,368. 
Furthermore, due to their high expression in the CNS, growing evidence established 
their protective effects in neurodegenerative and neuropsychiatric disorders 369–372.  
Among NAEs, the most important compound that has been studied for its pivotal role in 
the regulation of feeding behaviour is represented by the endogenous lipid signal OEA. 
Although OEA shares with its monounsaturated analogue, AEA, biosynthesis and 
degradation pathways 362,373, it exerts opposite effects in the control of feeding 
behaviour and lipid metabolism. In fact, OEA does not induce cannabimimetic effects 
and it does not show any affinity for the cannabinoid receptors 374.  
OEA is generated by enterocytes of the proximal small intestine from oleic acid, which 
is released upon the absorption of dietary fat 366. Growing evidence demonstrated the 
pro-satiety effect of OEA since it is able to significantly reduce food intake and body 
weight in both lean and obese rodents 36,37,359,375–384 as well as in humans 385.  
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1.6.1.  Synthesis and metabolism 
OEA and NAEs are synthesized on-demand from a phospholipid precursor within the 
membrane lipid bilayer. OEA biosynthesis is under the control of the sympathetic 
nervous system 386,387 and is mediated by two reactions (Fig. 1.7A). The first step is 
represented by the transfer of an acyl group, oleic acid, from the stereospecific 
numbering-1 (sn-1) position of a membrane phospholipid, such as phosphatidylcholine, 
to the amine group of phosphatidylethanolamine (PE) 366 (Fig. 1.7A). The enzyme 
responsible for catalyzing this reaction, named as N-acyltransferase (NAT), is a 
calcium-dependent enzyme involved in the production of a chemically heterogeneous 
family of N-acylphosphatidylethanolamines (NAPEs) 362,388. The second step is the 
release of OEA from NAPE, which contains oleic acid at the amine position (Fig. 
1.7A). This reaction is catalyzed by a NAPE-selective phospholipase D (NAPE-PLD) 
that hydrolyzes the distal phosphodiester bond of NAPE 362,388.  
Other NAEs may be produced by a similar biosynthetic pathway that involves the 
synthesis of the respective NAPEs as precursor 389.  
NAPE-PLD has been purified and molecularly cloned by Dr. Ueda and his collaborators 
373 and it is able to hydrolyze, with similar efficiency, a variety of analogs of the NAPE 
family 388. Moreover, experiments conducted in NAPE-PLD knock out (KO) mice 
revealed the existence of a redundant OEA biosynthetic pathway since in these mice 
OEA endogenous synthesis was not completely prevented 390,391.  
In this regard, a calcium-independent mechanism, through which NAPEs can be 
generated, has been identified and it involves the phospholipase A/acyltransferase 
(PLA/AT) family proteins 392. 
The main mechanism by which biological OEA effects are terminated is represented by 
the enzymatic hydrolysis of OEA to oleic acid and ethanolamine 362 (Fig. 1.7B). The 
intracellular enzymes involved in this process are amidases named as: fatty acid amide 
hydrolase (FAAH) 393 and N-acylethanolamine acid amidase (NAAA) 394. FAAH 
belongs to the serine-hydrolase family 393 and, although it is widely distributed in all 
mammalian tissues, it is predominantly expressed in the CNS, liver and small intestine 
396. By contrast, NAAA, which belongs to the family of fatty acid cysteine hydrolases, 
is mainly expressed in the periphery rather than in the brain. In particular, NAAA has 
been found in high concentrations in lung, spleen, thymus, intestine and in alveolar 
macrophages of rats 397 and has no homology with FAAH 394. 
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NAAA also differs from FAAH, since it mostly prefers PEA as a substrate for 
hydrolysis 394,398,399.  
Moreover, it has been demonstrated that NAAA might play a role in regulating NAEs 
levels during inflammation processes 398,400. However, its role in OEA metabolism 
remains poorly understood.  
Interestingly, a line of evidence showed that CD36, the fatty acid transporter presents on 
the enterocytes apical surface in the duodenum and jejunum, might contribute to OEA 
mobilization by facilitating, directly or indirectly, oleic acid absorption 362. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.7: Biosynthesis (panel A) and degradation (panel B) pathways of OEA 395 
 
A 
B 
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1.6.2. Receptors 
There is accumulating evidence showing that the pro-satiety effect of OEA is mediated 
by the activation of intestinal PPAR-α 401, which belongs to the family of peroxisome 
proliferator activated receptors (PPARs). PPARs are a family of transcription factors 
constituted by three different isoforms (α, β/δ, and γ), widely expressed in tissues with a 
higher oxidative capacity such as the cardiovascular system and, in particular, 
cardiomyocytes, endothelial cells, and vascular smooth muscle cells 402, but also in 
several brain areas and in peripheral tissues such as kidney, liver and intestine 368,403. 
After being activated by a ligand, PPARs stimulate gene expression by creating 
heterodimers with the retinoid X receptor (RXR), thereby binding to specific 
peroxisome proliferator response elements (PPREs) in the promotor region of target 
genes 404. They are involved in different biological processes, such as energy 
homeostasis, lipid and lipoprotein metabolism, cell proliferation and inflammation, 
blood pressure control and hypertensive-related complications, such as stroke and renal 
damage 405,406.  
Furthermore, among the different members of the PPARs family, PPAR-α and PPAR- δ 
have been demonstrated to exert distinct roles in the regulation of lipid metabolism 407. 
In this regard, once activated, PPAR- δ induces the expression of genes involved in the 
control of fatty acid oxidation and energy dissipation, thus improving lipid profiles and 
reducing adiposity 408. PPAR-α plays an important role in the regulation of lipid 
metabolism and energy homeostasis. As a matter of fact, it has been demonstrated that 
OEA pro-satiety effects are completely prevented in PPAR-α KO mice that are sensitive 
to other anorexic compounds, thus revealing the pivotal role of PPAR-α in mediating 
the satiety-inducing effects of OEA 401. 
Moreover, OEA appeared to stimulate the transcription of several target genes which 
encode for PPAR-α, such as PPAR-α itself, as well as fatty acid translocase 
(FAT/CD36), fatty acid transport protein 1 (FATP1), and inducible nitric oxide synthase 
(iNOS) 401.  
However, beyond binding PPAR-α there is increasing pharmacological evidence for 
additional receptor targets in mediating OEA biological action 361,362, such as the 
transient receptor potential vanilloid 1 (TRPV1) and the orphan GPCR 119 (GPR119) 
409,410. TRPV1 is a member of the vanilloid transient receptor potential cation channel 
subfamily, abundantly expressed in the cardiovascular system, peripheral nervous 
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system, CNS and in epithelial cells of the bladder and the gastrointestinal tract. It is 
known to act by activating protein kinase A (PKA) and the endothelial nitric oxide 
synthase (eNOS), thus stimulating the production of •NO and the release of calcitonin 
gene-related peptide and substance P 411,412, which, in turn, lead to the altered ion 
permeability 413. TRPV1 has been demonstrated to be involved in mediating 
inflammation mechanisms and pain 409. In accordance with this latter information, 
intraperitoneal (i.p.) or intradermic OEA injections cause short-lasting nociceptive 
responses in wild-type mice, but not in mice lacking TRPV1 409.  
Overton and colleagues have shown that OEA also acts as a medium-potency agonist 
for GPR119 (median effective concentration (EC50) ~ 3 μM) 410.  
The Gαs coupled-GPR119, primarily expressed in human and rodent pancreas, foetal 
liver, gastrointestinal tract and in rodent brain, stimulates adenylyl cyclase (AC) leading 
to increased intracellular adenosine 3′,5′-cyclic monophosphate (cAMP) levels, thus 
regulating incretin and insulin hormone secretion 414. In the gastrointestinal tract, 
GPR119 is expressed in enteroendocrine L-cells, which release GLP-1 in response to 
food ingestion.  
It has been demonstrated that, after an intraluminal infusion, OEA enhances GLP-1 
secretion from intestinal L-cells through a GPR119-dependent mechanism 415. 
However, OEA hypophagic action was still evident in TRPV1 and GPR119 KO mice 
thus excluding a direct involvement of these receptors in OEA-induced satiety 400,416. 
1.6.3. OEA and the control of food intake 
Growing evidence accumulated over the last 20 years demonstrated that OEA acts as a 
satiety signal since it is able to evoke consistent and sustained food intake suppression 
in rats and mice, following both i.p. and oral administration 359,377,380,382,401,417–419. 
Rodent feeding activity that occurs at dark onset, is organized into episodes called 
“meals” corresponding to a variable amount of food eaten (meal size) 388. The time 
interval between the dark onset and the particular moment in which the animal starts 
eating is defined as “latency”, while the gap occurring between a meal and the 
subsequent is called “inter-meal interval” and has a variable duration 380,381,417.  
Feeding-regulating compounds including neuropeptides, hormones or lipid mediators 
participate in different aspects of this patterned behaviour.  
For instance, the serotonergic anorexiant agent d-fenfluramine affects both latency and 
meal size 420, whereas CCK exerts a pro-satiety effect by only reducing meal size 421. 
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Conversely, OEA hypophagic effect depends on the feeding state of the animals 380,417 
and, in particular, in free feeding rats OEA (i.p, 1–20 mg kg-1) dose-dependently 
increases the latency to eating onset, prolonging the inter-meal interval, without 
affecting the meal size, while in food-deprived rats it acts at both levels by delaying 
feeding onset and reducing meal size 380,417.  
It is important to mention that the anorexic effects of OEA are not accompanied by 
stress, malaise, and nausea. In fact, OEA does not change plasma corticosterone levels 
and does not induce CTA in rats 359,422.  
Moreover, it has been clearly demonstrated that OEA has no effects on drinking 
behaviour or sodium appetite thus suggesting the specificity of OEA pro-satiety action 
359,422. 
It has been also demonstrated that, among the structural analogs of OEA such as the 
endocannabinoid AEA, oleic acid and some other NAEs (including LEA and PEA), 
OEA is the most active in reducing energy intake. In fact, when administered i.p. to 
laboratory rats, PEA is less active than OEA in reducing food intake; LEA is similar in 
potency to OEA, however AEA and oleic acid have no effect 359,423,424, thus suggesting 
that OEA anorexic effect is structurally selective.  
Additional evidence supporting the idea that endogenous OEA participates in satiety 
induction comes from the observation that OEA physiological levels are strictly 
dependent on the nutritional status of the animals 361,362.  
Moreover, it has been found that a dietary fat intake influences OEA endogenous 
intestinal levels suggesting a possible role for OEA as intestinal fat sensor 424. In 
particular, in rat chronically fed with a high fat-diet (HFD) OEA intestinal levels 
resulted considerable decreased. 
Additionally, several results reported that beyond reducing appetite, OEA might also 
regulate body weight through modulating peripheral lipid metabolism and enhancing 
fatty acid uptake in enterocytes 425. 
1.6.4. OEA effects in the central nervous system  
A large body of evidence revealed that the pro-satiety effect evoked by OEA requires 
the involvement of selected brain regions, which actively participate in the control of 
energy homeostasis and feeding behaviour. In this context, it has been observed that 
after being systemically administered, OEA (10mg kg-1 i.p.) significantly increases the 
transcription of the early gene c-fos (investigated as a marker of neuronal activation) in 
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the NST and AP of brainstem 37,359,382,383, and in the PVN and SON hypothalamic nuclei 
37,359,382,383. Moreover, in both hypothalamic areas, OEA has been found to 
simultaneously increase c-fos mRNA and protein in OXY expressing neurons 37,377,426, 
thus suggesting that the activation of these hypothalamic neuronal populations is 
accompanied by increased oxytocinergic tone. Interestingly, this effect appeared to be 
associated with increased levels of OXY mRNA and peptide neurosecretion, along with 
enhanced circulating OXY levels 37,427. 
The OEA-induced neurochemical effects evoked by its systemic administration are 
highly selective, as demonstrated by recent findings revealing that the levels of 
additional hypothalamic peptides implicated in energy balance (AVP and TRH in PVN 
and SON, and POMC expressed in the ARC) are not affected by OEA i.p. injection 37.  
Evidence accumulated over the years points to the involvement of different neuronal 
circuits in mediating OEA action as appetite suppressor, and they include oxytocinergic, 
noradrenergic and histaminergic neurons 388 (Fig. 1.8). As a matter of fact, the i.c.v. 
infusion of the OXY antagonist, L-368,889, which selective blocks the cerebral OXTR, 
has been demonstrated to prevent OEA anorexic effects thus confirming the pivotal role 
of oxytocinergic transmission in OEA-induced feeding suppression 37.  
Moreover, the requirement of hindbrain noradrenergic fibres (that from NST project to 
the PVN) in mediating OEA’s hypophagic effects has been demonstrated in rats 
subjected to the intra-PVN administration of the toxin saporin (DSAP), a substance able 
to selectively destroy hindbrain NST-PVN noradrenergic neurons since it is conjugated 
to an antibody against DBH 383.  
Very recently, Provensi and collaborators demonstrated that OEA also requires the 
integrity of the brain histaminergic system to fully exert its pro-satiety effect 426. The 
authors, in fact, showed that mice lacking the enzyme involved in histamine synthesis, 
such as HDC, or mice pharmacologically deprived of releasable brain histamine did not 
respond to the hypophagic effect of exogenously administered OEA as normal mice did 
426.  
Even though OEA has been demonstrated to induce satiety by activating key brain 
hypothalamic and hindbrain areas, the mechanism by which OEA reaches the brain 
from the periphery remained poorly understood.  
After being systemically or orally administered, OEA quickly reaches the bloodstream, 
however it cannot readily permeate the brain because of the high expression of its main 
degrading enzyme, FAAH, in the BBB 428. 
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For many years, vagal fibres were hypothesized to convey OEA’s effects from the 
periphery to the brain, as suggested by the observation that after a complete 
subdiaphragmatic vagotomy, the pro-satiety action of OEA is abolished 401. However, 
recent findings obtained in rats subjected to a subdiaphragmatic vagal deafferentiation 
(SDA), demonstrated that the hypophagic action of peripherally administered OEA does 
not require intact vagal afferents 380.  
Given these premises, circumventricular organs, such as the AP in the brainstem, are 
attracting a great deal of attention for their possible role in allowing the direct access to 
the brain for circulating peptides and other peripheral signals.  
In this background, previous results demonstrated that the systemic administration of 
OEA at a dose and at a time-point that causes a significant inhibition of eating (10 mg 
kg-1 i.p.), strongly activates neurons of the AP and significantly stimulates c-fos 
transcription in the SolC, a nucleus of the NST in close contact with the AP 382.  
This observation, together with recent findings demonstrating the high expression of 
PPAR-α in the AP of drug-naïve rats 377, suggests a possible involvement of this 
circumventricular organ in mediating OEA pro-satiety effect (Fig. 1.8). This hypothesis 
was then confirmed by novel findings obtained in rats in which the AP was surgically 
removed. These results revealed the crucial role of this brain area in OEA mechanism of 
action, since after the ablation of the AP both behavioural and neurochemical effects of 
OEA were completely abolished 377. The above-described observations led us to 
hypothesize that circumventricular organs, thanks to their absence of a functional BBB 
and being particularly enrich in PPAR-α receptors, could represent a receptive region 
for circulating OEA, which may exert its central effects through the direct activation of 
this brain circumventricular organ. 
The working model on the central mechanisms mediating OEA’s pro-satiety action is 
depicted in Fig. 1.8A, B.  
Furthermore, in the brain OEA is also able to affect monoaminergic transmission. In 
particular, Yu and collaborators found that after repeated oral administration, OEA 
increases NA and 5-HT levels in the total brain thus exerting antidepressant-like effects 
429. This result was further confirmed by very recent findings showing that OEA, both 
acutely and chronically administered, decreases the immobility time of mice exposed to 
the tail suspension test, a test used to evaluate the depressive-like state in rodents 430. 
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Fig. 1.8: schematic representation showing the central mechanism mediating OEA’s hypophagic 
action. Panel A: Peripherally administered OEA activates the AP, a brainstem region with fenestrated 
capillaries that lacks a functional blood-brain barrier (BBB). At this level, OEA may cause the activation 
of noradrenergic neurons projecting to the nucleus of the solitary tract (NST) and especially to the medial 
part (SolM) (panel B). Noradrenergic neurons within the NST could, in turn, activate oxytocinergic 
neurons of the paraventricular nucleus (PVN), stimulating oxytocin expression and release, and, in 
addition, could presumably activate the tuberomamillary nucleus (TMN), evoking histamine release from 
neurons projecting to the PVN. Finally, oxytocin released from neurons of the PVN can centrally act to 
inhibit eating (adapted by 377). 
 
This effect was parallel to the OEA-induced increase of 5-HT release (following acute 
K+ challenge) in the ventral hippocampus (vHipp) of mice lacking HDC, which 
appeared to be 'supersensitive' to K+ administration than wild type animals 430.  
Moreover, OEA has been found to influence the stress response by reducing the HPA 
axis activation, ACTH and CORT levels in an experimental paradigm inducing stress 
431,432.  
Interestingly, as reported by Tellez and co-authors 433, OEA is also able to modulate 
feeding behaviour acting within the hedonic non-homeostatic circuits. 
1.7. Aim of the thesis   
The goal of the present study is to evaluate the role of OEA as a potential novel 
pharmacological target for the treatment of obesity and eating disorders, two major 
health problems worldwide 1.  
OEA’s ability in inducing consistent and sustained food intake suppression in rats and 
mice, that is mediated by PPAR-α activation 401, has been well characterized over the 
last two decades from my laboratory and from other research groups 359,377,378,382,417. In 
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fact, it is now well recognized that the pro-satiety effect of OEA is strictly dependent on 
the involvement of key brain hypothalamic and hindbrain areas 37,377,382,383,426.  
However, a crucial aspect remained to be fully elucidated, such as the way by which 
systemically administered OEA can reach the CNS from the periphery and whether it is 
able to permeate the brain parenchyma.  
In this background, circumventricular organs, such as the AP in the brainstem, are 
attracting a great deal of attention for their possible role in allowing the direct access to 
the brain for circulating peptides and other peripheral signals. Moreover, previous data 
showed that the i.p. administration of OEA, strongly activates neurons of the AP and 
significantly stimulates c-fos transcription in the subpostremal part of the NST, which is 
the closest sub nucleus to the AP 382.  
Based on these premises, in order to better delineate the mechanism underlying the 
eating-inhibitory effects of OEA, the aim of chapter II was to investigate the 
involvement of the AP in mediating OEA hypophagic action.  
To this purpose, in collaboration with Prof. Thomas Lutz at University of Zurich, we 
subjected rats to a surgical ablation of the AP and evaluated the effects of i.p. OEA 
administration (10 mg kg−1) on food intake, on Fos expression, on OXY 
immunoreactivity at both PVN and neurohypophysial level and on the expression of 
DBH within the brainstem and PVN. Further, we aimed to assess the phenotype of 
neuronal populations activated by OEA in the brainstem of controls and lesioned rats; to 
this aim, we assessed, also, whether OEA induced Fos expression co-localized with 
DBH as marker for noradrenergic neurons. Finally, as last step of our study, we 
investigated PPAR-alpha expression within the AP. 
Furthermore, since there are no observations demonstrating the ability of OEA to 
permeate the brain parenchyma, in the chapter III I aimed to investigate whether 
systemically administered OEA might directly reach and permeate the CNS through 
circumventricular organs devoid of a functional BBB, such as the AP and the ME. 
To this purpose, in collaboration with Prof. Lutz and Prof Giulio Muccioli at Université 
Catholique de Louvain, male Wistar rats were sacrificed at different time points (2.5, 5, 
15, 30, 60 minutes) after acute administration of OEA (10 mg kg-1, i.p.). Plasma and 
different brain areas were collected for UPLC-MS/MS quantification of the main NAEs 
(including OEA, AEA, PEA, SEA, and LEA), and 2-arachidonoyl-glycerol (2-AG). In 
particular, in order to selectively investigate OEA concentrations within a variety of 
PPAR-α-expressing cerebral regions, selected brain areas of interest (AP, ME, NST, 
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ventral and dorsal hippocampus (vHipp and dHipp)) were microdissected and used in 
this study.  
Finally, since current knowledge supports a relationship between neurobiological as 
well as psychological aspects of overeating, in chapter IV I also investigated the 
OEA’s pro-satiety action in a rat model of BED, which is a prototypical eating-related 
maladaptive behaviour that may determine fluctuations in body weight and in some 
instance may cause obesity. 
Among the different networks involved in the behavioural effect of OEA, it has been 
demonstrated that the systemic administration of OEA to obese rodents restores a 
“normal brain dopaminergic activity”, which resulted dampened by the excess of fat 
intake 433. Moreover, evidence suggests that OEA attenuates the effect of stress by 
dampening the hyperactivity of the HPA axis 431. Since both the abnormal dopaminergic 
transmission and the hyperactivation of HPA axis are considered mechanisms 
underlying the pathophysiology of BED, by acting at both the two deregulated 
conditions OEA might represent a potential novel pharmacological target for controlling 
aberrant eating patterns occurring in BED 273,388,434.  
Based on these premises, in order to test this hypothesis in collaboration with Prof. 
Carlo Cifani of University of Camerino we evaluated OEA effects in a BED model in 
which female rats with a history of intermittent food restriction show binge-like 
palatable food consumption after a 15-minute exposure to the sight of the palatable food 
(frustration stress) 284,289,435.  
In this model, we investigated the anti-bingeing acute effects of OEA (2.5, 5 or 10 mg 
kg-1, i.p.) on HPF intake and analysed the neurobiological bases of these effects by 
focusing on the brain pattern of c-Fos expression, on DA release in the shell of the 
nucleus accumbens (AcbSh), on monoamine concentrations/turnovers in selected brain 
regions and on both CRF and OXY mRNA in hypothalamic and extra hypothalamic 
areas.  
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Abstract 
The satiety-promoting action of oleoylethanolamide (OEA) has been associated to the 
indirect activation of selected brain areas, such as the nucleus of the solitary tract (NST) 
in the brainstem and the tuberomamillary (TMN) and paraventricular (PVN) nuclei in the 
hypothalamus (HYPO), where noradrenergic, histaminergic and oxytocinergic neurons 
play a necessary role. Visceral ascending fibres were hypothesized to mediate such 
effects. However, our previous findings demonstrated that the hypophagic action of 
peripherally administered OEA does not require intact vagal afferents and is associated 
to a strong activation of the area postrema (AP). Therefore, we hypothesized that OEA 
may exert its central effects through the direct activation of this circumventricular organ. 
To test this hypothesis, we subjected rats to the surgical ablation of the AP (APX rats) 
and evaluated the effects of OEA (10 mg kg−1 i.p.) on food intake, Fos expression, 
hypothalamic oxytocin (OXY) immunoreactivity and on the expression of dopamine beta 
hydroxylase (DBH) in the brainstem and HYPO. We found that the AP lesion completely 
prevented OEA’s behavioural and neurochemical effects in the brainstem and the HYPO. 
Moreover OEA increased DBH expression in AP and NST neurons of SHAM rats while 
the effect in the NST was absent in APX rats, thus suggesting the possible involvement 
of noradrenergic AP neurons. These results support the hypothesis of a necessary role of 
the AP in mediating OEA’s central effects that sustain its pro-satiety action. 
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2.1.  Introduction  
The central nervous system (CNS) and the gastrointestinal tract are constantly in 
reciprocal communication, through the so-called “gut-brain axis”, a bidirectional system 
that involves neuronal, hormonal and immunological signals 1. Many of these signals play 
a role in the control of energy homeostasis, such as leptin, cholecystokinin 
(CCK), glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), which have been the 
best characterized 2,3. Among these “gut-derived signals” a great deal of attention has also 
been dedicated to oleoylethanolamide (OEA), an endogenous lipid generated in the 
intestine upon the ingestion of fat 4,5. OEA is structurally analogous to 
the endocannabinoid anandamide, although it does not show any affinity for the 
cannabinoid receptors, nor does it induce cannabinomimetic effects 6. Most of the 
consideration for OEA’s biological roles and mechanism of action derived from its 
potential interest as a novel pharmacological target for the treatment of obesity and eating 
disorders 5,7. In fact, as a drug, OEA reduces food intake and body weight gain in both 
lean and obese rodents 6,8-18, effects that appeared behaviourally selective: not linked to 
anxiety-like symptoms, visceral malaise, alterations in plasma corticosterone, changes of 
body temperature, pain threshold, or of glucose, leptin and insulin plasma levels 6. 
There is accumulating evidence showing that the OEA-induced satiety state 19,20 is 
mediated by the activation of the peroxisome proliferator-activated-receptor-alpha 
(PPAR-α) 21.  
This observation is supported by several findings: 1) in vitro experiments of saturation 
binding showed that OEA binds to the “ligand-binding domain” of PPAR-α receptor with 
a high affinity with a Kd of approximately 40 nM, and stimulates its transcriptional 
activity with a median effective concentration (EC50) of about 120 nM 21,22; 2) OEA’s 
pro-satiety effects are completely prevented in mice lacking a functional PPAR-α gene 
that still respond to other anorexic agents 21,22; 3) GW7647 and Wy-14643, two synthetic 
PPAR-α agonists, mimic OEA-induced food intake suppression 21,23; 4) feeding evokes 
an increase of OEA concentration in the intestinal mucosa to levels (300 nM) that are 
sufficient to fully activate PPAR-α 24,25. 
It has been previously demonstrated that the hypophagic effect evoked by systemic OEA 
administration is associated to the engagement of selected brain areas involved in the 
control of food intake, such as the nucleus of the solitary tract (NST) and the 
hypothalamic tuberomamillary (TMN), paraventricular (PVN) and supraoptic nuclei 
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(SON) 5, where noradrenergic, histaminergic and oxytocinergic neurons play a necessary 
role 5.  
OEA’s mechanism of action might also involve the activation of vagal fibres, as 
suggested by the observation that its effect after intraperitoneal (i.p.) administration is 
blunted in rats subjected to a complete subdiaphragmatic vagotomy or to a pre-treatment 
with a neurotoxic dose of capsaicin, which destroys vagal and non-vagal unmyelinated 
afferent nerve fibres 6,21,26. These observations, together with the finding that OEA does 
not reduce food intake when administered by intracerebroventricular (i.c.v.) infusion in 
rats 6, suggests that its mechanism of action could be peripheral rather than central and 
that the activation of both brainstem and hypothalamic areas might be indirectly mediated 
by ascending fibres. However, we recently showed that OEA does not require intact 
intestinal vagal afferents to reduce food intake 18, as observed in rats that underwent a 
selective subdiaphragmatic vagal deafferentiation (SDA), a surgery that removes all 
abdominal vagal afferents, but sparing approximately half of the efferents 27,28. These 
findings did not seem to support the hypothesis of a strictly peripheral mechanism and 
suggest that the blockade of OEA’s effects by total subdiaphragmatic vagotomy may be 
due to the absence of efferent rather than afferent innervation. 
Whether OEA signal can directly or indirectly reach the brain remained to be fully 
elucidated. Although systemically or orally administered OEA quickly reaches the blood 
stream 19,20, indirect evidence suggests that it does not readily permeate the whole CNS, 
presumably owing to the high expression of its degrading enzyme, fatty 
acid amide hydrolase (FAAH), in the blood brain barrier (BBB) 29. However, these 
findings do not necessarily exclude a possible action mediated by the circumventricular 
organs such as the area postrema (AP) in the brainstem. In fact, we recently reported that 
peripheral OEA induces a significant activation of AP neurons and in the subpostremal 
nucleus of the NST, as suggested by the increased transcription of c-fos in these areas 12. 
The AP lacks a functional BBB by virtue of its lack of tight junctions and the presence of 
fenestrated capillaries, therefore circulating peptides and other peripheral signals can gain 
direct access to neurons of the AP. On the basis of these observations, we hypothesized 
that OEA may exert its central effects through the activation of the AP. 
To test this hypothesis, we subjected rats to a surgical lesion of the AP (APX) and 
evaluated the effects of i.p. OEA administration (10 mg kg−1) on food intake, on Fos 
expression, on oxytocin (OXY) immunoreactivity at both PVN and neurohypophysial 
level and on the expression of dopamine beta hydroxylase (DBH) within the brainstem 
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and PVN. Further, we aimed to assess the phenotype of neuronal populations activated 
by OEA in the brainstem of SHAM-lesioned and APX rats; to this aim, we assessed, also, 
whether OEA induced Fos expression co-localized with DBH as marker for noradrenergic 
neurons. Finally, as last step of our study, we investigated PPAR-α expression within the 
AP. 
2.2. Materials and methods  
2.2.1.  Animals and housing  
Forty-one male Wistar rats (Charles River, Sulzfeld, Germany) were used in this study. 
In particular, forty rats underwent AP lesion or SHAM surgery, while one drug-naïve rat 
was used to assess PPAR-α expression within the AP. All animals, weighing 200–250 g 
upon arrival, were individually housed in acrylic cages under a 12:12 dark-light cycle in 
a climate-controlled room (22 ± 2 °C and 60% relative humidity). All rats were fed with 
standard chow pellets (N 3430, Provimi KIiba, Gossau, Switzerland) ad libitum, unless 
otherwise stated. All experiments were performed upon the approval of the Veterinary 
Office of the Canton of Zurich and according to the European Community directives 
2010/63/EU. The experimental timeline is depicted in Fig. 2.1A. 
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Fig. 2.1: Experimental timeline and AP surgical ablation.  
Panel A: Male Wistar rats were subjected to the surgical ablation of the area postrema (APX rats) or to a 
sham operation (SHAM rats); after a post-surgery recovery period of 2 weeks rats underwent a functional 
test to verify the lesion. Both APX and SHAM rats were administered with saline or salmon calcitonin 
(sCT, 5 μg kg−1, i.p.) and cumulative 2-h food intake was monitored. After 2 intervening days for drug 
washout all animals underwent the behavioural test: they received an i.p. injection of either vehicle (VEH) 
or OEA (10 mg kg−1) at dark onset, and food intake was measured within 24 h. After 2 days for washout, 
rats were treated again in a cross-over design with either VEH or OEA (10 mg kg−1); food intake was 
monitored for 2 h and at the end all animals were euthanized with an overdose of pentobarbital sodium and 
were subjected to transcardial perfusion. Fixed brains were collected and stored. 
Panel B: Representative photomicrographs (scale bar = 500 μm) showing Nissl staining of coronal 
hindbrain sections obtained from the brain of SHAM-operated rats (left panel) and APX rats (right panel). 
The superimposed diagrams show the different subnuclei of the nucleus of solitary tract, such as 
commisural part (SolC), medial part (SolM), dorsomedial part (SolDM) and ventrolateral part (SolVL), and 
also the dorsal motor nucleus of the vagus (DMV) and the central canal (CC). 
 
2.2.2.  Area postrema lesion surgery 
Rats were anesthetized using a mixture of ketamine (50 mg kg−1; Narketan, Vetoquinol 
AG, Ittingen, Switzerland), xylazine (2.5 mg kg−1, Xylazin; Streuli Pharma AG, Uznach, 
Switzerland) and acepromazine (0.75 mg kg−1, Prequillan; Arovet AG, Dietikon, 
Switzerland) and placed on a stereotaxic apparatus to be subjected to either APX (N = 
20) or SHAM (N = 20) surgery. To this aim, the head of each rat was flexed ventrally at 
an approximate 110° angle in a stereotaxic frame. Skin and three layers of neck 
musculature were cut and retracted for visualization of the foramen magnum. Under 
visual control with a surgical microscope, the cranial dura mater was penetrated and the 
cerebrospinal fluid was blotted. In the APX procedure, AP lesions were performed by 
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aspirating the AP with a blunted cannula tip fixed to a flexible tube attached to a vacuum 
pump 30,31. In SHAM-operated rats, the AP was exposed but not touched. Rats were given 
2 weeks to recover from surgery, receiving post-operative care 32, and were habituated to 
i.p. injections of saline. One rat subjected to APX died during the recovery period. 
As reported in previous studies 32,33, during the course of our experiment it became 
evident that APX rats were not hyperphagic and they did not gain more weight as 
compared to SHAM rats. Conversely, after surgery their weight gain was lower than 
SHAM operated rats and, on the test day, the body weight of APX rats was significantly 
(P < 0.001) lower than SHAM rats (SHAM rats: 363.8 g ± 5.65 g, APX rats; 265.1 g ± 
8.74 g). Nevertheless, if normalized to body weight (g kg−1), the daily consumption of 
food intake was similar between the two groups (data not shown). 
Success and specificity of the AP lesion was verified both functionally and histologically 
30,31,34,35. In particular, the functional verification was based on the lack of the 
anorexigenic effects of peripheral salmon calcitonin (sCT, 5 μg kg−1, i.p.), which requires 
an intact AP to inhibit food intake in rodents 32. 24 h before the functional test, SHAM 
and APX rats were administered with saline at dark onset and their 2-h food intake was 
recorded as amount of food eaten. On the functional test day, at dark onset, rats received 
sCT (5 μg kg−1, i.p.) and 2h-food intake was recorded. SHAM rats displayed a food intake 
reduction of minus 19.59 ± 6.79% after sCT compared to saline; most APX rats (14 out 
of 19 rats) showed no decrease of food intake after sCT compared to saline; in fact APX 
rats treated with sCT consumed 4.35 ± 0.73 g of food, while APX rats administered with 
saline consumed 3.25 ± 0.58 g, with no statistical difference between the two groups. Five 
of 19 APX animals displayed a significant 2-h food intake reduction (minus 79.15 ± 
7.71%) after sCT administration compared to saline, therefore they were suspected to be 
not properly lesioned. This was then confirmed by the histological verification performed 
in all animals at the end of the terminal experiment by an experimenter blind to the type 
of surgery, who evaluated the extent of AP lesion on Nissl-stained brain slices (Fig. 2.1B). 
Therefore, only data from 14 of 19 APX animals were analyzed, and data from 5 of 19 
APX animals were excluded from all further analyses. 
2.2.3.  Drugs and treatments 
OEA was administered (10 mg kg−1) by i.p. injections in a solution (2 ml kg−1) of 
saline/polyethylene glycol/Tween 80 (90/5/5, v/v/v). Control animals received the 
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injection of vehicle (VEH). Both VEH and OEA solutions were freshly prepared on each 
test day and administered about 10 minutes (min) before dark onset. 
2.2.4.  Food intake experiment 
On the day of the feeding experiment, the chow pellets were temporarily removed for 1 
hour (h) before the beginning of the dark phase and all animals were treated 10 min before 
dark onset. Pre-weighted standard chow pellets were returned at dark onset and food 
intake was measured manually using a digital scale at 5 different time-points (0.5, 1, 2, 
20, and 24 h) as the difference between the amount of food given after treatment and the 
food remaining after food access, with correction for spillage. To minimize the number 
of animals used in the study, the feeding experiment was carried out on two different days 
with two intervening days between trials, by using a cross-over design. In particular, VEH 
and OEA were administered in a randomized, latin square design, so that each animal 
within the APX and SHAM group was examined under both treatment conditions. The 
timing schedule, the dosage of OEA, and the route of administration were chosen 
according to our previous studies 11,14. 
2.2.5.  Terminal experiment 
On the day of the second behavioural test, rats were euthanized after 2 h from dark onset, 
by transcardial perfusion. The animals were deeply anesthetized with pentobarbital 
sodium (80 mg kg−1; Kantonsapotheke, Zurich, Switzerland) and transcardially perfused 
with ice-cold phosphate buffer saline (0.1 M PBS, pH 7.4), followed by fixative solution 
containing 4% paraformaldehyde. Fixed brains and pituitary glands were collected, 
postfixed overnight, cryoprotected in 20% sucrose-phosphate buffer (for 48 h at 4 °C), 
and then snap frozen in dry-ice-cold 2-methylbutane (−60 °C), to be stored at −80 °C until 
processing. All the brains and the pituitary glands were processed in the 
immunohistochemistry study, so that the immunohistochemical analyses were performed 
in the same rats that were used for the behavioural experiment. Moreover, the drug-naïve 
rat was sacrificed by decapitation and the brain was collected and processed for PPAR-α 
immunohistochemistry. 
2.2.6.  Immunohistochemistry study 
Brains were cut on a cryostat (model HM550; Thermo Fisher Scientific, Kalamazoo, MI, 
USA) into five series of 20-μm coronal sections containing hypothalamic and brainstem 
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structures, and mounted on positively charged microscope slides (SuperFrost Plus, 
Menzel, Germany) and stored at −20 °C. 
- Fos fluorescent immunostaining 
Fos immunostaining was performed on brain section series containing AP, NST, PVN, 
and TMN. We adapted the protocol for antigen retrieval described by Shi and 
collaborators 36 by submerging brain sections in a sodium citrate buffer (10 mM pH 6.0) 
heated at 95 °C for 5 min. Sections were then rinsed with PBS (0.1 M pH 7.4) and 
incubated for 30 min in a solution containing 0.3% Triton X-100 (Sigma–Aldrich) and 
10% of Normal Goat Serum (Jackson Immunoresearch, Baltimore Pike, Pennsylvania). 
After additional washes, sections were incubated with a solution containing the primary 
antibody (rabbit anti-Fos polyclonal primary antibody, 1:500 dilution, Santa Cruz 
California) overnight at 4 °C. Sections were then incubated with an anti-rabbit Alexa 
Fluor 594 secondary antibody (1:300 dilution; Invitrogen) for 90 min at room temperature 
in the presence of Hoechst 33258 (1:5000 dilution; Sigma–Aldrich), used to detect cell 
nuclei. After final washes slides were cover-slipped with fluoromount (eBioscience). 
- Fos and DBH double fluorescent immunostaining 
A second series of sections containing AP and NST was double-stained for Fos and DBH 
to assess their co-expression within these brainstem structures. Sections were rinsed with 
PBS and incubated for 1 h in a solution containing 5% Triton X-100 (Sigma-Aldrich) and 
2% of Normal Goat Serum (Jackson Immunoresearch) in PBS. Sections were then 
incubated with mouse anti-DBH monoclonal primary antibody (1:500 dilution, MAB308, 
Millipore) for 2 overnights at 4 °C. After 1 overnight incubation at room temperature with 
goat anti-mouse Alexa Fluor 488 secondary antibody (1:250 dilution, Invitrogen), 
sections were subjected to the Fos immunostaining procedure following the protocol 
described in the previous paragraph. 
- DBH and OXY chromogenic immunostaining 
One series containing AP/NST, two series of PVN sections and a series of sagittal sections 
of the pituitary gland (15 μm thick) were used for DBH or OXY immunostaining using 
the 3,3′-diaminobenzidine (DAB)-H2O2-horseradish peroxidase detection method, 
following the procedure described in our previous work 14,37. Briefly, sections were 
rehydrated in PBS (pH 7.4) and then incubated for 2 h in a solution containing 2% BSA 
(Sigma Aldrich) in 5% Triton X-100, followed by incubation with the respective primary 
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antibodies (mouse anti-DBH monoclonal primary antibody 1:500 in BSA/PBST, 
Millipore or mouse anti-OXY monoclonal primary antibody 1:10000 dilution, MAB 
5296, Millipore) at 4 °C. Sections were then incubated with the respective secondary 
antibodies (Donkey anti-mouse biotinylated secondary antibody; Jackson 
Immunoresearch, 1:200, for DBH staining, and 1:500, for OXY staining) in 5% PBST 
overnight at room temperature. After incubation for 1 h with the ABC Kit (Vectastain 
ABC kit; Vector Laboratories), sections were stained by incubation in DAB (Vector 
Laboratories) chromogen solution. The slides were then rinsed with PBS, dehydrated in 
graded alcohol, immersed in xylene and cover-slipped with Eukitt (Sigma–Aldrich). 
- PPAR- α fluorescent immunostaining 
PPAR-α immunostaining was performed on brain sections containing the AP of a drug-
naïve rat, to investigate qualitatively the expression of PPAR-α within the AP. Briefly, 
sections were rinsed with PBS (0.1 M pH 7.4) and incubated for 1 h in a solution 
containing 0.3% Triton X-100 (Sigma–Aldrich) and 5% of BSA (Sigma Aldrich) at 37 
°C. After additional washes, sections were incubated with a solution containing the 
primary antibody (rabbit anti-PPAR-α polyclonal primary antibody, 1:200 dilution, 
Abcam ab8934) overnight at 4 °C. Sections were then incubated with an anti-rabbit Alexa 
Fluor 594 secondary antibody (1:300 dilution; Invitrogen) for 90 min at room temperature 
in the presence of Hoechst 33258 (1:5000 dilution; Sigma–Aldrich), used to detect cell 
nuclei. After final washes, slides were cover-slipped with fluoromount (eBioscience). 
Moreover, to control for the staining specificity, an additional series of slices containing 
the AP, underwent the same protocol procedure except for the incubation with the primary 
antibody. 
2.2.7.  Brain section analyses 
All brain and pituitary sections obtained from SHAM and APX animals included in the 
analyses were observed under a Nikon Eclipse 80i microscope equipped with a color 
charge-coupled device camera and controlled by the software NIS-Elements-BR (Nikon). 
Slices were photographed under epifluorescent conditions or in light field, where 
appropriate. The rat brain atlas by Paxinos and Watson 38 was used as reference for the 
localization of the brain areas of interest. Moreover, following the criteria already used 
in our previous work 12 we referred to the following subdivision of the NST subnuclei: 
commisural part (SolC), medial part (SolM), dorsomedial part (SolDM), ventrolateral 
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part (SolVL) (Fig. 2.1 B). The analyses of Fos positive cells were conducted manually by 
counting each Fos positive cell of the NST, PVN and TMN. Moreover, to assess Fos and 
DBH co-expression in AP and SolM, the percentage of DBH-positive cells within Fos 
−positive neurons was determined by counting also the number of double-stained cells. 
DBH and OXY DAB-immunostaining were measured semi-quantitatively as optical 
density (OD) by using the Scion Image software and considering, for background 
normalization, the averaged OD either of non-immunoreactive regions or of white matter 
structures within the same brain slice. The investigator was blind to animal treatment; 
measurements were obtained in at least three consecutive tissues sections per animal 
containing the desired structure. Finally, AP-containing slices, which were 
immunostained for PPAR- α, were photographed under a FV1000 confocal microscope 
(Olympus, Tokyo, Japan), using a PlanApo (Olympus) objective 60× oil A.N. 1.42. 
Excitation light was obtained by a Laser Dapi 408 nm for Hoechst detection and a Diode 
Laser HeNe (561 nm) for Alexa 597. Hoechst emission was recorded from 415 to 485 
nm, Alexa 555 emission was recorded from 583 to 628 nm. 
2.2.8.  Statistical analyses 
Feeding data were statistically analyzed by two-way ANOVA for repeated measures, with 
“time” and “treatment” as the two factors, followed by Bonferroni’s post hoc test for 
multiple comparisons (IBM SPSS, version 22, IBM Analytics). Immunohistochemical 
data were statistically analyzed by two-way ANOVA, with “surgery” and “treatment” as 
the two factors. Tukey’s test was used as a post hoc test to perform multiple comparisons. 
Moreover, because of the difference in the number of slides examined and the high degree 
of freedom, the error degrees of freedom were kept constant at a value based on the actual 
number of animals per group used in each experiment. In all instances, the threshold for 
statistical significance was set at P < 0.05. Data obtained from rats that were not properly 
lesioned were excluded from the analyses.  
2.3. Results  
2.3.1.  APX prevents the hypophagic effect of OEA
We hypothesized that AP neurons are activated by and are necessary for peripherally 
administered OEA to reduce eating. Therefore, our first aim was to evaluate whether the 
surgical lesion of the AP would prevent OEA’s pro-satiety action. We followed the same 
76 
 
protocol used in our previous studies 11,12,14, according to which OEA was administered 
i.p. to rats few minutes before dark onset and at a dosage (10 mg kg−1) that does not 
readily allow penetration into the brain but is able to inhibit food intake in free-feeding 
animals 11,12,14. Cumulative food intake was monitored at 0.5, 1, 2, 20 and 24 h after dark 
onset. The experimental timeline is depicted in Fig. 2.1A and representative 
photomicrographs showing Nissl staining of coronal hindbrain sections obtained from the 
brains of SHAM-operated and APX rats are reported in Fig. 2.1B. The two-way ANOVA 
analyses for repeated measures of the cumulative food intake of SHAM rats showed a 
significant effect of treatment (Ftreatment = 18.598 df = 1/8, P < 0.01), a significant effect 
of time (Ftime = 1805.834, df = 4/32, P < 0.001) and no interaction between treatment and 
time (Finteraction = 1.556, df = 4/32, P = 0.238). Consistently with our previous observations 
5, post hoc analyses revealed that the systemic administration of OEA markedly reduced 
food intake in SHAM-operated rats at all the time points considered, i.e. without inducing 
compensatory hyperphagia in response to the early reduction in eating (0.5 h: P < 0.05; 1 
h and 2 h; P < 0.001; 20 h; P < 0.01 24 h: P < 0.05; Fig. 2.2, left panel).The two-way 
ANOVA for repeated measures of the cumulative food intake of APX groups showed no 
effect of treatment (Ftreatment = 0.041 df = 1/5, P = 0.847), a significant effect of time (Ftime 
= 43.078, df = 4/20, P < 0.001) and no interaction between treatment and time (Finteraction 
= 0.222, df = 4/20, P = 0.709). Hence, as we hypothesized, the AP lesion completely 
prevented OEA’s hypophagic effect, since post hoc analyses revealed that APX rats 
consumed similar amounts of food, regardless of the acute treatment with VEH or OEA 
(Fig. 2.2, right panel). 
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Fig. 2.2. The surgical ablation of the AP prevents OEA’s hypophagic action. 
Time course of cumulative food intake (normalized to body weight, g kg−1) at different time-points (0.5, 1, 
2, 20 and 24 h) after vehicle (VEH) or OEA (10 mg kg−1, i.p.) administration to SHAM (left panel N = 20) 
and APX rats (right panel N = 14–15). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 
0.001 vs VEH in the same surgery group (Bonferroni’s test). 
 
2.3.2.  OEA induces Fos in DBH neurons of the AP 
Previous studies demonstrated that OEA’s effect on food intake is paralleled by a 
selective induction of c-fos in specific brain areas 5; these areas include the AP 12. We 
now confirmed this observation by counting Fos-positive neurons in the AP of selected 
slices obtained from the brain of SHAM rats (Fig. 2.3A). The number of Fos-positive 
cells in the AP of SHAM rats treated with OEA was about 2.5 fold higher than in SHAM 
rats treated with VEH (P < 0.001, Fig. 2.3B). Moreover, in our previous study 14, we 
demonstrated that noradrenergic brainstem-HYPO projections are crucially involved in 
the activation of the OXY system in the PVN, which, in turn, mediates OEA's pro-satiety 
action. Therefore, the second aim of our study was to evaluate the effect of peripheral 
administration of OEA on DBH immunoreactivity of the AP. Double 
immunohistochemical experiments revealed that OEA-induced Fos expression occurred 
in DBH-expressing neurons (Fig. 2.3C). In particular, we found that OEA increased (by 
almost three-fold) the percentage of neurons co-expressing Fos and DBH within the AP 
(P < 0.05, Fig. 2.3D). Other neuronal populations activated by OEA administration in the 
AP were not identified in the present study. The semiquantitative densitometric analyses 
of DBH-immunostaining of the AP (Fig. 2.4A) showed that OEA treatment also 
significantly increased DBH expression in the AP of SHAM rats (P < 0.05, Fig. 2.4B). 
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Fig. 2.3. OEA treatment increases Fos immunoreactivity and induces Fos expression in DBH-
expressing neurons in the AP of SHAM rats.  
Representative fluorescent photomicrographs (scale bar = 100 µm) showing Fos 
immunostaining/Hoechst (red/blue, panel A) and Fos/dopamine beta hydroxylase (DBH) (red/green, 
panel C) double-immunostaining of the area postrema (AP) in brain slices collected from SHAM rats 
treated with either vehicle (VEH) or OEA (10 mg kg−1, i.p.) and sacrificed 2 h after treatment. Number 
of Fos positive cells (panel B) and percentage of cells co-expressing Fos and DBH (panel D) within the 
AP of SHAM rats treated with either VEH or OEA (10 mg kg −1, i.p.) and sacrificed 2 h after treatment. 
Data are expressed as mean ± SEM. *P < 0.05; ***P < 0.001 vs VEH in the same surgery group 
(Unpaired student t-test; N = 3). 
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2.3.3.  APX prevents OEA-induced DBH and Fos expression in the NST 
Neurons from the AP project, among others, to neurons of  the NST, which, in turn, 
project extensively to other key regions involved in the control of food intake, such as the 
HYPO, the amygdala, and the nucleus accumbens 39–44. Therefore, we hypothesized that 
DBH-positive neurons of the AP activated by OEA might, in turn, activate neurons of the 
NST. To test this hypothesis, we evaluated whether an AP lesion prevents the effects of 
OEA on DBH and Fos expression in the different subnuclei of the NST. From the 
semiquantitative densitometric analyses of DBH immunostaining (Fig. 2.4 panels C–F), 
we found that the signal was different among the different NST subnuclei, with the 
highest immunoreactivity observed in the SolM (Fig. 2.4D). Moreover, OEA treatment 
significantly increased DBH expression in most NST subnuclei of SHAM rats, while the 
AP lesion prevented such increase, without affecting per se DBH immunostaining in 
VEH-treated rats (Fig. 2.4 panels C–E). The DBH immunostaining of the SolVL of 
SHAM rats was unaffected by OEA treatment (Fig. 2.4F). Similar results were obtained 
by counting the number of Fos- positive cells in the different NST subnuclei (Fig. 2.5 
panels A–D), with the highest number being found in the SolM (Fig. 2.5B). Moreover, 
the number of Fos-positive cells was increased in all NST subnuclei of SHAM rats treated 
with OEA, as compared to SHAM rats treated with VEH. Such increase was completely 
prevented by the AP lesion (Fig. 2.5 panels A–D). The lesion per se did not affect the 
baseline number of Fos-positive cells, so that APX-VEH rats did not differ from SHAM-
VEH rats. The results from the two-way ANOVA analyses conducted for each of the 
brain areas and for both DBH and Fos expression levels are reported in Table 2.1; the 
results from the post-hoc analyses are reported in Fig. 2.4 and 2.5, respectively. Double 
immunohistochemical experiments revealed that at the level of SolM, OEA-induced Fos 
expression in SHAM rats included DBH-expressing neurons (Fig. 2.5E).The two way 
ANOVA of the percentage of neurons co-expressing Fos and DBH in this area, calculated 
with respect to the total number of neurons showing Fos immunolabeling (Fig. 2.5F), 
revealed significant effects of treatment, surgery, and their interaction (Ftreatment = 50.646, 
df = 1/11, P < 0.001; Fsurgery = 49.611, df = 1/11, P < 0.001; Finteraction = 51.121, df = 1/11, 
P < 0.001). The post hoc analysis demonstrated that OEA treatment caused a marked 
increase of Fos-positive neurons expressing DBH only in SHAM rats (P < 0.001 vs their 
VEH-administered controls) but not in APX rats (P = 0.981; Fig. 2.5F). This observation, 
together with the strongest DBH and Fos immunostaining of SolM suggests that this 
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subnucleus might be a putative pathway through which the OEA signal, originating in the 
AP, can reach higher brain centers. Future studies should address this hypothesis.  
 
 
Fig. 2.4. Effects of OEA on DBH expression in the AP and NST of SHAM and APX rats. 
Representative photomicrographs (scale bar = 500 µm, panel A) showing dopamine beta hydroxylase 
(DBH) immunostaining within the area postrema (AP) and the nucleus of the solitary tract (NST) in brain 
slices collected from SHAM and APX rats treated with either vehicle (VEH) or OEA (10 mg kg −1, i.p.) 
and sacrificed 2 h after treatment. Semiquantitative densitometric analysis of DBH expression within the 
AP (panel B) and the different subnuclei of the NST, such as commisural part (SolC, panel C), medial part 
(SolM, panel D), dorsomedial part (SolDM, panel E) and ventrolateral part (SolVL, panel F), of SHAM 
and APX rats treated with either VEH or OEA (10 mg kg−1, i.p.) and sacrificed 2 h after treatment. Data are 
expressed as mean ± SEM. *P < 0.05; **P < 0.01 vs VEH in the same surgery group; ◦ P < 0.05; ◦◦ P < 
0.01vs SHAM in the same treatment group (AP: unpaired student t-test; N = 4-6; NST: Tukey’s test; 
SHAM: N = 3–6; APX: N = 3–6). 
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Fig. 2.5. The surgical ablation of the AP prevents OEA-induced increase of Fos immunoreactivity in 
the NST and reduces the percentage of cells co-expressing Fos and DBH in the SolM. Number of Fos 
positive cells (panels A-D) in the different subnuclei of the nucleus of solitary tract (NST), such as 
commisural part (SolC, panel A), medial part (SolM, panel B), dorsomedial part (SolDM, panel C) and 
ventrolateral part (SolVL, panel D), and percentage of cells co-expressing Fos and dopamine beta 
hydroxylase (DBH) within the SolM (panel F) in SHAM and APX rats treated with either vehicle (VEH) 
or OEA (10 mg kg−1, i.p.) and sacrificed 2 h after treatment. Data are expressed as mean ± SEM. **P<0.01; 
***P<0.001 vs VEH in the same surgery group; ◦P<0.05; ◦◦P<0.01; ◦◦◦P<0.001 vs SHAM in the same 
treatment group (Tukey’s test; SHAM: N = 3; APX: N = 3–4). Panel E: representative photomicrographs 
(scale bar = 100 µm) of double Fos/DBH immunofluorescent staining (red/green) in brain slices containing 
the SolM, collected from SHAM and APX rats treated with either VEH or OEA (10 mg kg−1, i.p.) and 
sacrificed 2 h after treatment. 
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Table 2.1. Results of the two-way ANOVA analyses of Fos and DBH expression observed in the NST 
subnuclei of both SHAM and APX rats after intraperitoneal injection of OEA or vehicle 
 
  Ftreatment Fsurgery Finteraction df 
Fos 
SolC 5.882 (P < 0.05) 0.487 (P = 0.498) 5.045 (P < 0.05) 1/12 
SolM 17.582 (P < 0.01) 8 (P < 0.05) 19.392 (P < 0.001) 1/12 
SolDM 13.140 (P < 0.01) 1.392 (P = 0.260) 10.105 (P < 0.01) 1/12 
SolVL 14.992 (P < 0.01) 0.429 (P = 0.524) 17.856 (P < 0.01) 1/12 
DBH 
SolC 5.102 (P < 0.05) 6.408 (P < 0.05) 0.779 (P = 0.389) 1/18 
SolM 3.691 (P = 0.071) 7.371 (P < 0.05) 0.995 (P = 0.332) 1/17 
SolDM 5.067 (P < 0.05) 0.429 (P = 0.520) 3.947 (P = 0.06) 1/19 
SolVL 0.478 (P = 0.498) 0.319 (P = 0.579) 0.546 (P = 0.469) 1/18 
 
SolC (Nucleus of Solitary Tract Commissural part), SolM (Nucleus of Solitary Tract Medial part), SolDM 
(Nucleus of Solitary Tract Dorsomedial part), SolVL (Nucleus of Solitary Tract Ventrolateral part. 
 
2.3.4.  APX prevents OEA induced Fos in the PVN and TMN 
Our previous work demonstrated that two hypothalamic regions, namely TMN and PVN, 
participate in OEA’s effect on eating 11,45, showing an increase of Fos expression. 
Therefore, in the present work we evaluated whether this effect could be prevented by the 
surgical lesion of the AP (Fig. 2.6A, B). By counting Fos-positive neurons in the PVN 
(Fig. 2.6C) and analyzing the results by two-way ANOVA, we obtained a significant 
effect of treatment (Ftreatment = 12.787, df = 1/12, P < 0.01), of surgery (Fsurgery = 8.443 df 
= 1/12, P < 0.05) and a significant interaction between the two factors (Finteraction = 5.365 
df = 1/12, P < 0.05). The results from the two-way ANOVA of the TMN data sets (Fig. 
2.6D) revealed significant effects of treatment and surgery, while there was no significant 
interaction between the two factors (Ftreatment = 9.998 df = 1/12, P < 0.01; Fsurgery = 7.036 
df = 1/12, P < 0.05; Finteraction = 1.586 df = 1/12, P = 0.231). 
The results from the test for multiple comparisons showed that, in keeping with our 
previous observations 11,45, OEA treatment significantly induced Fos expression in the 
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PVN and TMN of SHAM- operated rats (P < 0.001 and P < 0.01, respectively) but did 
not exert any effect in both areas of APX rats, thus suggesting that the AP might play a 
necessary role for the activation of PVN and TMN induced by OEA. The AP lesion, also 
in this case, did not affect per se the number of Fos-positive neurons at baseline (i.e. in 
the APX- VEH group versus the SHAM-VEH group) either in the PVN or in the TMN 
(Fig. 2.6C, D). 
 
Fig. 2.6. The surgical ablation of the AP prevents the increase of Fos immunoreactivity induced by 
OEA in the PVN and TMN of the HYPO. 
Representative photomicrographs (scale bar = 300 µm) showing Fos immunofluorescent staining of brain 
slices containing the paraventricular (PVN, panel A) and the tuberomamillary (TMN, panel B) nuclei 
collected from SHAM and APX rats treated with either vehicle (VEH) or OEA (10 mg kg−1, i.p.) and 
sacrificed 2 h after treatment. 
Number of Fos positive cells in the PVN (panel C) and TMN (panel D) in SHAM and APX rats treated 
with either VEH or OEA (10 mg kg −1, i.p.) and sacrificed 2 h after treatment. Data are expressed as mean 
± SEM. **P < 0.01; ***P < 0.001 vs VEH in the same surgery group; ◦ P < 0.05; ◦◦◦ P < 0.001 vs SHAM 
in the same treatment group (Tukey’s test; PVN, SHAM: N = 3; APX: N = 3–4. TMN, SHAM: N = 3–4; 
APX: N = 3). 
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2.3.5.  APX prevents OEA-induced DBH and OXY expression in the PVN 
OXY neurons of the PVN receive a direct excitatory input arising from the A2 
noradrenergic cell group in the NST 46. We previously demonstrated that these 
noradrenergic projections mediate OEA’s effects on eating and on hypothalamic OXY 
transmission 14. Therefore, the next step of the present work was to evaluate whether the 
surgical lesion of the AP prevented the effects of OEA on OXY and DBH expression in 
the PVN (Fig. 2.7A, B). Both OXY and DBH immunostaining were semiquantitatively 
evaluated by optical densitometry and data are reported in Fig. 2.7, panels C–D. The 
results obtained from the two-way ANOVA of OXY OD revealed a significant effect of 
the treatment (Ftreatment = 4.531 df = 1/28, P < 0.05), a significant interaction between 
surgery and treatment (Finteraction = 19.584 df = 1/28, P < 0.001) and no effect of the surgery 
(Fsurgery = 1.927 df = 1/28, P = 0.176). A significant interaction between the surgery and 
treatment was also found by analyzing the OD of DBH staining (Finteraction = 10.907 df = 
1/26, P < 0.01), while no significant effect was found either for the treatment (Ftreatment = 
0.098 df = 1/26, P = 0.756) or for the surgery (Fsurgery = 0.139 df = 1/26, P = 0.712). 
Post hoc analyses revealed that OEA treatment significantly increased the expression of 
both OXY and DBH within the PVN in SHAM rats (Fig. 2.7C, D; P < 0.001 and P < 0.05 
respectively). The AP lesion completely prevented such increases without per se altering 
the baseline levels found in VEH-treated rats. 
Finally, we investigated whether the AP lesion would prevent the effects of OEA on OXY 
immunoreactivity of the posterior pituitary gland (Fig. 2.7E) 11,14. The results of the two-
way ANOVA of the OD measured in the pituitary glands immunostained for OXY 
revealed a significant effect of treatment (Ftreatment = 11.013, df = 1/22, P < 0.01) a 
significant effect of the surgery (Fsurgery = 5.033, df = 1/22, P < 0.05) and a significant 
interaction between the two factors (Finteraction = 12.301, df = 1/22, P = 0.01). The post hoc 
test for multiple comparisons demonstrated that OEA caused a significant increase of 
OXY immunostaining in the posterior pituitary gland of SHAM rats (Fig. 2.7F, P < 0.001 
vs their VEH-administered controls) and that the AP lesion completely prevented such 
increase without per se altering the baseline OXY expression found in VEH-treated rats. 
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Fig. 2.7. The surgical ablation of the AP prevents the increase of OXY immunoreactivity induced by 
OEA at PVN and pituitary gland level and inhibits DBH immunoreactivity induced by OEA in the 
PVN. Representative photomicrographs of oxytocin (OXY, panel A) and dopamine beta hydroxylase 
(DBH, panel B) immunostaining (scale bar = 300 µm) of brain slices containing the paraventricular nucleus 
(PVN), collected from SHAM and APX rats treated with either vehicle (VEH) or OEA (10 mg kg−1, i.p.) 
and sacrificed 2 h after treatment. Semiquantitative densitometric analysis of OXY (panel C) and DBH 
(panel D) immunostaining within the PVN of SHAM and APX rats treated with either VEH or OEA (10 
mg kg−1, i.p.). Data are expressed as mean ± SEM. *P < 0.05; ***P < 0.001 vs VEH in the same surgery 
group; ◦◦ P < 0.01; ◦◦◦ P < 0.001 vs SHAM in the same treatment group (Tukey’s test; OXY, SHAM: N = 
8–10; APX: N = 5–6. DBH, SHAM: N = 8–9; APX: N = 4–6). Representative photomicrographs (scale bar 
= 500 µm, panel E) and semiquantitative densitometric analysis (panel F) of OXY immunostaining of 
slices containing the posterior pituitary gland collected from SHAM and APX rats treated with either VEH 
or OEA (10 mg kg−1, i.p.) and sacrificed 2 h after treatment. Data are expressed as mean ± SEM. ***P < 
0.001 vs VEH in the same surgery group; ◦◦◦ P < 0.001 vs SHAM in the same treatment group (Tukey’s 
test; SHAM: N = 3–9; APX: N = 4-7). 
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2.3.6.  PPAR-α receptors are expressed at AP level 
Finally, we qualitatively investigated the expression of PPAR-α within the AP. Our 
results show for the first time that a large number of PPAR-α −immunoreactive cells are 
present in the AP (Fig. 2.8A). The specificity of the immunostaining was assessed by the 
absence of signal in control brain sections containing the AP that underwent the same 
protocol procedure except for the incubation with the primary antibody (Fig. 2.8B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.8. PPAR-α expression in the AP. 
Representative fluorescent photomicrographs (scale bar = 50 µm) showing PPAR-α 
immunostaining/Hoechst (red/blue) of the area postrema (AP, panel A) and negative control 
photomicrographs (slices processed without primary antibody) (panel B) in brain slices collected from a 
drug-naïve rat. White arrows in panel A represent PPAR-α −immunoreactive cells of the AP. 
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2.4. Discussion 
The AP is a critical circumventricular organ that conveys information from the periphery 
to the CNS; projections from the AP/NST to the HYPO are involved in the control of 
eating and energy metabolism 47–50. Both physiological and anatomical evidence reveal 
that the AP displays a weak BBB and is located in close contact with the cerebral 
ventricles 51. These properties allow the permeation of blood-born substances, which do 
not readily reach other areas of the brain parenchyma across the BBB 47–50,52. Therefore, 
we hypothesized that the AP might represent a receptive region for circulating OEA and 
that AP neurons might be the first central target of this lipid signal. 
The present study reveals for the first time a necessary role for the AP in mediating the 
anorexigenic effects of peripherally administered OEA. In particular, our results suggest 
that neurons of the AP are a necessary component of the circuit responsible for the 
stimulation of brainstem noradrenergic neurons projecting to the hypothalamic OXY 
system, which, in turn, sustains the inhibitory control of food intake exerted by OEA. The 
evidence supporting these conclusions was collected by comparing the effects induced by 
peripherally administered OEA in rats subjected to a surgical lesion of the AP, which we 
defined as APX rats, and in control rats that were SHAM operated. 
In our previous studies we demonstrated that selected brainstem areas, including the AP 
and different NST subnuclei, respond to systemic OEA administration by increasing the 
transcription of c-fos, an early gene widely used as a marker of cellular activation 6,11,12. 
In accordance with these findings, peripheral OEA administration induced an increase of 
Fos expression in the AP and in all the NST subnuclei analyzed in SHAM rats, an effect 
that was completely absent in APX rats. Moreover, by double immunofluorescence, we 
demonstrated that, within the AP, OEA induced Fos in neurons expressing the 
noradrenaline synthesizing enzyme DBH, whose expression was also increased. A similar 
increase of DBH immunostaining was observed in almost all the NST subnuclei of 
SHAM rats, but it was completely prevented by the surgical ablation of the AP. These 
results are in accordance with our previous findings demonstrating the necessary role 
played by NST-PVN noradrenergic projections in mediating OEA anorexigenic and 
neurochemical effects in vivo 14. 
Anterograde labeling experiments, performed by Van der Kooy and Koida in 1983 51, 
through the injection of wheat germ agglutinin conjugated to horseradish peroxidase into 
the AP, demonstrated that AP neurons are connected with brain structures participating 
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to the transmission of visceral enteroceptive informations, including the NST 51. 
Moreover results obtained by Armstrong and collaborators in 1981 53, from experiments 
of immunocytochemical localization of DBH, suggest the presence of a reciprocal 
noradrenergic connection between the AP and the SolM of the NST 53. Based on these 
previous observations, we hypothesize that the ability of OEA to activate brainstem 
neurons might be the result of a direct activation of noradrenergic neurons located in the 
AP. Moreover, we suggest that the activation of these neurons might be synaptically 
transmitted to noradrenergic neurons of the NST, particularly SolM neurons. This idea is 
raised by the observations that Fos and DBH expression in the NST, which are 
particularly evident in the SolM, were induced by OEA administration to SHAM rats, 
whereas they were completely abolished in APX rats. Moreover, double 
immunofluorescent staining revealed that, within the SolM, OEA induced a five-fold 
increase of Fos expression in DBH- positive neurons and this effect was completely 
prevented by the AP lesion. 
This latter finding is particularly significant for at least two reasons: 1) the SolM is the 
subnucleus of the NST mostly innervated by neurons of the AP 54; 2) A2 noradrenergic 
neurons are mostly prevalent within the SolM 54 and send projections to the PVN and the 
TMN 54, two hypothalamic nuclei involved in the pro-satiety effects of OEA 5. A2 NST-
PVN projections mediate the effects of OEA on oxytocinergic transmission in the HYPO, 
which, in turn, is responsible for the inhibition of food intake, as demonstrated by our 
previous observations in rats subjected to a saporin-mediated lesion of these fibers 14. In 
keeping with these latter results, in the present study AP ablation completely abolished 
the ability of OEA to increase Fos, DBH and OXY expression within the PVN. Moreover, 
OEA increased the OXY immunoreactivity of the pituitary gland of SHAM rats, while 
the AP lesion completely prevented such increase. On the basis of this latter result, we 
hypothesize that the AP lesion prevents OXY accumulation in the neurohypophysis, 
which, in turn, might lead to a decreased OXY release into the blood stream. Finally, 
Provensi and his collaborators 45 demonstrated that OEA recruits also the hypothalamic 
histaminergic system, which, in turn, is able to stimulate oxytocinergic neurons of the 
PVN to mediate OEA anorexiant actions. In our study, the absence of an intact AP 
completely prevented the increase of Fos expression in the TMN of rats treated with OEA 
and this result raises the possibility that secondary noradrenergic neurons from the NST 
could project to OXY neurons of the PVN either directly or indirectly, through the 
activation of histaminergic neurons of the TMN. 
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Altogether, the results from the present study suggest that all the three central pathways 
associated so far to the anorexigenic effects of OEA, namely the brainstem noradrenergic 
and the hypothalamic oxytocinergic and histaminergic systems, require an intact AP, 
which likely acts as a primary site of action of an AP/NST- HYPO circuit, although the 
specific molecular target of OEA at AP level deserves further studies. 
To this regard several lines of evidence support that PPAR-α activation mediates the 
hypophagic effect of OEA 21–25. 
Even though previous findings demonstrated the expression of PPAR-α within most of 
the brain areas included in the present study 55, the scientific literature is still scarce on 
PPAR-α expression in the AP. Preliminary results obtained in the present study after 
PPAR-α  immunostaining in the AP clearly show the expression of this receptor at this 
site. Therefore, we interpret our findings suggesting a direct recruitment of AP neurons 
exerted by OEA, through the activation of PPAR-α, although we cannot exclude the 
interaction with other eating signals acting at this brain structure such as amylin, PYY, 
GLP-1, apolipoprotein A-IV, CCK and adiponectin 11,16,33,40,56. In fact, we might also 
hypothesize that the ablation of the AP could interfere with the activity of these signals 
and therefore blunt OEA’s hypophagic action. However, this hypothesis is not supported 
by previous findings demonstrating that OEA suppresses feeding without altering 
circulating plasma levels of several peripheral signals, including insulin, leptin, ghrelin, 
PYY, and apolipoprotein A-IV, or the brain levels of different neuromodulators, such as 
CCK, vasopressin, and thyrotropin releasing hormone 11,16,56. Of note, the eating 
inhibitory effect of OEA in free feeding animals differs from that of CCK or amylin 
because the latter hormones reduce eating by a meal size effect whereas OEA seems to 
influence mainly the latency to eat 19. Future studies, with siRNA and/or optogenetic gene 
expression manipulation might allow a deeper exploration of this aspect, thus extending 
the current novel findings that pave the way for the understanding of the key role of the 
AP in the central effects of OEA. 
Furthermore, because the AP plays a critical role in the formation of conditioned taste 
aversion (CTA) 57, our results might suggest that the hypophagic response  induced  by  
peripherally  administered OEA could be, at least in part, the manifestation of a CTA that 
can be prevented by the surgical ablation of the AP. However, this hypothesis is confuted 
by previous findings demonstrating that OEA does not induce a CTA after its peripheral 
administration to rats, even at a two-fold higher dose than the ones used in the present 
study 6. In keeping with this conclusion, OEA was also previously found unable to 
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increase stress hormone levels 6 or to induce a conditioned place preference or a 
conditioned place aversion in rodents 58. 
The pivotal role of the AP in mediating the behavioural effect of OEA is also supported 
by our previous observation that OEA reduces feeding in rats subjected to SDA; these 
rats have both an intact and functional brainstem and an intact 50% vagal efferent 
innervation, whereas they lack functional vagal afferent fibers ascending from the small 
intestine 18. We recently demonstrated that these rats still respond to the anorexigenic 
effects of OEA, a result that appears in contrast with pioneering similar studies on 
vagotomised rats or on capsaicine-deafferentiated rats 6,21. In fact, the results of the former 
studies demonstrated that the anorexigenic effects of OEA were blunted in rats subjected 
to a total subdiaphragmatic vagotomy (which also lesions all vagal efferents) or to a pre-
treatment with a neurotoxic dose of capsaicin, which destroys vagal, but also non-vagal 
unmyelinated afferent nerve fibers 6,21. These data, together with the findings that OEA 
was unable to inhibit food intake when injected into the brain ventricles 6, suggested at 
that time the conclusion that its mode of action might involve peripheral, rather than 
central mechanisms. 
This hypothesis was weakened by the opposite findings on SDA rats, although a possible 
explanation for the discrepant findings remained elusive. Because the total vagotomy 
removes both vagal afferents and efferents, the first more simplistic interpretation for the 
opposite results might lay on the possible effects of OEA on gastrointestinal secretory 
and motor functions that could be destroyed in totally vagotomised rats, whereas remain 
intact in SDA rats. Furthermore, in light of the current novel set of information, the 
apparent contradictory findings on SDA vs capsaicine-deafferentiated rats can be 
reconciled by considering that capsaicin treatment exerts neurotoxic effects also on 
neurons of the NST and AP, which receive projections from unmyelinated primary 
sensory neurons destroyed by the capsaicin treatment 59,60 and being left intact by the 
SDA procedure. Last, but not least, why i.c.v. administration of OEA did not inhibit food 
intake remained unexplored. One possible explanation might be based on the high 
expression of the enzyme FAAH found in the rat brain ventricles, in particular at the 
choroid plexus level 29,61,62. This enzyme is responsible for the hydrolysis of N-
acylethanolamides, including OEA. Therefore its high expression in the rat choroid 
plexus probably reduced the cerebral availability of i.c.v. administered OEA, hence 
precluding its accumulation to a critical concentration in the AP to inhibit food intake. 
Interestingly, FAAH levels were reported to be undetectable in both neurons and glia of 
91 
 
the AP 62, thus supporting the conclusions from the current study that circulating OEA 
might reach the neurons of this area, which lack a BBB, and trigger the central cascade 
of effects that inhibit food intake. We previously suggested that OEA might represent a 
novel and safer anti-obesity alternative to cannabinoid receptors antagonists 13 like 
rimonabant, which failed mostly due to its significant central side effects. Although OEA 
shares similar powerful effects on food intake with rimonabant, it presents a different 
impact on feeding behaviour and on the brain circuits involved, thanks to its 
pharmacodynamics properties. In fact, differently to rimonabant, OEA does not block 
cannabinoid receptors and is not accountable for the wide spectrum of unwanted effects 
typically observed with CB1 antagonists/reverse agonists. Conversely, by acting as a 
functional antagonist, OEA might counteract the biological actions of endocannabinoids 
on appetite stimulation and on the control of energy balance. 
2.5. Conclusions 
Although further studies are necessary, the results collected over the last 20 years clearly 
support that OEA might represent a promising candidate for the development of more 
effective anti-obesity therapies. The present findings suggesting the AP as the primary 
central target for this lipid, expand our knowledge on the central mechanism of action of 
OEA in the control of feeding behaviour and might contribute to open novel perspectives 
for the potential clinical use of this compound. 
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oleoylethanolamide and its analogues after acute 
systemic administration in rats 
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Abstract 
The gut-derived satiety signal oleoylethanolamide (OEA), which belongs to the family 
of N-acylethanolamides (NAEs) is a potent activator of the alpha type peroxisome 
proliferator-activated receptor (PPAR-α) and is able to inhibit food intake and control 
lipid metabolism both in rodents and humans. The hypophagic action of OEA has been 
associated to the activation of selected brain areas, particularly in the brainstem and 
hypothalamus, although how OEA signal reaches the brain remained to be fully 
elucidated. Recent findings demonstrated a necessary role of the area postrema (AP), a 
circumventricular organ with a weak blood brain barrier (BBB) and a high density of 
PPAR-α receptors, for i.p. injected OEA to reduce eating, suggesting that this brain area 
could represent a receptive region for circulating OEA. 
Based on these premises, in order to fully elucidate whether systemically administered 
OEA might directly reach and permeate the brain parenchyma through 
circumventricular organs, such as the AP and the median eminence (ME), male rats 
were sacrificed at different time points (2.5, 5, 15, 30, 60 minutes) after acute 
administration of OEA (10 mg kg-1, i.p.); plasma and different brain areas (AP, ME, 
nucleus of the solitary tract, ventral and dorsal hippocampus) were microdissected and 
NAEs, including OEA, were extracted and measured by UPLC-MS/MS. Vehicle treated 
animals were used as controls.  
Our results revealed that OEA was able to permeate all the brain areas analysed as early 
as 5 minutes after its systemic administration. OEA levels resulted considerably higher 
than those of vehicle-treated animals at 15 minutes in all the brain areas studied and 
particularly in the AP, where it reached the highest increase. In accordance, plasma 
OEA levels increased as early as 2.5 minutes after i.p. administration with a maximum 
increase registered at 15-30 minutes. OEA administration did not significantly affect the 
levels of other NAEs in the brain, whereas in the plasma we observed an increase of 
anandamide (AEA), palmitoylethanolamide (PEA), stearoylethanolamide (SEA), and 
linoleoylethanolamide (LEA), which deserves further studies. 
Overall, these results showed that OEA is able to reach and permeate the brain 
parenchyma as an intact molecule within few minutes after i.p administration. 
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3.1. Introduction  
Obesity and eating disorders are currently considered as major worldwide public health 
issues. Moreover, the limited and poorly efficacious anti-obesity therapies highlight the 
urgency to find novel pharmacological targets for controlling the so called “obesity 
epidemic”. In this background, growing attention has been focused on the N-
acylethanolamides (NAEs), a family of bioactive lipid mediators which are synthesized 
“on demand” by the fatty acid amidation of membrane phospholipid precursors (N-
acylphosphatidylethanolamines, NAPEs) 1.  
Among NAEs, anandamide (AEA), oleoylethanolamide (OEA), palmitoylethanolamide 
(PEA), stearoylethanolamide (SEA) and linoleoylethanolamide (LEA) are the most 
widely characterized and, in addition to feeding 2–7, they have been shown to participate 
in many physiological and pathological conditions including inflammation, pain and 
memory consolidation 8,9. Besides cannabinoid receptors, NAEs have been found to 
interact with different receptor targets (depending on the nature of the N-linked acyl 
chain), including also the transient receptor potential vanilloid 1 (TRPV1) and 
peroxisome proliferator activated-receptor alpha (PPAR-α) 7,10–13.  
Within these lipid mediators, OEA has been the most studied for its pivotal role as a key 
regulator of food intake 4,5,7. OEA is a gut-derived compound generated by enterocytes 
of the proximal small intestine from oleic acid, which is released upon the absorption of 
dietary fat 4. Although OEA shares biosynthesis and degradation pathways with its 
monounsaturated analogue, AEA, it exerts opposite effects in the control of feeding 
behaviour and lipid metabolism 4,14. In fact, growing evidence accumulated over the last 
20 years demonstrated that OEA acts as a satiety signal since it is able to significantly 
reduce food intake and body weight in obese rodents 5,19–30 and humans 27 through the 
activation of PPAR-α, for which OEA shows a high affinity 10.  
A large body of observations revealed that the pro-satiety effect evoked by OEA 
requires the involvement of selected brain regions, which actively participate in the 
control of energy homeostasis and feeding behaviour, such as the nucleus of solitary 
tract (NST) and area postrema (AP) of brainstem 5,19,22,24, and the paraventricular (PVN) 
and supraoptic (SON) hypothalamic nuclei 5,19,22,24.  
Although OEA has been demonstrated to induce satiety by activating key brain 
hypothalamic and hindbrain areas, the mechanism by which OEA reaches the central 
nervous system (CNS) from the periphery is still debated. After being systemically or 
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orally administered, OEA quickly reaches the bloodstream, however it cannot readily 
permeate the brain parenchyma because in the blood brain barrier (BBB) there is a high 
expression of its main degrading enzyme, fatty acid amide hydrolase (FAAH) 28.  
In this context, prior knowledge considering vagus nerve as the primary responsible for 
conveying OEA’s effects from the periphery to the CNS 10, failed after the observation 
that the anorexic effect of OEA is still present in animals lacking functional vagal 
afferent fibres 21. 
Moreover, a novel study revealed that after the ablation of the AP, a circumventricular 
organ devoid of a functional BBB, both behavioural and neurochemical effects of OEA 
were completely prevented 18, thus suggesting the crucial role of this brain area in 
mediating OEA pro-satiety effect.  
In this background, the AP and other circumventricular organs such as the median 
eminence (ME), are attracting a great deal of attention for their privileged properties: 1) 
the weakness of the BBB, by virtue of the absence of tight junctions and the presence of 
fenestrated capillaries, and 2) the location in close contact with the cerebral ventricles.  
These observations, together with very recent findings demonstrating the high 
expression of PPAR-α in the AP 18 and in the ME (not published data), point to a 
possible role of these circumventricular organs as receptive brain regions for OEA and 
other peripheral signals.  
On the basis of these premises, we hypothesized that the AP and the ME could represent 
the first central targets of this lipid signal in the brain.  
Based on this background, the goal of the present study was to fully elucidate whether 
systemically administered OEA might directly reach and permeate the brain 
parenchyma through circumventricular organs devoid of a functional BBB, such as the 
AP and the ME.  
OEA tissue levels in the brain have been already quantified by Oveisi and collaborators 
after an acute oral administration of this gut-derived lipid mediator (50 mg kg−1) 29. The 
authors hypothesized that OEA was not able to penetrate the brain since, after being 
orally administered, cerebral OEA levels were comparable to those observed in vehicle 
(veh)-treated rats used as controls 29. However, it is important to mention that in this 
experiment, rats were sacrificed 4 hours after treatment, therefore we cannot exclude an 
increase in central OEA levels at shorter time-points.  
To this purpose, male Wistar rats were sacrificed at different time points (2.5, 5, 15, 30, 
60 minutes) after acute administration of OEA (10 mg kg-1, i.p.). Plasma and different 
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brain areas were collected for UPLC-MS/MS quantification of the main NAEs 
(including OEA, AEA, PEA, SEA, and LEA), and 2-arachidonoyl-glycerol (2-AG). In 
particular, in order to selectively investigate OEA concentrations within a variety of 
PPAR-α-expressing cerebral regions, selected brain areas of interest (AP, ME, NST, 
ventral and dorsal hippocampus (vHipp and dHipp)) were microdissected and used in 
this study. Vehicle treated animals were used as controls. 
3.2. Materials and Methods 
3.2.1. Animals and housing  
Eighty male Wistar-Han rats (Janvier Labs, Le Genest-Saint-Isle, France), weighing 
275–325 g upon arrival, were individually housed in wire mesh cages under a 12:12 
dark-light cycle in a climate-controlled room (22 ± 2°C and 60% relative humidity) and 
received ad libitum standard chow pellets (N 3430, Provimi KIiba, Gossau, 
Switzerland) and water. All experiments were performed upon the approval of the 
Veterinary Office of the Canton of Zurich and according to the European Community 
directives 2010/63/EU.  
3.2.2. Drugs and treatments  
OEA was synthesized as previously described 30, dissolved in a veh solution (2 ml kg-1) 
of saline/polyethylene glycol/Tween 80 (90/5/5, v/v/v), and administered 10 mg kg-1 via 
i.p. injections. Veh treated animals were used as controls. Both veh and OEA solutions 
were freshly prepared on test day and administered about 30 minutes before dark onset. 
3.2.3. Tissue collection 
After the injection, animals were deeply anesthetized with isoflurane and sacrificed at 
the following time points: 2.5, 5, 15, 30 and 60 min. From these animals, blood was 
withdrawn from the heart and collected in glass tubes pre-coated with K3-EDTA and 
immediately centrifuged at 4°C, 3000 rcf for 15 minutes for plasma separation. Brain 
areas of interest (AP, NST, dHipp, vHipp and the periventricular area of the 
hypothalamus including the ME) were freshly microdissected and snap frozen in liquid 
nitrogen. The experimental timeline is depicted in Fig. 3.1.   
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Fig. 3.1: Experimental timeline. 
 
3.2.4. N-acylethanolamides extraction 
All the tissues collected were subjected to the lipid extraction procedure. Briefly, as 
previously described 31 brain frozen tissues were homogenized in cold dichloromethane 
(CH2Cl2, 8 mL), followed by the addiction of: internal standards (5 pmol of d4-OEA, 
d4-AEA, d4-PEA, d4-SEA and 15 pmol of d5-2-AG), 4 mL of cold methanol (MeOH, 
+ 0.175% BHT) and 2 mL of bi-distilled water (H2O, + EDTA 7mM). The extracting 
vials were then subjected to vigorous mixing and sonication in ice-cold water, prior to 
be centrifuged for 10 min, 700xg at 4 °C. The organic layer was then collected and 
evaporated to dryness under a stream of nitrogen. A pre-purification of the resulting 
lipid fraction was obtained by solid-phase extraction (SPE) over silica (as stationary 
phase), using 6 mL of hexane-isopropanol (99:1, v/v) to elute highly lipophilic 
compounds and cholesterol. 3.6 mL of hexane-isopropanol (7:3, v/v) were then added to 
the SPE columns in order to allow NAEs (OEA, AEA, PEA, SEA, and LEA) and 2-AG 
elution. The fraction of interest was dried under a nitrogen stream and the dry residue 
reconstituted with 30µL of MeOH for the UPLC-MS/MS analysis. 
Plasma samples were extracted with the same procedure, by adding 100 μL of sample in 
each extraction vial.  
3.2.5. UPLC-MS/MS analyses 
The resulting lipid extracts were analyzed by UPLC-MS/MS using a Xevo TQ-S mass 
spectrometer (Waters, Ireland, UK) coupled to an Acquity UPLC® class H (Waters, 
Ireland, UK). The analytes were separated using an Acquity UPLC BEH C18 column 
(1.7 μm, 2.1 × 50 mm; Waters, Ireland, UK) connected to an in-line filter unit and 
maintained at 40°C. Mobile phases A and B were composed of MeOH-H2O-acetic acid 
(75:24.9:0.1, v/v/v) and MeOH-acetic acid (99.9:0.1, v/v), respectively. The injection 
volume was 1 μl. The gradient (0.2 mL/min) was designed as follows: transition from 
100% A to 0% A linearly over 2.3 min, followed by a 4.7 minutes plateau before re-
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equilibration at 100% A during 3 min. An electrospray ionization (ESI) source in 
positive mode was used. Precursor ions, product ions, multiple reaction monitoring 
(MRM) transitions, optimal cone voltage and collision energies were established for 
each analyte. The MRM mode was used to profile two transitions per compound, one 
quantitative (Q) and one qualitative (q). The MRM transitions used were: 326,5->61,9 
(Q) and 326,5->309,2 (q) for OEA; 348,2->61,9 (Q), 348,2->90,9 (q) and 348,2->287,3 
(q) for AEA; 300,3->61,9 (Q) and 300,3->283 (q) for PEA; 328,2->61,9 (Q) and 328,2-
>311 (q) for SEA; 324,5->61,9 (Q) and 324,5->306,5 (q) for LEA; 379,2->287,3 (Q), 
379,2->269,3 (q), 379,2->90,9 (q) for 2-AG; 330,5->65,9 (Q) and 330,5->313,2 (q) for 
d4-OEA; 352,2->65,9 (Q) and 352,2->287,3 (q) for d4-AEA; 304,3->65,9 (Q) and 
304,3->287 (q) for d4-PEA; 332,2->65,9 (Q) and 332,2->315 (q) for d4-SEA; 384,3-
>287,3 (Q) and 384,3->269,3 (q) for d5-2-AG.  
ESI conditions were as follows: capillary voltage at 2800 V; desolvation temperature at 
550 °C; desolvation and cone gas flow at 1100 and 170 L/H, respectively; nebuliser gas 
flow at 7.0 bar.  
During the analysis, the autosampler was maintained at 5 °C. For data acquisition and 
processing, the MassLynx® software (Waters, Ireland, UK) was used.  
NAEs were identified based on their mass and by retention time matching (by using a 
reference solution containing deuterated standards and pure NAE standards injected at 
the beginning and at the end of each sequence of injections).  
A calibration curve for each compound of interest was established by preparing 
standard solutions, containing an appropriate amount for each selected compound, 
which were then diluted to obtain 10 calibration points (0, 2.5, 5, 10, 25, 50, 100, 200, 
400, 800 fmol on column for NAEs and 0, 50, 100, 200, 500, 1000, 2000, 4000, 8000, 
16000 fmol on column for 2-AG). For OEA 3 additional points were added (1600, 
3200, 6400 fmol on column). The ranges for the calibration curves were chosen for 
each standard based on preliminary data obtained in rat brain test tissues. Both 
deuterated standards and diluted solutions of non-deuterated standards were then 
subjected to the same procedure as the biological samples.  
The amounts of the compounds analysed were determined by linear interpolation from 
calibration curves; data were analysed by normalizing the pmol amount of each 
compound to the weight of the brain tissue samples (pmol/g) and to the volume of 
plasma samples (pmol/mL). 
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3.2.6. Statistical analyses 
All data were expressed as mean ± SEM and statistically analysed by two-way ANOVA 
with “time” and “treatment” as the two factors. Tukey’s test was used as a post hoc to 
perform multiple comparisons (IBM SPSS, version 22, IBM Analytics). Additionally, a 
one-way ANOVA followed by Dunnett’s post hoc test was performed in order to 
evaluate differences among the veh-treated rats (by using as control the group of rats 
sacrificed 2.5 minutes after administration of veh). In all instances, the threshold for 
statistical significance was set at P < 0.05.  
3.3. Results  
3.3.1. Effects of OEA systemic administration on the levels of OEA and its 
analogues in selected brain areas 
- OEA distribution in the brain 
The data obtained by UPLC-MS/MS analysis revealed, for the first time, that OEA 
was able to reach the CNS and to permeate all the brain areas analysed within few 
minutes of its administration. In particular, OEA levels were significantly higher as 
early as 2.5 minutes after treatment in the ME (P<0.05), dHipp (P<0.01) and vHipp 
(P<0.05) of rats acutely treated with OEA, as compared to those administered with 
veh (Fig. 3.2 C-E); whereas, in the AP and NST OEA reached significant levels 
compared to those evaluated in control rats as early as 5 minutes after its systemic 
administration (Fig. 3.2 A, B; AP: P<0.05, NST: P<0.01).  
The maximum increase of OEA was registered 15 minutes after its acute injection. In 
fact, at this time point OEA levels (expressed as pmol/g of wet tissue) resulted 
considerably higher in OEA- than in veh-treated animals in all the brain areas studied 
(Fig. 3.2 B-E; P<0.001) and particularly in the AP, where it reached the highest 
increase (Fig. 3.2 A; P<0.001) supporting our hypothesis concerning the crucial role 
of this area in conveying OEA signal to the brain. This finding is more clearly shown 
by expressing OEA levels as a percentage of those evaluated in the respective controls 
(Fig. 3.2 F-J). These graphs show that 15 minutes after its systemic administration, 
OEA levels were up to 3-fold higher in the AP and 1.5-fold higher in the other brain 
areas (ME, NST, dHipp and vHipp) in OEA animals vs veh-treated controls (Fig. 3.2 
F-J).  
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Moreover, OEA endogenous levels in veh- treated rats appeared to be not significantly 
different over the time in all the brain areas analysed except for the AP where they 
were statistically higher at 30 minutes compared to those quantified at 2.5 minutes 
(Fig. 3.2 A; P<0.01). The results obtained from the two-way ANOVA analyses of 
OEA levels (expressed as pmol/g and as percentage of controls) are reported in Table 
3.1; while significant differences among groups evaluated by the post hoc analysis are 
indicated in Fig. 3.2. 
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Fig. 3.2: OEA Concentration expressed in pmol/g and OEA levels expressed as % of control in the area 
postrema (AP; panels A, F), nucleus of the solitary tract (NST; panels B, G), median eminence (ME; 
panels C, H), dorsal and ventral hippocampus (dHipp (panels D, I) and vHipp (panels E, J)) of rats 
sacrificed at different time points (2.5, 5, 15, 30, 60 minutes) after acute administration of OEA (10 mg 
kg-1, i.p.) or vehicle (veh). Data are expressed as mean ± SEM. (N=6-8). * P<0.05, ** P<0.01, *** 
P<0.001 vs veh in the same time point (Tukey’s test). ## P<0.01 vs veh 2.5 minutes (Dunnett’s test). 
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Table 3.1: Results of the two-way ANOVA analyses of NAEs and 2-AG quantified in different brain 
areas and in the plasma of rats sacrificed at different time points after intraperitoneal injection of 
OEA or vehicle. 
Abbreviations: 2-AG, 2-arachidonoyl-glycerol; AEA, anandamide; AP, area postrema; dHipp, dorsal 
Hippocampus; LEA, linoleoylethanolamide; ME, median eminence; NST, nucleus of solitary tract; OEA, 
oleoylethanolamide; PEA, palmitoylethanolamide; SEA, stearoylethanolamide; vHipp, ventral 
Hippocampus. 
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- N-acylethanolamides distribution in the brain 
Whole tissue concentrations of NAEs (including AEA, PEA, LEA, and SEA), and 2-
AG were measured in selected brain regions such as AP, ME, NST, dHipp and vHipp 
of rats treated with either OEA (10 mg kg-1, i.p.) or veh and sacrificed at different 
time-points after treatment. All data, expressed as pmol/g of wet tissue, are reported in 
Table 3.2.  
Overall, our results revealed that OEA systemic administration did not significantly 
affect the levels of other NAEs and 2-AG in all the brain areas analyzed, except for the 
Hipp.  
In fact, in the dHipp OEA acute injection induced a significant decrease of AEA levels 
in OEA- than in veh-treated rats 30 minutes after treatment (P<0.01). Whereas in the 
vHipp we observed a decrease of both PEA (P<0.05) and SEA (P<0.05) few minutes 
after OEA administration compared to animals treated with veh.  
Results obtained from two-way ANOVA analyses conducted for each parameter are 
reported in Table 3.1, whereas the results from the post hoc analyses (Tukey’s and 
Dunnett’s test) are reported in Table 3.2. 
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Table 3.2: NAEs and 2-AG concentration expressed in pmol/g in selected brain areas of interest in 
rats after intraperitoneal injection of OEA or vehicle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are expressed as mean ± SEM. *P<0.05 vs veh in the same time point (Tukey’s test); # P<0.05 vs 
veh 2.5 minutes (Dunnett’s test); § P<0.05; §§ P<0.01 vs OEA 2.5 minutes (Dunnett’s test). N = 5-8.  
Abbreviations: 2-AG, 2-arachidonoyl-glycerol; AEA, anandamide; AP, area postrema; dHipp, dorsal 
Hippocampus; LEA, linoleoylethanolamide; ME, median eminence; NST, nucleus of solitary tract; OEA, 
oleoylethanolamide; PEA, palmitoylethanolamide; SEA, stearoylethanolamide; veh, vehicle; vHipp, 
ventral Hippocampus.  
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3.3.2. Effects of OEA systemic administration on the levels of OEA and its 
analogues in the plasma  
Plasma concentration of NAEs (including OEA, AEA, PEA, SEA, and LEA), and 2-AG 
were expressed as pmol/ml and are reported in Fig. 3.3.  
In keeping with the results obtained in the different brain areas, plasma OEA levels 
significantly increased within minutes of its administration (as early as 2.5 minutes after 
injection; P<0.001) with a maximum increase registered at 15-30 minutes (60-fold 
higher than controls; P<0.001) (Fig. 3.3 A). Conversely from what observed in the 
brain, OEA systemic injection significantly affected the levels of other NAEs in the 
plasma of OEA-treated rats as compared to control animals (Fig. 3.3 B-E). In particular, 
we observed that OEA treatment was able to significantly increase the amount of AEA, 
PEA, LEA and SEA with different kinetics compared to control rats. The maximum 
increase was registered at 15 minutes for AEA (P<0.01), PEA (P<0.001) and LEA 
(P<0.001) whereas SEA reached the maximum levels 30 minutes after OEA systemic 
administration (P<0.001). Overall, no change was observed for 2-AG levels except for 
those measured at 15 minutes after treatment, when OEA administration induced a 
significant reduction of 2-AG amount as compared to controls (Fig. 3.3 F; P<0.01).   
Results obtained from two-way ANOVA analyses conducted for each parameter are 
reported in Table 3.1, while the results from the post hoc analyses (Tukey’s test) are 
reported in Figure 3.3. 
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Fig. 3.3: Concentration of OEA (panel A) and other NAEs (AEA, panel B; PEA, panel C; LEA, panel 
D; SEA, panel E) and 2-AG (panel F) expressed in pmol/ml in the plasma of rats sacrificed at different 
time points (2.5, 5, 15, 30, 60 minutes) after acute administration of OEA (10 mg kg-1, i.p.) or vehicle 
(veh). Data are expressed as mean ± SEM. (N=7-8). * P<0.05, ** P<0.01, *** P<0.001 vs veh in the 
same time point (Tukey’s test). 
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3.4. Discussion  
OEA is a gut-derived satiety lipid signal that has gained a great deal of attention over 
the last two decades for its ability to evoke consistent and sustained food intake 
suppression in both rodents and humans 5,15,18,22,27,32 through the activation of intestinal 
PPAR-α receptors 10. It is now well recognised that the hypophagic action of this lipid 
mediator is associated to the involvement of selected brain areas, particularly in the 
brainstem and hypothalamus 18,19,22,24,33, although how OEA signal reaches the brain 
remained to be fully elucidated.  
Recent findings demonstrated a necessary role of the AP, a circumventricular organ 
with a weak BBB and a high density of PPAR- α receptors, for i.p. injected OEA to 
reduce eating 18, suggesting that this brain area could represent a receptive region for 
circulating OEA. 
However, previous findings suggested that OEA was not able to penetrate the brain 
parenchyma 29 thus proposing that its pro-satiety mechanism of action could be 
peripheral rather than central.  
In particular, the authors revealed that OEA levels, measured in total brain of animals 
acutely administered with OEA (50 mg kg−1, oral capsules) and sacrificed 4 hours after 
treatment, were comparable to those quantified in veh-treated rats 29. However, these 
results cannot exclude a possible increase in central OEA levels at shorter time-points.  
In accordance with this latter hypothesis and as confirmed by previous reports, OEA 
inhibitory effect on food intake appeared evident within minutes of its administration 
18,21. 
These observations further supported the possibility that OEA signal could reach the 
CNS and exert its neurochemical effects very quickly, thus suggesting also a non-
transcriptional mechanism involved in such a rapid action for OEA.  
With these concepts in mind, in this study we measured OEA levels in rat brain by 
UPLC-MS/MS system at shorter time-points after its systemic administration (at a dose 
that causes a significant inhibition of eating, 10 mg kg-1), such as 2.5, 5, 15, 30, 60 
minutes after treatment.  
In particular, in order to selectively investigate the tissue distribution of exogenous 
OEA within a variety of PPAR-α-expressing cerebral regions, we here quantified OEA 
and other NAEs levels in selected brain areas of interest such as AP, ME, NST, vHipp 
and dHippo.  
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Surprisingly, our results demonstrated, for the first time, that OEA is able to directly 
reach and permeate all the brain areas analysed as early as 5 minutes after being acutely 
injected.  
Overall, the maximum increase of OEA in the brain was registered 15 minutes after its 
acute administration and this is in accordance with our previous behavioural findings 
demonstrating that OEA significantly suppresses cumulative food intake in rats as 
early as 30 minutes following injection 18,21.  
The rapidity through which OEA is able to exert its pro-satiety effect reveals the 
existence of an additional non-transcriptional mechanism for PPAR-α, whose 
transcriptional changes, conversely, unfold over a period of hours 4.  
Accordingly, Gaetani and collaborators in 2003 demonstrated that plasma concentration 
of OEA, after i.p. administration of a single dose (5 mg kg-1), were significantly higher 
than control at 15 and 30 minutes after the injection 32. However, to date, no 
pharmacokinetics studies have been performed to test OEA (10 mg kg-1) absorption and 
distribution in the brain in such short time points.  
As already described in the text, brain distribution of OEA have been analysed by 
Oveisi research team only 4 hours after its oral administration 29. Moreover, at this time 
point, the authors also investigated tissue distribution of orally administered OEA, and 
they found increased OEA concentration in the initial segment of the gastrointestinal 
tract (stomach, duodenum, and jejunum) and in the liver in OEA- than in veh-treated 
rats 29.  
Interestingly, in our study we found that 15 minutes after treatment, OEA amount 
reached the highest increase in the AP, where it was up to 3-fold higher in OEA- than 
in veh-treated rats, as compared to the other brain areas analysed, such as ME, NST, 
dHipp and vHipp, where OEA levels were only 1.5 fold higher than controls.  
This result further supports the crucial role of the AP in mediating OEA mechanism of 
action, and is in line with our previous study in which, after the surgical ablation of the 
AP, both behavioural and neurochemical effects of OEA were completely prevented 18.  
Additional evidence confirming the idea of a pivotal role of the AP in OEA-induced 
satiety comes from the observation of physiological OEA. In fact, OEA endogenous 
levels in veh- treated rats appeared to be not significantly different over the time in all 
the brain areas analysed except for the AP, where they were statistically higher at 30 
minutes than those quantified at 2.5 minutes.  
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OEA endogenous levels are, indeed, strictly dependent on the nutritional status of the 
animals 2,4. For instance, it has been observed that fasting decreases OEA content in the 
proximal segment of the small intestine, while feeding stimulates OEA mobilization 
from the mucosal layer of the duodenum and jejunum 3,34.  
Based on this premises, since the experiments have been conducted during the dark 
phase (when rats are active), the increased endogenous levels of OEA measured in the 
AP of rats treated with veh, are strictly dependent on the fact that animals are 
consuming food.  
The observation that endogenous OEA reaches a statistically significant increase during 
feeding around 30 minutes after the beginning of the dark phase, selectively in the AP, 
corroborates our hypothesis of the necessary function of this hindbrain area in 
regulating feeding behaviour and in mediating OEA anorexic effect.  
Moreover, the considerable increase of OEA levels in the AP and ME, following its 
systemic administration, could be explained by the decreased activity of FAAH enzyme 
in these regions of the CNS 35. FAAH is the enzyme mainly responsible for the 
hydrolysis of NAEs, including OEA, and highly expressed in the BBB 28. 
The BBB, formed by the brain capillary endothelial cells, represents the physical 
protective barrier between the blood and the CNS 36, a property that is allowed by the 
presence of highly developed tight junction complexes and a lack of fenestrations 37. 
Because of its intrinsic structure, the BBB restricts the diffusion of molecules and 
solutes into the brain, including fatty acids.  
In this scenario, the AP and the ME are defined as circumventricular organs since they 
lack a functional BBB and they are highly vascularised, being in close contact with 
cerebral ventricles 38. This property, together with their abundant expression in PPAR-α 
18, further suggests their crucial role as receptive brain regions for circulating OEA and 
confirms our results showing OEA capability to reach and permeate the brain 
parenchyma.  
Moreover, we were not surprised that OEA was able to penetrate the CNS by reaching 
high levels also in the NST, since this is a nucleus in close contact with the AP 22 and 
with a high density of PPAR-α. Therefore, by virtue of the strict connection and 
reciprocal communication between AP and NST neurons 18,39, we propose that the AP 
might also be a putative pathway through which OEA can diffuse to the nearby NST. 
However, the high levels of OEA measured in the dHipp and vHipp as early as 2.5 
minutes after its systemic administration, led us to hypothesise that OEA increase in 
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these brain regions is not the consequence of OEA entrance into the brain through the 
AP.  
In this regard, the research is currently shedding light on possible protein-mediated 
transport mechanisms that could allow fatty acid import into the brain 36.  
Mitchell and collaborators demonstrated that the precursor of OEA, oleic acid, is 
transported across confluent cultures of primary human brain microvessel endothelial 
cells through the engagement of fatty acid transport proteins. The authors showed that 
RNAi knockdown of fatty acid transport protein 1 (FATP-1) or fatty acid translocase 
(FAT/CD36), which are specific fatty acid transporters, significantly decreased oleic 
acid transport through these microvessel endothelial cells 40.  
Both FATP-1 and FAT/CD36, together with an additional class of fatty acid transporter 
(fatty acid-binding protein (FABPs)), have been shown to be specific for long-chain 
fatty acids 41 and their genes are regulated by PPAR-α 42.  
Moreover, CD36, along with FABP5 subtype of FABPs family, has been found to be 
highly expressed also within the endothelial cells of the brain microvasculature 43,44.  
These observations, together with the finding that FABP5 is expressed (both gene and 
protein) in the lateral ventricles of both developing and adult mice CNS, led us to 
speculate that OEA penetration within the dHipp and vHipp might be mediated by the 
involvement of this fatty acid transporter, being the Hipp a region of the CNS in close 
contact with the lateral ventricles 45. Further studies should test such hypothesis.  
Interestingly, the rapidity trough which OEA reaches and permeates the brain 
parenchyma could be determinant not only in allowing a rapid inhibition of food intake 
but also in sustaining the cognitive properties of this lipid compound. Studies, in fact, 
reveal the ability of OEA (10 mg kg-1 i.p.) to enhance memory consolidation, after 
behavioural training, in two aversively motivated task: the inhibitory avoidance task 8 
and in the contextual fear conditioning 46. Moreover, OEA has also been shown to 
improve spatial cognitive deficits in a rat model of acute cerebral ischemic injury 
through enhancing the neurogenesis in the Hipp 47. 
In keeping with these findings, we can speculate that the rapid increase of OEA 
concentration that we registered in all the brain areas analysed and, particularly in the 
Hipp, as early as 2.5 minutes after its systemic administration, could be crucial for OEA 
ability in improving memory retention, and in regulating memory processes (two 
conditions which require the involvement of both the Hipp and amygdala). 
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As second aim of our study, we also investigated the levels of other NAEs (including 
AEA, PEA, SEA, and LEA), and 2-AG in the different brain areas following OEA 
systemic administration.  
Among their biological functions, PEA, SEA, and LEA have been proposed to play also 
a role in the regulation of feeding behaviour, effect mediated by their ability to activate 
PPAR-α.  
However, OEA has been found to be the most active in reducing energy intake. In fact, 
when administered i.p. to laboratory rats, PEA, SEA and LEA are less active than OEA 
in inducing satiety 5,13,48, thus suggesting the structural selectivity of OEA anorexic 
effect.  
In line with these observations, although NAEs share the same biosynthetic and 
catabolic pathways with OEA, our results demonstrated overall that OEA administration 
did not significantly affect the levels of other NAEs in all the brain areas analyzed 
except for AEA in the Hipp.  
In the dHipp OEA systemic administration appeared to reduce AEA levels in OEA- 
treated rats 30 minutes after treatment. The same trend was observed within the ventral 
part of the Hipp, although in this brain structure OEA-induced reduction of AEA levels 
did not reach the statistical significance.  
The present result is in line with the scientific literature showing that AEA is an 
endocannabinoid compound, which binding to cannabinoid receptors type 1 (CB1) and 
2 (CB2) exert opposite effects in the control of feeding behavior as compared to OEA 
48. Thereby, OEA-induced reduction of AEA levels in the dHipp might have an effect in 
lowering food intake since the hippocampal formation is enriched with CB1 receptors 
49,50
. The Hipp is not directly involved in the control of feeding, however it has been 
demonstrated to play important roles in hedonic aspects of eating 51. 
Similarly to what observed for NAEs, OEA did not significantly affect the levels of 2-
AG in all the brain areas analysed in the present study.  
In keeping with the results obtained in the brain, plasma OEA levels increased within 
minutes of its administration and, in particular, as early as 2.5 minutes after i.p. 
injection with a maximum increase registered at 15-30 minutes (60-fold higher than 
controls).  
Interestingly, 60 minutes after treatment, OEA levels were still up to 30-fold higher than 
those measured in control rats treated with veh. This is supported by previous findings 
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demonstrating that 4 hours after its oral administration, the levels of OEA in plasma 
were still 2 fold higher than controls 29.  
Although OEA has a prolonged pro-satiety action 18,29, many of its effects are rather 
considered relatively short-lived 29,32. In this regard, Astarita and colleagues 
demonstrated that plasmatic OEA levels, following either its systemic (10 mg kg-1) or 
oral (100 mg kg-1) administration, are characterized by a rapid clearance since they 
sharply increased within few minutes after treatment (reaching a maximum 
concentration at 15 minutes) returning to baseline levels within 4 hours (i.p.) or 6 hours 
(per os) of administration 52. This time course probably reflects a rapid distribution and 
metabolism of OEA 17,52, which is known to be hydrolyzed to oleic acid and 
ethanolamine by FAAH 53–55.  
Conversely form what observed in the brain, OEA systemic injection significantly 
increased also the amount of the other NAEs in the plasma.  
The maximum increase was registered at 15 minutes for AEA, PEA and LEA whereas 
SEA reached the maximum levels 30 minutes after OEA systemic administration.  
The OEA-induced increase of circulating NAEs levels could be a result of the 
“entourage” effect of this lipid bioactive mediator, which consists on the ability to 
increase the amount of AEA and other members of this family, by competing with them 
for FAAH, thereby reducing their hydrolysis 56–58. 
The discrepancy of these findings compared to what we observed in the brain, where 
NAEs levels were not affected by OEA injection, could be explained by a lower activity 
in the brain of calcium-dependent N-acyltransferase (NAT), the enzyme involved in the 
first step of NAEs synthesis.  
This is supported by the literature since it has been demonstrated that two structurally 
distinct PPAR-α agonists, GW-7647 and PEA, cause a rapid decrease in the amplitude 
of evoked calcium transients in mouse sensory neurons 59 after binding to PPAR-α. In 
line with this observation, we can speculate that OEA-induced PPAR-α activation is 
responsible for the reduction of intracellular calcium concentration in the brain thus 
resulting in the attenuation of cerebral NAT activity, with a consequence reduction in 
endogenous NAEs synthesis in the CNS. This could be the reason why OEA systemic 
administration does not induce an “entourage” effect in the brain.  
This PPAR-α mediated mechanism has been investigated by many electrophysiological 
studies supporting PPAR-α ability to influence membrane ion-channel activities by 
117 
 
recruiting intracellular signal transduction pathways that are gene expression 
independent 60.  
Since there is no evidence supporting the existence of this mechanism in plasma, we can 
speculate that OEA-induced reduction of endogenous NAEs synthesis, which is 
mediated by PPAR-α activation, might be selectively restricted to the brain. However, 
this hypothesis deserves further analyses.  
Overall, the findings obtained in the present study suggest that OEA is able to directly 
reach and permeate the brain parenchyma as an intact molecule within few minutes after 
i.p administration. Furthermore, our data indicate that OEA has a very extensive brain 
penetration capability, and its effect on feeding behavior following systemic 
administration may be mediated by either the brain regions in close proximity to the 
circumventricular organs or sites outside of the BBB, including AP and ME. 
Finally, our results further support the crucial role played by the AP in the complex 
circuitry underlying OEA pro-satiety effect.  
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Chapter IV 
 
Satiety factor oleoylethanolamide prevents binge-
like palatable food consumption induced by stress 
in female rats with a history of food restriction 
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Abstract 
Binge-eating disorder (BED) is a proto-typical eating-related maladaptive behaviour 
characterized by compulsive and uncontrollable overeating of highly palatable food 
(HPF). A large body of evidence suggests that the neurobiological mechanisms of BED 
converge on the activation of the mesocorticolimbic dopamine (DA) system, as well as 
on the impairment of brain serotonin (5-HT) and noradrenaline (NA) signalling. 
Moreover, a number of observations revealed that the combination of dieting and stress 
is a common trigger for people suffering from BED, who displays a hyperactivation of 
the hypothalamic-pituitary-adrenal (HPA) axis and higher cortisol levels, as compared 
to obese people not affected by BED. Current BED therapies lack sufficient efficacy 
and are complicated by high relapse rates and a wide range of side effects. In this 
background, the satiety signal oleoylethanolamide (OEA), an endogenous gut-derived 
lipid compound released from enterocytes during meal consumption, might represent a 
better pharmacological target for the treatment of BED. OEA reduces food intake and 
body weight gain in obese rodents and humans through the activation of the peroxisome 
proliferator-activated-receptor-alpha (PPAR-α). Besides its pro-satiety effect, OEA has 
been also demonstrated to: 1) restore a normal brain dopaminergic response (when it is 
deregulated by an excessive dietary fat intake); 2) exert anti-depressant-like effect in 
rodents by regulating 5-HT and NA levels in the brain; 3) attenuate the effect of stress 
by dampening the hyperactivity of the HPA axis. Based on these premises, in order to 
test our hypothesis that OEA might be a novel target for BED treatment, in this study 
we used a BED model in which female rats with a history of intermittent food 
restriction show binge-like palatable food consumption after a 15-minute exposure to 
the sight of HPF. In this model, we investigated the anti-bingeing acute effects of OEA 
(2.5, 5 or 10 mg kg-1, i.p.) on HPF intake and analysed the neurobiological bases of 
these effects by focusing on the brain pattern of c-Fos expression, on DA release in the 
shell of the nucleus accumbens (AcbSh), on monoamine concentrations/turnovers in 
selected brain regions and on both corticotropin-releasing factor (CRF) and oxytocin 
(oxy) mRNA. Our results showed that OEA treatment was able to selectively prevent 
binge eating in BED rats. This effect was associated to an increase of hypothalamic oxy 
mRNA levels and to a decrease of CRF mRNA levels within the CeA. Moreover, we 
found that OEA decreased both DA efflux and DA tissue concentration in the Acb. We 
finally observed that OEA enhanced 5-HT transmission in most of the brain areas 
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analysed selectively in BED rats. Overall, these results support the hypothesis that OEA 
might represent a novel potential pharmacological target for the treatment of BED. 
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4.1. Introduction  
Binge-eating disorder (BED) is the most frequent eating disorder occurring in 2-5% of 
the adult population, with a higher prevalence among women than man (10:1 ratio) 1–3. 
BED is characterized by uncontrollable and compulsive episodes of excessive 
consumption of high palatable food (HPF) accompanied by a strong sense of loss of 
control, feeling of shame, guilt, disgust and anxiety. Although BED is associated to an 
increased responsivity to food-associated cues 4 inducing food cravings, overeating and 
obesity 5,6, a significant part of the people affected by BED has a normal body-weight 
7,8. 
Different factors might contribute to the development of BED, including genetic and 
biological factors, psychological disturbances and the occurrence of other eating 
disorders 9. A large body of evidence suggests that the combination of dieting and stress 
is a common trigger for people suffering from BED, who displays a hyperactivation of 
the hypothalamic-pituitary-adrenal (HPA) axis and higher cortisol levels, as compared 
to obese people not affected by BED 10,11. Additionally, both animal and human studies 
have identified the involvement of different neurotransmitter signalling pathways in the 
pathophysiology of BED 12–15. In particular, it has been introduced the concept of 
addiction to explain the compulsive basis and neural mechanisms of BED 16,17; in fact, 
BED shares a variety of commonalities with drug addiction, including physiological and 
emotional-affective dependence, cue-induced craving, escalation of consumption, and 
high relapse rate 17.  
Palatable food is a strong activator of the dopaminergic reward system and may induce 
addictive behaviour leading to eating disorders 18,19; on this line, a large body of 
evidence suggests that the neurobiological mechanisms of BED converge on the 
activation of the mesocorticolimbic dopamine (DA) system 20,21, as well as on the 
impairment of brain serotonin (5-HT) and noradrenaline (NA) signalling 22–25. In 
keeping with this observation, drugs increasing 5-HT content (e.g. fluoxetine and d-
fenfluramine) 26–29 and lorcaserin, a selective 5-HT2c receptor agonist that stimulates 
central dopaminergic neuronal activity 30, have been demonstrated to suppress binge 
eating.  
Nevertheless treatments for BED lack sufficient efficacy and are complicated by high 
relapse rates and a wide range of side effects 31,32. Lisdexamfetamine (LDX), a pro-drug 
of d-amphetamine, is the first medication approved for the treatment of BED in the 
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United States 33 that acts primarily by enhancing brain dopaminergic and noradrenergic 
neurotransmission 33, however it causes several adverse effects 34–36. Several 
observations have been accumulated by our and other research groups suggesting that 
the lipid-derived messenger oleoylethanolamide (OEA) might represent a better 
pharmacological target for the treatment of BED 37–39. OEA reduces food intake and 
body weight gain in obese rodents and humans 40–53 mainly through the activation of the 
peroxisome proliferator-activated-receptor-alpha (PPAR-α), for which OEA shows a 
high affinity (EC50= 120.0 ± 10.7 nM) 54. The hypophagic effect of OEA is associated 
to the induction of a satiety state 55 and appears behaviourally selective: i.e. not linked 
to anxiety, malaise, changes of body temperature, pain, motor impairment, or HPA axis 
activation 40. Moreover, this effect has been associated to the indirect activation of 
selected brain areas, such as the nucleus of the solitary tract (NST) and the area 
postrema in the brainstem 44,50, as well as the tuberomammillary (TMN) 56 and 
paraventricular (PVN) 47 nuclei in the hypothalamus (HYPO), where noradrenergic 51, 
histaminergic 57 and oxytocinergic 58 neurons play a necessary role. Interestingly, OEA 
seems to modulate feeding behaviour acting not only within the caloric-homeostatic 
control system but also within the hedonic non-homeostatic circuits, as reported by 
Tellez and co-authors 59, who focused on the hypofunction of the dopaminergic reward 
system induced by excessive dietary fat intake. In particular, these authors reported that 
the systemic treatment with OEA can re-establish a normal sensitivity to the rewarding 
properties of fat and suppresses fat ingestion in diet-induced obese mice 59. Moreover, it 
has been demonstrated that OEA administration is able to exert anti-depressant-like 
effects in different animal models 60, by regulating BDNF 61, 5-HT and NA levels in the 
brain 62. 
In recent years different animal models of BED have been developed and validated 
offering important research tools with face, predictive and construct validity to 
investigate the neurobiological bases of this disorder and to search for novel efficacious 
and safe pharmacological targets 63–65. In this study, we used a rat model of binge-like 
palatable food consumption 66–68 to test the hypothesis that OEA might be a novel target 
for BED treatment.  
In our binge model adult female rats, which underwent three 8-day cycles of 
intermittent food restriction with limited access to HPF, show binge-like HPF 
consumption (i.e. intake of a large amount of HPF within the first few minutes (min) of 
access) after the exposure to a 15-min “frustration stress”, consisting of the sight and 
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smell of HPF placed out of reach 66. We will refer in the text to dietary restricted (R) vs 
non restricted (NR) rats and exposed to stress (S) vs non exposed to stress (NS) rats 
(Fig. 4.1A). 
In this model, the putative interaction of dieting and negative-valence states plays a key 
role in stimulating binge eating behaviour and inducing neuro-endocrine alterations that 
present elements of similarity with the human symptomatology 67,69.  
To evaluate whether OEA might represent a potential target for novel BED treatment, 
we investigated on this model the anti-bingeing effects of OEA (2.5, 5 or 10 mg kg-1, 
i.p.) on HPF intake and analysed the neurobiological bases of these effects.  
To this second aim, we first evaluated whether the interaction between dietary regimen 
and stress exposure is characterized by a specific pattern of brain activation (assessed by 
the neuronal activity marker c-Fos) and whether OEA treatment is able to modulate 
such pattern.  
Secondly, we investigated the effect of OEA administration on DA release in the shell 
of the nucleus accumbens (AcbSh), a ventral striatal brain structure receiving 
dopaminergic projections from the ventral tegmental area (VTA) and involved in the 
motivational/reinforcing properties of addictive drugs and food 70,71. Furthermore, we 
analysed the tissue concentrations of monoamines (DA, 5-HT, NA) and their main 
metabolites to evaluate monoamine turnover in the principal neural nodes that control 
different aspects of food intake in the brain. Specifically, we focused on limbic 
structures, such as nucleus accumbens (Acb) and caudate putamen (CPu), which 
regulate the habituation and hedonic value of food; VTA and substantia nigra (SN) 
crucial for the salience and motivation; cortical structures involved in the decision 
making, such as the medial prefrontal cortex (mPFC); HYPO, which coordinates 
arousal with energy homeostasis; amygdala (AMY) that, together with the hippocampus 
(HIPP), regulates emotional or memory processes and conditioned responses; the two 
brainstem nuclei, dorsal raphe (DR) and locus coeruleus (LC), which send, respectively, 
serotonergic and noradrenergic inputs to the VTA 72.  
Finally, we evaluated the impact of OEA administration on the corticotropin-releasing 
factor (CRF) system, which plays a critical role in stress-induced binge eating in our rat 
model 67 and on the hypothalamic oxytocinergic system playing a necessary role in the 
hypophagic action of OEA 47,58. 
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4.2. Methods and Materials 
4.2.1. Experimental procedure for Binge-eating induction  
Female Sprague Dawley rats were purchased from Charles River and were used when 
their body weight was 200–225 g at the beginning of the experiments. Rats were group 
housed under a 12 h light/dark cycle (lights on at 8:00 A.M.), at constant temperature 
(20 –22°C) and humidity (45–55%) and with access to food and water ad libitum for 2 
weeks before the experiments. All experiments were carried out in accordance with the 
European directive 2010/63/UE governing animal welfare and with the Italian Ministry 
of Health guidelines for the care and use of laboratory animals. According to the dietary 
schedule, the rats were given standard food pellets (4RF18; Mucedola; 2.6 kcal/g) or 
HPF (3.63 kcal/g) consisting in a paste prepared by mixing Nutella (FerreroR) chocolate 
cream (5.33 kcal/g; 56, 31, and 7% from carbohydrate, fat, and protein, respectively), 
ground food pellets (4RF18), and water in the following w/w/w percent ratio: 52% 
Nutella, 33% food pellets, and 15% water. The procedure for binge eating induction 
was performed according to our previous studies 66–68. Briefly, two groups of female 
rats were housed individually in metal cages (30 x 30 x 30 cm) and exposed (or not 
exposed) for 24 days to three 8-day cycles of intermittent food restriction (66% of chow 
intake on days 1–4 and free feeding on days 5–8 of each cycle), during which they were 
given access to HPF for 2 h during the light cycle between 10:00 A.M. and 12:00 A.M. 
(2 h after the onset of the light cycle) on days 5–6 and 13–14 of the first two cycles 
(total of four exposures) 67. We will refer in the text to dietary restricted (R) and non 
restricted (NR) rats. On the test day (day 25), at 10 A.M., half of the animals in each 
group was subjected to a 15 min frustration stress, consisting of the exposure to HPF 
placed out of reach 66. During this 15 min period, the rats could smell and see the HPF 
and repeatedly attempted to reach it. The second half of animals in each group was not 
exposed to the stress manipulation, therefore we will refer in the text to stressed (S) and 
non stressed (NS) rats. After 15 min stress exposure, the HPF cup was placed inside the 
cage. In accordance with our previous studies 66–68, binge eating behaviour occurred in 
R+S rats (Fig. 4.2), as demonstrated by the immediate and persistent consumption of a 
large amount HPF within the first 15 min access. Vaginal smears were collected at the 
end of experiments to exclude from the results those rats resulting in the estrous phase 
69. 
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The experimental paradigm is depicted in Fig. 4.1A. This paradigm was used in four 
different experiments, in which the consumption of the HPF was allowed for 2 h, 1 h, or 
0 h, depending on the endpoints analyzed (Fig. 4.1B). 
4.2.2. Experiment 1: Effects of OEA on stress-induced binge-eating 
The first set of rats (n = 115) was divided into 16 groups (n = 6-8 per group) in a 2 
(history of intermittent food restriction: no, yes, R or NR rats) × 2 (stress during testing: 
no, yes, S or NS rats) × 4 (OEA dose: 0, 2.5, 5 and 10 mg kg-1) factorial design, to 
evaluate the behavioural effects of OEA during the test day. To this aim OEA or vehicle 
(veh) were administered 60 min before the access to HPF; rats were exposed (or not 
exposed) to the 15-min frustration stress; and once they gained access to the HPF, the 
intake was measured at the following time points (15, 30, 60, and 120 min). The 
experimental paradigm is depicted in Fig. 4.1B (EXP.1). 
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Fig. 4.1: (Panel A) Different groups of female rats were exposed (Restricted Rats, R) or not exposed 
(Non restricted Rats, NR) for 24 days to three 8-day cycles of food restriction (66% of chow intake) on 
days 1–4 and free feeding on days 5–8 of each cycle. During the “free feeding” exposure, both NR and R 
rats were given access to high palatable food (HPF) for 2 hours (h) during the light cycle on days 5–6 and 
13–14 of the first two cycles. On the day 25 both R and NR rats were exposed (R+S and NR+S) or not 
exposed (R+NS and NR+NS) to frustration stress. (Panel B) EXP. 1: on test day (day 25), after the third 
cycle, both NR and R rats were administered with vehicle (veh) or 3 different doses of OEA (2.5, 5 and 
10 mg kg-1 i.p.). 45 min after the treatments, both NR and R rats were exposed (stressed: NR+S and R+S) 
or not exposed (not stressed: NR+NS and R+NS) to a 15 min stress procedure. 1 h after the respective 
treatments rats were given free access to HPF and food intake was monitored for 2 h. EXP. 2: NR+S and 
R+S rats were administered with veh or OEA (10 mg kg-1 i.p.) and were allowed to consume the HPF 
only for 1 h. At the end of this procedure rats were sacrificed, their brains immediately collected for 
immunohistochemical evaluation of the pattern of Fos expression and HPLC analyses of monoamine 
turnover. EXP. 3: NR+S and R+S rats were administered with veh or OEA (10 mg kg-1, i.p.) and 
underwent brain microdialysis in the shell of the nucleus accumbens (AcbSh) for the analysis of 
dopamine (DA) extracellular levels (the detailed paradigm of the microdialysis experiment is described in 
the legend of the Fig. 4.5). EXP. 4: NR+S and R+S rats were administered with veh or OEA (10 mg kg-1, 
i.p.) and immediately sacrificed at the end of stress procedure. Their brains were collected for in situ 
hybridization experiment. 
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4.2.3. Experiment 2: Effects of OEA on the pattern of c-Fos expression and 
on monoamine turnover in selected brain areas 
- Brain dissection and sample preparation 
Based on the results obtained from the behavioural study, a second experiment (EXP. 2) 
was conducted focusing on the NR+S and R+S groups of rats treated with either veh or 
OEA at the dose of 10 mg kg-1. In this experiment we evaluated whether the interaction 
between dietary regimen and stress exposure is characterized by a specific pattern of 
brain activation (assessed by the neuronal activity marker c-Fos) and whether OEA 
treatment is able to modulate such pattern. Moreover, as a further aim of this 
experiment we analyzed the effects of OEA on the tissue concentrations of monoamines 
(DA, 5-HT, NA) and their main metabolites in the principal neural nodes that control 
different aspects of food intake in the brain. 30 rats were subjected to the same 
procedure used in EXP.1, but were allowed to consume the HPF only for 1 hour (Fig. 
4.1B). At the end of this procedure all rats were sacrificed, their brains immediately 
collected, snap frozen in 2-metylbutane (-60°C) and stored at -80°C until analysis. The 
experimental paradigm is depicted in Figure 4.1B (EXP.2). The brain analyses included 
immunohystochemical evaluation of the pattern of c-Fos expression and HPLC analyses 
of monoamine turnover. Each brain was sliced into 20 μm serial coronal sections by 
using a cryostat (model HM550; Thermo Fisher Scientific, Kalamazoo, MI, USA). The 
coronal slices were partly mounted on positively charged slides (SuperFrost Plus, 
Menzel, Germany) and stored at -20°C until further analysed for 
immunohystochemistry, partly microdissected into ten regions of interest that were 
collected in microtubes (pooled from both hemispheres), weighed to a high degree of 
accuracy by using a microbalance and stored at -80°C until the HPLC analysis for 
monoamine turnover. These regions included mPFC, striatum (comprising CPu and 
Acb), HYPO, AMY, HIPP, SN, VTA, DR and LC.   
- Immunohistochemistry 
c-Fos immunohistochemistry was performed in brain areas controlling different aspects 
of eating and eating-related behaviour that included the AMY and the PVN, which are 
crucially involved in the control of stress and hedonic/homeostatic feeding respectively, 
different limbic areas (Acb, CPu, VTA and SN), which regulate the reinforcement and 
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the motivational aspects of feeding, the ventral pallidum (VP) and the pedunculopontine 
nucleus (PP), which regulate the activity of DA neurons within the VTA 73.  
The immunohistochemistry protocol was based on our previous study 44. Briefly, brain 
slices containing the desired brain areas underwent antigen retrieval procedure by 
submerging selected slides in a sodium citrate buffer (10 mM pH 6.0) heated at 95°C 
for 5 min 44. Sections were then rinsed with PB (0.1 M pH 7.4) and incubated for 1 h in 
a solution containing 0.1% Triton X-100 (Sigma–Aldrich) and 2% of Normal Donkey 
Serum (Jackson Immunoresearch, Baltimore Pike, Pennsylvania). After additional 
washes, sections were incubated with a solution containing the primary antibody (rabbit 
anti-c-Fos polyclonal primary antibody, 1:5000 dilution, Santa Cruz California) for 2 
overnight at 4°C. The sections were then incubated with biotinylated donkey anti-rabbit 
IgG (1:500 in 0.3% PBT, Jackson Immunoresearch, Baltimore Pike, Pennsylvania) for 2 
h at room temperature. After incubation for 1 h with the ABC Kit (Vectastain ABC kit; 
Vector Laboratories), sections were stained by incubation in DAB (Vector Laboratories) 
chromogen solution. The slides were then rinsed with PBS, dehydrated in graded 
alcohol, immersed in xylene and cover-slipped with Eukitt (Sigma–Aldrich). For the 
semi-quantitative analysis of the slices processed by immunohystochemistry, all brain 
sections were observed under a Nikon Eclipse 80i microscope equipped with a colour 
charge-coupled device camera and controlled by the software NIS-Elements-BR 
(Nikon). Slices were photographed in light field using a 4× objective, and the rat brain 
atlas by Paxinos and Watson 74 was used as reference for the localization of the brain 
areas of interest. c-Fos DAB-immunostaining was measured semi-quantitatively as 
optical density (OD) by using the Scion Image J software and considering, for 
background normalization, the averaged OD either of non-immunoreactive regions or of 
white matter structures within the same brain slice. For this analysis, the investigator 
was blinded to experimental groups and measurements were obtained in at least five 
consecutive tissues sections per animal containing the desired structure. 
- Monoamine- and monoamine metabolite-assay in brain tissues 
Brain samples obtained by microdissections from NR+S and R+S rats, treated with 
either OEA or veh and sacrificed 1 h after gaining access to the HPF, were 
ultrasonicated in ice-cold 0.1 M perchloric acid and then centrifuged at 15000 × g for 20 
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min at 4°C as previously described 75. Supernatants were collected and used for HPLC 
analyses to determine monoamine- and monoamine metabolite concentrations.  
- HPLC analysis 
DA, NA, 5-HT and both 5-HT and DA metabolites, 5-Hydroxyindoleacetic acid (5-
HIAA), homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were 
detected and quantified by HPLC, as previously described by 75,76. Monoamines and 
their metabolites were analysed by microbore HPLC; the detection was accomplished 
with a Unijet cell (BAS) with a 6-mm diameter glassy carbon electrode set at +650 mV 
vs an Ag/AgCl reference electrode, connected to an electrochemical amperometric 
detector (INTRO, Antec Leyden, Netherlands). The analytes were separated using a 
SphereClone 150-mm × 2-mm column (3-μm packing) and a mobile phase composed of 
85 mM of sodium acetate, 0.34 mM EDTA, 15 mM sodium chloride, 0.81 mM of 
octanesulphonic acid sodium salt, 6% methanol (v/v) (pH = 4.85) delivered at a flow 
rate of 800 μl/min for a total runtime of 35 min. For each analysis, a set of standards 
containing various concentrations of each compound (monoamines and their 
metabolites) was prepared in the acid solution to obtain appropriate calibration curves. 
The concentrations of neurotransmitters were determined by linear interpolation from 
standard curves; for tissue monoamines we normalized their concentration to the weight 
of the wet tissue sample. Concentrations of monoamines were reported in pg ml-1 for 
DA extracellular levels and in ng mg-1 for tissue monoamines. DA and 5-HT turnover 
were calculated as the ratio between the metabolite and the monoamine 
(DOPAC+HVA/DA for the DA and 5HIAA/5-HT for the 5-HT). 
Samples of selected brain regions (mPFC, Acb, CPu, HYPO, AMY, HIPP, SN, VTA, 
DR and LC) of all animal groups were processed simultaneously to minimize 
experimental errors. 
4.2.4. Experiment 3: Effects of OEA on dopamine transmission in the 
AcbSh 
- In vivo microdialysis  
NR and R (15-20 per group) rats were deeply anaesthetized with equithesin (3 ml kg-1, 
i.p.), placed on a stereotaxic apparatus (David Kopf Instruments) and implanted with a 
guide cannula (MAB4.15.IC Microbiotech/se AB, Stockholm, Sweden) for 
microdialysis probes (cod. MAB 4.15.2.CU Microbiotech/se AB, Stockholm, Sweden) 
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placed vertically 2mm above the left or the right AcbSh, according to the following 
coordinates 74: (AP = + 2.7 mm from bregma, ML = ± 1.2 mm from midline and DV = - 
5.6 mm from skull; Fig. 4.5A). When the animals had fully recovered from the surgery, 
a probe was inserted in the guide cannula and the microdialysis was carried out in freely 
moving rats, according to our previous study 77. Each microdialysis probe was perfused 
with a KrebsRinger phosphate (KRP) buffer as previously described 78 at a constant 
flow rate of 1.5 μl min-1 and dialysate samples were collected every 15 min in minivials 
containing 5 μl of 10% acetic acid. After an initial wash out period (at least 1h) three 
baseline samples (no more than 10% difference among four consecutive samples) were 
collected before treating rats. Thereafter, rats were administered with OEA (10 mg kg -1, 
i.p.) or veh and after 45 min underwent the stress procedure for 15 min. At the end of 
this procedure, they gained access to HPF for 1h (Fig. 4.1B, EXP.3). After 30 min from 
the end of the HPF exposure, rats were acutely challenged with amphetamine (0.5 mg 
kg-1) administered subcutaneously. Microdialysates were collected up to 1.5 h after 
amphetamine treatment. Each microdialysis sample was analysed by HPLC, that was 
performed as described in the previous section. The correct placement of the probe was 
verified histologically with a post mortem Nissl staining procedure (data not shown) 
and data from animals with incorrect probe implant were excluded from the statistical 
analyses.  
4.2.5. Experiment 4: effects of OEA on frustration stress exposure  
- In situ hybridization of oxy and CRF mRNA  
A third set of 33 rats from the NR and R group was administered with veh or OEA (10 
mg kg-1, i.p.) 45 min before the frustration stress exposure and immediately sacrificed at 
the end of stress. Their brains were collected, immediately snap frozen in 2-
methylbutane (-60°C) and stored at -80°C until they were cut in 20 μm serial coronal 
sections. On these sections we performed in situ hybridization with an antisense [35S]-
labelled riboprobe of rat oxy 47,50 or with an antisense [35S]-labelled riboprobe of rat 
CRF that were both used in our previous studies 47,50,79, to detect oxy mRNA in the PVN 
and CRF mRNA in both PVN and central AMY (CeA).  
Briefly, oxy and CRF riboprobes were generated from linearized vector constructs, by 
in vitro transcription using SP6 RNA polymerases (Roche Diagnostic, Monza, Italy), 
respectively in the presence of both [35S]-CTP and [35S]-UTP. Brain sections were 
then hybridized at 60°C for 16 h in a buffer containing [35S] cRNA (~45,000 dpm 
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ml−1), 10% dextran sulfate, 50% formamide, 1× Denhardt's solution, 100 μg ml−1 
denatured salmon sperm DNA, 0.15 mg ml−1 tRNA and 40 mM dithiothreitol as 
previously described 47. After hybridization, brain sections were exposed to Kodak 
Biomax film (Sigma-Aldrich) for 16 or 4 h to the detect CRF or oxy mRNA, 
respectively. 
The effects of OEA on oxy and CRF mRNA were determined by a semi-quantitative 
autoradiography analysis, as previously described 47,50,79. For semi-quantitative 
autoradiography analysis, films were first scanned (Epson perfection 3200 PHOTO) at 
high resolution (1200 dpi). A brain atlas 74 was used to define the localization of the 
brain structures of interest. Quantitative analyses of hybridized signals were performed 
using the Scion Image software. Optical densities were converted into radioactivity 
concentrations by densitometric analysis of 14C-microscale standards (American 
Radiolabeled Chemicals), so as to create for each film a calibration curve with a linear 
coefficient r2 > 0.9. In every brain section, the OD of the corpus callosum was used as 
background and an integrated OD value was calculated as radioactivity per extension of 
hybridized area. 
For this analysis the investigator was blinded to animal treatment, measurements were 
obtained in at least five consecutive tissues sections per animal containing the desired 
structure. 
4.2.6. Statistical Analyses 
All data were expressed as mean ± SEM. Feeding data were statistically analysed by 
two-way ANOVA for repeated measures, with time as within-subject factor and 
treatment as between-subject factor, followed by Bonferroni’s post hoc test for multiple 
comparisons (IBM SPSS, version 22, IBM Analytics). 
Data obtained from immunohistochemistry, HPLC analysis of tissue monoamines and 
in situ hybridization were statistically analysed by two-way ANOVA, with “diet 
regimen” and “treatment” as the two factors. Tukey’s test was used as a post hoc to 
perform multiple comparisons. Moreover, for analysis of data obtained from the semi-
quantitative densitometric analyses, because of the difference in the number of slices 
examined and the high degree of freedom, the error degrees of freedom were kept 
constant at a value based on the actual number of animals per group used in each 
experiment 44,80.  
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The results from microdialysis experiments resulted homoscedastic and were analysed 
by two-way ANOVA for repeated measures, with time as the within variable and 
treatment as the between variable, followed by Dunnett’s and Bonferroni’s post hoc 
tests for multiple comparisons. Overall, DA extracellular levels were calculated as 
percentages of baseline, which was defined as the average of the first three consecutive 
samples with stable level of neurotransmitters. Unpaired t-test was used to evaluate a 
difference between the marginal means of the first three dialysate samples (basal 
values).  In all instances, the threshold for statistical significance was set at P < 0.05. 
4.3. Results 
4.3.1. The combination of caloric restriction and stress exposure induced 
BED 
In keeping with our previous studies 66–68, we found that, in rats with a history of 
intermittent food restriction, the exposure to 15 min frustration stress increased HPF 
consumption at all the time point of the feeding test conducted on day 25; this stress 
manipulation had no effect on food intake in rats that were not food restricted (Fig. 4.2). 
Three-way ANOVA for repeated measures showed a significant effect of diet regimen 
(Fdiet regimen =14.601 df=1/26, P<0.01), a significant effect of stress (Fstress = 7,336, df = 
1/26, P<0.05) and a significant effect of time (Ftime = 44,017, df = 3/78, P<0.001); no 
interaction between the three factors was observed (Finteraction (time x diet regimen) = 0.214, df = 
3/78, P=0.728; Finteraction (time x stress) = 0.869, df = 3/78, P=0.392; Finteraction (diet regimen x stress) 
= 2.287, df = 1/26, P=0.142; Finteraction (time x diet regimen x stress) = 1.401, df = 3/78, P=0.254). 
The results obtained by Bonferroni post hoc test are indicated in Fig. 4.2. 
 
 
 
 
 
Fig. 4.2: Time course of cumulative HPF intake (kcal kg-1) at different time-points (15, 30, 60, 120 min) 
in NR+NS (non restricted – non stressed), NR+S (non restricted – stressed), R+NS (restricted – non 
stressed) and R+S (restricted – stressed) rats (N=30) after vehicle (veh) administration. Data are 
expressed as mean ± SEM. **P<0.01; ***P<0.001 vs NR+NS veh at the same time point (Bonferroni’s 
test for between groups comparisons). 
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4.3.2. OEA treatment selectively prevented binge-like eating in a dose 
dependent manner 
We found that an acute treatment with OEA, systemically administered to rats  60 min 
before giving free access to HPF (Fig. 4.1B, EXP. 1), was able to selectively prevent 
binge-like eating in animals with a history of intermittent food restriction and exposed 
to stress (R+S rats, Fig. 4.3D), without significantly altering feeding behaviour in the 
other experimental groups (Fig. 4.3 A, B and C). although a trend toward decreased 
food intake, which did not reach statistical significance, was observed in NR+NS rats 
treated with the highest dose of OEA (Fig. 4.3A).  
In particular, OEA decreased frustration stress-induced HPF overconsumption in a 
dose- and time-dependent manner, with the strongest and long-lasting effect observed at 
the dosage of 10 mg kg-1 i.p. (R+S group, Fig. 4.3D), which was effective at all the time 
points considered (i.e. 15, 30, 60 and 120 min). The intermediate dose of OEA (5 mg 
kg-1 i.p.) was effective only during the first 30 min, while no effect was detected in rats 
administered with the lowest dose of OEA, 2.5 mg kg-1 i.p..  
The reduction of HPF intake displayed by R+S rats treated with 10 mg kg-1 OEA ranged 
from a percentage of -62,7%, at the earliest time-point, up to -34,02%, at 120 min (Fig. 
4.3D). Conversely, the initial decrease of HPF consumption observed in R+S rats 
treated with 5 mg kg-1 OEA (-36,3% and –29,8% at 15 and 30 min, respectively), was 
compensated at later time points (Fig. 4.3D).  
The two-way ANOVA for repeated measures of the cumulative food intake of R+S 
group showed a significant effect of treatment (Ftreatment=15.602 df=1/27, P<0.001), a 
significant effect of time (Ftime = 48.741, df = 3/81, P < 0.001) and a significant 
interaction between treatment and time (Finteraction = 4.167, df = 9/81, P < 0.01). 
Significant differences among groups evaluated by the post hoc analysis are indicated in 
Fig. 4.3. 
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Fig. 4.3: Time course of cumulative HPF intake (kcal kg-1) at different time-points (15, 30, 60, 120 min) 
after vehicle (veh) or 3 different doses of OEA (2.5, 5 and 10 mg kg-1 i.p.) administration to NR+NS 
(panel A, non restricted - non stressed, N = 30), NR+S (panel B, non restricted – stressed, N = 26), 
R+NS (panel C, restricted - non stressed, N = 28) and R+S (panel D, restricted – stressed N = 31) rats. 
Data are expressed as mean ± SEM. *P<0.05; **P<0.01; ***P<0.001 vs R+S veh at the same time point 
(Bonferroni’s test for between groups comparisons). 
 
 
4.3.3. OEA treatment affected the brain pattern of c-Fos expression in 
bingeing rats 
Previous studies demonstrated that OEA’s effect on food intake is paralleled by a 
selective induction of c-Fos at the level of the HYPO and brainstem 44,47,50, key brain 
regions involved in the control of feeding 81. In the present work we have expanded our 
previous findings by examining the impact of OEA treatment on the brain pattern of c-
Fos immunostaining in response to 60 min-HPF consumption in female rats with 
different diet histories and exposed to acute stress (R+S vs NR+S, Fig. 4.1B, EXP. 2). 
In particular, we focused our attention on brain areas (Fig. 4.4A) controlling different 
aspects of eating and eating-related behaviour that included the AMY and the PVN, 
which are crucially involved in the control of stress and hedonic/homeostatic feeding 
respectively, different limbic areas (Acb, CPu, VTA and SN), which regulate the 
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reinforcement and the motivational aspects of feeding, the VP and PP, which regulate 
the activity of DA neurons within the VTA 73.  
The results obtained from the semiquantitative analyses of immunostaining optical 
densities revealed that the interaction between intermittent food restriction and stress 
exposure induced an increase of c-Fos expression in the Acb, CPu, AMY, and SN (Fig. 
4.4 C, D, F, and H) of bingeing rats (R+S veh), with respect to non-bingeing rats (NR+S 
veh), and that OEA treatment (10 mg kg-1 i.p.) was able to completely prevent such 
increase, in accordance with the behavioural effects on binge eating. Conversely, c-Fos 
expression within the PVN, PP and VTA (Figure 4.4 E, G and I) resulted unchanged in 
bingeing rats (R+S veh), with respect to non-bingeing rats (NR+S veh), but significantly 
increased by OEA treatment (R+S OEA vs R+S veh), which induced a similar effect 
also in the AMY and PP of NR rats (Fig. 4.4 F, and G, respectively). No difference was 
observed within the VP nucleus among all animal groups (Fig. 4.4B). 
The results from the two-way ANOVA analyses of c-Fos expression levels conducted 
for each of the brain areas considered are reported in Table 4.1; the results obtained 
from the post-hoc analyses are reported in Fig. 4.4. 
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Fig. 4.4: Representative photomicrographs (scale bar = 500 μm, panel A) showing c-Fos immunostaining 
within the ventral pallidum (VP), nucleus accumbens (Acb), caudate putamen (CPu), paraventricular 
nucleus (PVN), amygdala (AMY), pedunculopontine nucleus (PP), substantia nigra (SN) and ventral 
tegmental area (VTA) in brain slices collected from both NR+S (non restricted – stressed) and R+S 
(restricted – stressed) rats treated with either vehicle (veh) or OEA (10 mg kg −1, i.p.) and sacrificed 2 h 
after treatment. Semiquantitative densitometric analysis of c-Fos expression within the VP (panel B), 
Acb (panel C), CPu (panel D), PVN (panel E), AMY (panel F), PP (panel G), SN (panel H) and VTA 
(panel I) of NR+S and R+S rats treated with either veh or OEA (10 mg kg −1, i.p.) and sacrificed 2 h after 
treatment. Data are expressed as mean ± SEM. *P<0.05; ***P<0.001 vs veh in the same diet regimen 
group; °P<0.05; °°P<0.01; °°°P<0.001 vs NR+S in the same treatment group (Tukey’s post hoc test; 
N = 3). 
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Table 4.1: Results of the two-way ANOVA analyses of c-Fos expression observed in different brain 
areas of both NR+S and R+S rats after intraperitoneal injection of OEA or vehicle 
 
Abbreviations: Acb, nucleus accumbens; AMY, amygdala; CPu, caudate putamen; PP, pedunculopontine 
nucleus; PVN, paraventricular nucleus; SN, substantia nigra; VP, ventral pallidum; VTA, ventral 
tegmental area. 
  
  F diet regimen F treatment F interaction df 
VP 1,84 (p=0,202) 0,124 (p=0,73) 0,094 (p=0,76) 1/11 
Acb 3,291 (p=0,097) 13,462 (p<0,01) 14,821 (p<0,01) 1/11 
CPu 0,005 (p=0,945) 1,538 (p=0,241) 16,172 (p<0,01) 1/11 
PVN 2,281 (p=0,159) 7,668 (p<0,05) 0,721 (p=0,414) 1/11 
AMY 14,812 (p<0,01) 12,933 (p<0,01) 43,259(p<0,001) 1/11 
PP 0,622 (p=0,447) 10,574 (p<0,01) 0,039 (p=0,847) 1/11 
SN 1,329 (p=0,273) 0,613 (p=0,450) 4,627 (p=0,054) 1/11 
VTA 0,409 (p=0,536) 0,709 (p=0,418) 4,038 (p=0,069) 1/11 
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4.3.4. OEA treatment dampened AcbSh DA release induced by stress 
exposure or amphetamine challenge 
To investigate whether OEA was able to attenuate binge eating by affecting the central 
dopaminergic response to appetitive/reinforcing stimuli, in a third experiment (Fig. 
4.1B, EXP. 3), 15-min consecutive microdialysate samples were collected from NR and 
R rats through a vertical probe stereotaxically placed in the left or the right AcbSh (Fig. 
4.5A). After an initial wash out period, three baseline samples were collected before 
treating rats with OEA (10 mg kg-1, i.p.) or veh; 45 min later rats underwent the stress 
procedure for 15 min and then they gained access to HPF for 1h; 30 min from the end of 
the HPF exposure, rats were subcutaneously administered with amphetamine (0.5 mg 
kg-1), to burst DA release, and microdialysis was terminated 90 min later. Each 
microdialysate sample was analysed by HPLC and results were expressed as pg/ml for 
basal values (Fig. 4.5B) and as % of basal levels for the time-course of extracellular DA 
levels (Fig. 4.5C and D). 
The basal values were pooled as average of dialysate samples 1–3, and no significant 
difference was detected between the two experimental groups (p=0.7089, unpaired 
student t-test, Fig. 4.5B). OEA administration did not alter DA basal levels, but was 
able to prevent or significantly dampen DA efflux evoked by frustration stress or by 
amphetamine challenge, independently from the history of caloric restriction (Fig. 4.5C 
and D). The results obtained by the two-way ANOVA for repeated measures performed 
in R+S and NR+S rats revealed a significant effect of time, treatment and a significant 
interaction between the two factors (R+S: Ftime = 17.252 df = 18/234, P < 0.001, Ftreatment 
= 27.407 df = 1/13, P < 0.001, Finteraction = 5.018 df = 18/234, P < 0.01; NR+S: Ftime = 
15.216 df = 18/324, P < 0.001, Ftreatment = 6.154 df = 1/18, P < 0.05, Finteraction = 3.142 df 
= 18/234, P < 0.05). The results obtained by post hoc tests are reported in Fig. 4.5. 
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Fig. 4.5: Brain diagram (panel A) illustrating the average sites (red lines) where microdialysis probe was 
implanted. Basal dopamine (DA) extracellular levels (panel B, calculated as marginal means of the first 
three dialysate samples) in the Shell of the nucleus accumbens (AcbSh) of NR+S (non restricted – 
stressed) and R+S (restricted – stressed) rats during microdialysis experiment. Data are expressed as 
mean ± SEM (Unpaired student t-test; N=16-22). 
Time course of extracellular DA levels (expressed as % of basal values) of NR+S (panel C, N = 9-11) 
and R+S (panel D, N = 6-9) rats during microdialysis experiment. The first three samples were collected 
before treating rats with vehicle (veh) or OEA (10 mg kg-1, i.p.) and used as baseline; 45 min after 
treatment rats were subjected to the stress procedure for 15 min and subsequently exposed to HPF for 1 h. 
30 min after the HPF exposure, the rats were given a challenge of amphetamine (0.5 mg kg-1, s.c.).  
Data are expressed as mean ± SEM. *P<0.05; **P<0.01; ***P<0.001 vs the mean of the first three 
samples (basal values) within the same group (Dunnett’s multiple comparison test). °P<0.05; °°P<0.01; 
°°°P<0.001 vs OEA in the same time point (Bonferroni’s test for between group comparisons). Red 
arrow: veh or OEA (10 mg kg −1, i.p.) administration; blue arrow: amphetamine challenge (0.5 mg kg-1, 
s.c.).  
 
4.3.5. OEA treatment affected monoaminergic system in bingeing rats 
Whole tissue concentrations of DA, NA, 5-HT and the metabolites DOPAC, HVA and 
5-HIAA were measured in selected brain regions of both R+S and NR+S animals 
treated with either OEA or veh and consuming the HPF for 1 h (Fig. 1B, EXP. 2), to 
evaluate possible effects on monoaminergic systems. Specifically, we focused not only 
144 
 
on those areas where c-Fos expression was affected by OEA treatment, such as Acb, 
CPu, VTA, SN, VTA, and HYPO, but also on structures involved in the decision 
making, mood tone, memory processes and conditioned responses such as the medial 
prefrontal cortex (mPFC), the hippocampus (HIPP), and the two brainstem nuclei, 
dorsal raphe (DR) and locus coeruleus (LC), which send, respectively, serotonergic and 
noradrenergic inputs to the VTA 72. These brain areas were microdissected and 
monoamines and metabolites were extracted and analysed by HPLC; the results were 
expressed as ng mg-1 of wet tissue, as reported in Table 4.2. DA and 5-HT turnovers 
were calculated as the concentration ratios DOPAC+HVA/DA and 5HIAA/5-HT, 
respectively (Table 4.2). Results obtained from two-way ANOVA analyses conducted 
for each parameter are reported in Table 4.3, whereas the results from the post hoc 
analyses (Tukey’s test) are reported in Table 4.2. Overall, the results revealed that OEA 
treatment affected mainly monoaminergic tissue concentration/turnover in bingeing rats, 
rather than in NR+S rats, and that the baseline differences between the two 
experimental groups resulted quite limited (NR+S veh vs R+S veh). In fact, in NR+S 
rats the effects of OEA treatment included only an increase of NA and DA 
concentration within the HYPO and VTA, respectively, and an increase of 5-HT 
turnover in the Acb. When compared to NR+S rats administered with veh, bingeing rats 
(R+S veh) showed per se an increased DA turnover in the mPFC and AMY, as well as 
an increased 5-HT turnover and 5-HT tissue concentration in the AMY and HYPO, 
respectively. These increased turnovers were completely prevented by OEA treatment, 
which was able to increase both DA and 5-HT concentration in the mPFC, causing also 
a decrease of 5-HT turnover in R+S rats. DA tissue concentrations were affected by 
OEA treatment also in Acb (where it decreased) and VTA (where it increased) of R+S 
rats, without producing any effect on DA turnover. Similarly, OEA administration to 
R+S rats caused a marked increase of 5HT tissue concentrations also in Acb, HYPO, 
HIPP, VTA, and LC, without affecting 5-HT turnover in these areas. Finally, OEA 
treatment caused a significant increase of NA concentration in the CPu, HYPO, VTA, 
and LC.  
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Table 4.2: concentrations of tissue monoamines (expressed in ng mg-1 of wet tissue) and their 
turnover in the brain regions of interest in NR+S and R+S rats after intraperitoneal injection of 
OEA or vehicle. 
 
Data are expressed as mean ± SEM. *P<0.05; **P<0.01 and ***P<0.001 vs veh in the same diet regimen 
group, °P<0.05; °°P<0.01 vs NR+S in the same treatment group (Tukey’s post hoc test; N = 4-8). 
Abbreviations: Acb, nucleus accumbens; AMY, amygdala; CPu, caudate putamen; DR, dorsal raphe; 
HIPP, hippocampus; HYPO, hypothalamus; LC, locus coeruleus; mPFC, medial prefrontal cortex; OEA 
(10 mg kg −1, i.p.); SN, substantia nigra; veh, vehicle; VTA, ventral tegmental area. 
VEH OEA VEH OEA
DA 0,05 ± 0,01   0,05 ± 0,005   0,03 ± 0,002 0,06 ± 0,01
DOPAC+HVA/DA 3,07 ± 0,16 2,69 ± 0,52 4,48 ± 0,41 2,11 ± 0,19
NA 0,20 ± 0,03 0,20 ± 0,02 0,20 ± 0,02 0,19 ± 0,03
5HT 0,08 ± 0,01 0,09 ± 0,01 0,07 ± 0,01 0,14 ± 0,03
5HIAA/5HT 4,13 ± 0,67 3,54 ± 0,80 5,15 ± 1,11 2,44 ± 0,31
DA 1,40 ± 0,28 0,81 ± 0,16 1,29 ± 0,18 0,64 ± 0,16
DOPAC+HVA/DA 0,74 ± 0,23 0,96 ± 0,13 1,02 ± 0,16 0,86 ± 0,22
NA 0,12 ± 0,03 0,12 ± 0,03 0,12 ± 0,02 0,12 ± 0,02
5HT 0,07 ± 0,02 0,06 ± 0,01 0,06 ± 0,01 0,13 ± 0,03
5HIAA/5HT 0,63 ± 0,08 0,99 ± 0,17 0,68 ± 0,06 0,42 ± 0,08
DA 2,56 ± 0,52 2,74 ± 0,64 2,34 ± 0,36 2,18 ± 0,52
DOPAC+HVA/DA 0,59 ± 0,14 0,65 ± 0,14 0,69 ± 0,08 0,48 ± 0,06
NA 0,07 ± 0,01 0,10 ± 0,01 0,10 ± 0,01 0,14 ± 0,01
5HT 0,15 ± 0,02 0,11 ± 0,02 0,12 ± 0,02 0,12 ± 0,02
5HIAA/5HT 2,43 ± 0,51 3,21 ± 0,62 2,87 ± 0,65 2,77 ± 0,76
DA 0,28 ± 0,03 0,39 ± 0,11 0,25 ± 0,06 0,35 ± 0,03
DOPAC+HVA/DA 0,52 ± 0,10 0,48 ± 0,06 0,50 ± 0,07 0,36 ± 0,05
NA 0,90 ± 0,07 1,45 ± 0,11 1,06 ± 0,14 1,56 ± 0,21
5HT 0,24 ± 0,03 0,32 ± 0,04 0,44 ± 0,06 0,59 ± 0,07
5HIAA/5HT 3,13 ± 0,61 2,30 ± 0,88 2,17 ± 0,24 1,23 ± 0,18
DA 0,40 ± 0,13 0,43 ± 0,07 0,59 ± 0,24 0,36 ± 0,09
DOPAC+HVA/DA 0,59 ± 0,09 0,46 ± 0,08 0,92 ± 0,16 0,47 ± 0,07
NA 0,24 ± 0,05 0,23 ± 0,04 0,28 ± 0,08 0,19 ± 0,03
5HT 0,10 ± 0,03 0,16 ± 0,04 0,07 ± 0,02 0,10 ± 0,03
5HIAA/5HT 0,94 ± 0,41 1,39 ± 0,36 3,16 ± 1,22 1,16 ± 0,37
DA 0,02 ± 0,01 0,03 ± 0,01 0,02 ± 0,01 0,03 ± 0,01
DOPAC+HVA/DA 3,11 ± 0,75 3,86 ± 1,06 3,67 ± 1,00 2,88 ± 0,84
NA 0,22 ± 0,04 0,20 ± 0,02 0,23 ± 0,04 0,27 ± 0,03
5HT 0,11 ± 0,02 0,12 ± 0,03 0,09 ± 0,02 0,22 ± 0,05
5HIAA/5HT 4,27 ± 0,73 3,85 ± 0,51 4,83 ± 0,75 4,08 ± 0,42
DA 0,18 ± 0,03 0,17 ± 0,03 0,13 ± 0,03 0,15 ± 0,01
DOPAC+HVA/DA 0,93 ± 0,09 0,94 ± 0,07 1,07 ± 0,10 0,73 ± 0,10
NA 0,17 ± 0,03 0,23 ± 0,05 0,19 ± 0,03 0,24 ± 0,02
5HT 0,19 ± 0,05 0,26 ± 0,07 0,14 ± 0,04 0,24 ± 0,03
5HIAA/5HT 3,11 ± 0,90 3,60 ± 0,86 2,90 ± 0,55 1,30 ± 0,21
DA 0,17 ± 0,02 0,34 ± 0,07 0,18 ± 0,03 0,34 ± 0,06
DOPAC+HVA/DA 0,90 ± 0,11 0,79 ± 0,09 0,95 ± 0,08 0,73 ± 0,08
NA 0,24 ± 0,02 0,28 ± 0,07 0,20 ± 0,03 0,34 ± 0,03
5HT 0,13 ± 0,02 0,16 ± 0,04 0,11 ± 0,02 0,24 ± 0,04
5HIAA/5HT 1,78 ± 0,59 1,92 ± 0,47 1,72 ± 0,41 1,43 ± 0,29
DA 0,05 ± 0,01 0,09 ± 0,01 0,07 ± 0,01 0,09 ± 0,03
DOPAC+HVA/DA 0,31 ± 0,04 0,17 ± 0,03 0,33 ± 0,08 0,33 ± 0,06
NA 0,15 ± 0,02 0,21 ± 0,02 0,18 ± 0,05 0,19 ± 0,05
5HT 0,04 ± 0,01 0,08 ± 0,01 0,11 ± 0,03 0,19 ± 0,06
5HIAA/5HT 1,07 ± 0,47 1,30 ± 0,68 1,67 ± 0,74 1,13 ± 0,43
DA 0,07 ± 0,01 0,08 ± 0,01 0,06 ± 0,01 0,10 ± 0,01
DOPAC+HVA/DA 0,87 ± 0,14 0,71 ± 0,16 0,64 ± 0,06 0,70 ± 0,08
NA 0,32 ± 0,06 0,29 ± 0,07 0,22 ± 0,05 0,40 ± 0,05
5HT 0,07 ± 0,03 0,10 ± 0,04 0,06 ± 0,01 0,16 ± 0,04
5HIAA/5HT 2,76 ± 0,95 2,41 ± 0,37 2,63 ± 0,34 2,98 ± 0,53
DR
LC
RestrictionNo restriction
Acb
HIPP
mPFC
CPu
VTA
SN
HYPO
AMY
* 
* 
*
, 
° 
°° 
*
, 
° 
* 
* 
* 
** 
° 
° 
** 
*** 
* 
* 
* * 
° °° 
* 
° 
° 
** 
* 
° 
° 
* 
* 
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Table 4.3: Results of the two-way ANOVA analyses of brain tissue monoamines and their turnover 
in NR+S and R+S rats after intraperitoneal injection of OEA or vehicle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: Acb, nucleus accumbens; AMY, amygdala; CPu, caudate putamen; DR, dorsal raphe; 
HIPP, hippocampus; HYPO, hypothalamus; LC, locus coeruleus; mPFC, medial prefrontal cortex; SN, 
substantia nigra; VTA, ventral tegmental area. 
F diet regimen F treatment F interaction df
DA 0,009 (p=0,927) 5,930 (p<0,05) 3,705 (p=0,069) 1/23
DOPAC+HVA/DA 1,332 (p=0,262) 14,739 (p<0,01) 7,648 (p<0,05) 1/23
NA 0,045 (p=0,834) 0,041 (p=0,842) 0,001 (p=0,978) 1/24
5HT 1,242 (p=0,281) 4,512 (p<0,05) 2,719 (p=0,118) 1/20
5HIAA/5HT 0,003 (p=0,960) 4,361 (p=0,051) 1,818 (p=0,194) 1/21
DA 0,449 (p=0,511) 8,902 (p<0,01) 0,023 (p=0,882) 1/22
DOPAC+HVA/DA 0,191 (p=0,666) 0,021 (p=0,886) 0,890 (p=0,356) 1/25
NA 0,000 (p=0,984) 0,007 (p=0,933) 0,041 (p=0,842) 1/27
5HT 2,211 (p=0,152) 2,175 (p=0,155) 4,308 (p=0,050) 1/24
5HIAA/5HT 7,405 (p<0,05) 0,209 (p=0,654) 10,034 (p<0,01) 1/18
DA 0,596 (p=0,447) 0,000 (p=0,984) 0,107 (p=0,747) 1/29
DOPAC+HVA/DA 0,103 (p=0,751) 0,444 (p=0,511) 1,600 (p=0,217) 1/29
NA 5,602 (p<0,05) 6,349 (p<0,05) 0,622 (p=0,438) 1/28
5HT 0,119 (p=0,733) 1,279 (p=0,269) 1,032 (p=0,320) 1/27
5HIAA/5HT 0,000 (p=0,998) 0,262 (p=0,613) 0,450 (p=0,508) 1/29
DA 0,307 (p=0,585) 2,715 (p=0,114) 0,009 (p=0,926) 1/25
DOPAC+HVA/DA 0,931 (p=0,345) 1,570 (p=0,223) 0,512 (p=0,482) 1/25
NA 0,729 (p=0,402) 11,151 (p<0,01) 0,019 (p=0,891) 1/25
5HT 17,355 (p<0,01) 3,940 (p=0,062) 0,362 (p=0,554) 1/22
5HIAA/5HT 3,842 (p=0,065) 2,911 (p=0,104) 0,012 (p=0,913) 1/22
DA 0,146 (p=0,706) 0,468 (p=0,501) 0,696 (p=0,413) 1/26
DOPAC+HVA/DA 2,699 (p=0,113) 7,952 (p<0,01) 2,542 (p=0,124) 1/27
NA 0,000 (p=0,999) 0,826 (p=0,373) 0,589 (p=0,451) 1/25
5HT 2,458 (p=0,131) 2,062 (p=0,165) 0,270 (p=0,608) 1/25
5HIAA/5HT 2,094 (p=0,163) 1,285 (p=0,270) 3,202 (p=0,088) 1/24
DA 0,004 (p=0,947) 1,254 (p=0,268) 0,071 (p=0,791) 1/27
DOPAC+HVA/DA 0,055 (p=0,816) 0,000 (p=0,985) 0,688 (p=0,411) 1/27
NA 1,317 (p=0,256) 0,037 (p=0,847) 0,862 (p=0,357) 1/28
5HT 1,355 (p=0,250) 3,698 (p=0,060) 2,743 (p=0,104) 1/28
5HIAA/5HT 0,395 (p=0,532) 0,875 (p=0,354) 0,067 (p=0,797) 1/28
DA 1,756 (p=0,198) 0,056 (p=0,815) 0,335 (p=0,568) 1/27
DOPAC+HVA/DA 0,134 (p=0,717) 2,881 (p=0,103) 3,383 (p=0,078) 1/27
NA 0,058 (p=0,812) 2,591 (p=0,121) 0,015 (p=0,905) 1/26
5HT 0,489 (p=0,492) 3,032 (p=0,095) 0,040 (p=0,843) 1/26
5HIAA/5HT 3,293 (p=0,083) 0,668 (p=0,422) 2,277 (p=0,146) 1/25
DA 0,027 (p=0,871) 12,471 (p<0,01) 0,005 (p=0,942) 1/24
DOPAC+HVA/DA 0,007 (p=0,933) 3,643 (p=0,068) 0,377 (p=0,545) 1/28
NA 0,136 (p=0,716) 5,210 (p<0,05) 1,378 (p=0,251) 1/29
5HT 0,857 (p=0,363) 7,130 (p<0,05) 2,811 (p=0,106) 1/29
5HIAA/5HT 0,396 (p=0,535) 0,033 (p=0,858) 0,24 (p=0,629) 1/29
DA 0,055 (p=0,817) 3,049 (p=0,094) 0,278 (p=0,603) 1/27
DOPAC+HVA/DA 2,945 (p=0,101) 1,707 (p=0,205) 1,428 (p=0,245) 1/24
NA 0,031 (p=0,862) 0,656 (p=0,427) 0,224 (p=0,640) 1/25
5HT 6,361 (p<0,05) 2,978 (p=0,099) 0,310 (p=0,584) 1/23
5HIAA/5HT 0,110 (p=0,744) 0,060 (p=0,809) 0,353 (p=0,559) 1/22
DA 0,066 (p=0,799) 2,962 (p=0,098) 1,069 (p=0,311) 1/28
DOPAC+HVA/DA 1,296 (p=0,266) 0,196 (p=0,622) 1,196 (p=0,285) 1/27
NA 0,019 (p=0,892) 1,688 (p=0,206) 3,115 (p=0,090) 1/27
5HT 0,575 (p=0,456) 3,573 (p=0,071) 0,756 (p=0,393) 1/27
5HIAA/5HT 0,184 (p=0,672) 0,000 (p=0,996) 0,459 (p=0,506) 1/24
DR
LC
Acb
HIPP
HYPO
mPFC
Cpu
VTA
SN
AMY
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4.3.6. OEA treatment affected CRF mRNA level in the AMY and oxy 
expression in the PVN of bingeing rats  
Our previous studies demonstrated the crucial role of oxytocinergic neurotransmission 
in mediating the hypophagic effect of OEA 47 and the pivotal role of CRF system in 
sustaining binge eating behaviour in our rat model 68. Since both oxy and CRF can be 
affected by frustration stress, we assessed the “pure” effects of OEA on stress response 
without the potential impact of food intake to evaluate whether the anti-bingeing effects 
of OEA in this model might be attributed to a reduced effect of stress exposure. To this 
aim, we measured both CRF and oxy mRNA by in situ hybridization of radiolabelled 
probes in the brains of NR+S and R+S rats treated with either OEA or veh and 
sacrificed at the end of the stress exposure (Fig. 4.1B, EXP. 4). As shown in the 
representative autoradiography reported in Fig. 4.6A and C, CRF mRNA signal was 
detected in the CeA and in the PVN.  
The results of the densitometric analyses of CeA were statistically analysed by two-way 
ANOVA that revealed no effect of caloric restriction and no effect of treatment 
(Frestriction = 3.026 df = 1/19, P = 0.098, Ftreatment = 0.169 df = 1/19, P =0.6856 
respectively) but a significant interaction between the two factors (Finteraction = 9.491 df = 
1/19, P < 0.01). Post hoc analyses, demonstrated that OEA treatment was able to reduce 
CRF mRNA in the CeA of bingeing rats, without affecting the same parameter in the 
PVN (Fig. 4.6B and D, respectively), where the two-way ANOVA revealed no 
significant effect (Frestriction = 0.455 df = 1/21, P =0.507, Ftreatment = 0.468 df = 1/21, P = 
0.50, Finteraction = 1.066 df = 1/21, P = 0.587).  
This observation confirms our previous data supporting the crucial role of CRF system 
at extra-hypothalamic level in binge-like HPF consumption in our rat model 68.  
We previously demonstrated that peripheral administration of OEA was able to activate 
a subpopulation of PVN neurons that included mostly, albeit not exclusively, 
oxytocinergic neurons 47. Based on these observations, the last aim of our study was to 
evaluate whether the combination of caloric restriction, frustration stress exposure and 
OEA treatment could affect oxy mRNA expression in the PVN (Fig. 4.7A). The two-
way ANOVA of data obtained from the semiquantitative densitometric analyses 
revealed a significant effect of food restriction (Frestriction = 9.897 df = 1/232, P = 0.0051) 
no effect of treatment, (Ftreatment = 1.058 df = 1/232, P = 0.3159) and a significant 
interaction between the two factors (Finteraction = 5.544 df = 1/232, P = 0.0288). The post-
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hoc analyses demonstrated that oxy mRNA expression was significantly increased in 
bingeing rats treated with OEA (Fig. 4.7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.6: Representative in situ hybridization images (scale bar = 1 mm) of corticotropin-releasing factor 
(CRF) mRNA expression within the central amygdala (CeA, panel A) and the paraventricular nucleus 
(PVN, panel C) of NR+S (non restricted – stressed) and R+S (restricted – stressed) rats treated with 
either vehicle (veh) or OEA (10 mg kg −1, i.p.) and sacrificed 1 h after the treatment. Semiquantitative 
densitometric analyses of CRF mRNA in the CeA (panel B) and PVN (panel D) of NR+S and R+S rats 
treated with either veh or OEA (10 mg kg −1, i.p.) and sacrificed 1 h after treatment. Data are expressed as 
mean ± SEM. *P<0.05 vs veh in the same diet regimen group; °°P<0.01 vs NR+S in the same treatment 
group (Tukey’s post hoc test; CeA: N = 4-6, PVN: N = 5-6). 
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Fig. 4.7: Representative in situ hybridization images (scale bar = 1 mm) of oxytocin (oxy) mRNA 
expression in the paraventricular nucleus (PVN, panel A) of NR+S (non restricted – stressed) and R+S 
(restricted– stressed) rats treated with either vehicle (veh) or OEA (10 mg kg −1, i.p.) and sacrificed 1 h 
after treatment. Semiquantitative densitometric analyses of oxy mRNA expression in the PVN (panel B) 
of NR+S and R+S rats treated with either veh or OEA (10 mg kg −1, i.p.) and sacrificed 1 h after 
treatment. Data are expressed as mean ± SEM. *P<0.05 vs veh in the same diet regimen group; 
°°°P<0.001 vs NR+S in the same treatment group (Tukey’s post hoc test; N = 5-6).  
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4.4. Discussion  
This study demonstrates for the first time that OEA prevents binge-like palatable food 
consumption induced by stress in female rats with a history of food restriction, 
suggesting that this lipid signal might represent a potential target for the development of 
more efficacious and safer treatments for BED or for other eating disorders 
characterized by binge episodes. 
The effect of OEA was dose- and time-dependent, being long-lasting at the dose of 10 
mg kg-1 i.p.. According to previous reports from our laboratory and from other research 
groups 40,44,47,50,51, this dosage is able to induce satiety in both free-feeding and food-
deprived rats, without causing motor impairment, malaise, pain or hormonal and body 
temperature alterations in adults rats. The same dosage is also able to reduce food intake 
in fasted/refed Magel2 knock out mice, an animal model of Prader-Willi syndrome, 
characterized by hyperphagia and overweight with respect to wild type littermates 82.  
In particular, 10 mg kg-1 OEA selectively reduces HPF consumption in bingeing rats at 
all the time points considered and the HPF intake reduction ranges from a percentage of 
-62,7% at earliest time-point until -34,02% at 120 minutes, when, according with 
previous behavioural OEA studies 55, rats treated with OEA did not compensate the 
food they did not eat during the earlier time points.  
The mechanism accounting for this selective anti-binge effect remains to be fully 
elucidated; it is known that the compulsive eating during the BED is also associated to a 
stimulation of the HPA axis and an elevation of CORT levels, indeed our rats display an 
increase of serum CORT levels at the end of the stress procedure which corresponds to 
the access to the HPF 66. Interestingly, as reported in the introduction, OEA is able to 
influence the stress response by reducing the HPA axis activation, ACTH and CORT 
levels in an experimental paradigm inducing stress 61,83, thus suggesting that in our 
circumstances the behavioural effect of OEA might be attributed, at least in part, to its 
effect in dampening the HPA axis hyperactivation. Moreover, CORT is able to motivate 
drug-seeking behaviour in rats 84 and we hypothesize that in our rat model it might play 
a crucial role in compulsive behaviour towards food, which resembles the driving 
motivated behaviour typical of a state of addiction. On this regard, it has been shown 
that OEA and PPAR-α agonists decrease nicotine self-administration and nicotine 
seeking in rats and monkeys by preventing nicotine-induced excitation of dopaminergic 
neurons in the AcbSh 85. Similarly, it has been shown that the inhibition of fatty acid 
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amide hydrolase enzyme, which increases the bioavailability of OEA, impedes nicotine-
induced activation of neurons in the AcbSh 86. Additionally OEA has been 
demonstrated to block cue-induced reinstatement of alcohol- self administration and -
seeking behaviour 87 and to block the acquisition and expression of cocaine-induced 
conditioned place preference and cocaine-induced sensitization 88. On the bases of these 
observations, we hypothesize that the inhibition of compulsive eating in our rat model 
exerted by OEA, resembles the capability of this compound to counteract the addiction-
related behaviours described so far. 
Moreover, in the present study we were unable to detect any significant effect of OEA 
on feeding behaviour of female rats belonging to the three other experimental groups, 
which did not show binge-like palatable food intake within the timeframe of the 
experiment. This observation suggested us that the anti-binge effect observed after OEA 
administration was not the expression of an anorexiant action due to satiety induction, 
as found in previous studies, but rather the consequence of the selective inhibition of 
“hedonic hunger”, which refers to the compulsive consumption of food for pleasure and 
not to maintain energy homeostasis 89,90. 
Based on this result, we focused our attention on the so called “dopamine motive 
system”, according to the definition adopted by Dr. Wolkow and colleagues, that refers 
to the brain areas controlling the reinforcement and motivational aspects of feeding 72. 
By analyzing neuronal activation of brain areas that partake directly or indirectly to this 
circuit, we found that OEA treatment is able to restore a “normal” brain activity, by 
reducing the stress-induced c-Fos increase in brain areas regulating the dopaminergic 
signalling namely the Acb, the CPu, and the SN. Interestingly opposite effects were 
observed within the VTA, where DA cell bodies projecting to the Acb through the 
mesolimbic pathway are located, and at the level of the PP (Fig. 4.8A). No effect has 
been observed within the VP, which sends gabaergic projections to the VTA, where it 
guarantees basal DA cell activity (tonic DA release) (Fig. 4.8A) 73. The fact that OEA 
has no effect on the activation of the VP, is therefore consistent with its ability to 
increase VTA neuronal activity (see discussion in the text regarding tissue monoamine 
concentrations). Moreover, the OEA-induced c-Fos increase in the PP is also consistent 
with the increase of VTA neuronal activity in bingeing rats after OEA administration. In 
fact, the PP is implicated in promoting burst-firing of DA cells (phasic DA release, 
action potential) within the VTA, and an activation of the PP is strictly related to the 
activation of VTA dopaminergic neurons (Fig. 4.8A) 73. We hypothesize that the results 
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obtained within the AMY, where OEA significantly decreases stress-induced c-Fos 
activation in bingeing rats, might refer to the ability of this lipid to counteract the 
neurological mechanism related to stress. At the level of the CeA, in fact, the CRF 
system, whose activation is crucially involved in frustration stress-induced binge eating 
in our rat model 67, coordinates the affective reactions to stress 91. In keeping with this 
latter observation, and overlapping the trend obtained by the c-Fos analysis within the 
AMY, we found that OEA was able to decrease CRF mRNA at the level of the CeA in 
bingeing rats, while no significant differences were observed in CRF mRNA levels 
within the PVN (Fig. 4.8B), thus confirming recent findings demonstrating that 
hypothalamic CRF system is not sufficient to account for binge-like HPF consumption 
in our BED model 68. Furthermore, the ability of OEA to increase c-Fos expression 
within the PVN of bingeing rats might be linked to the activation of oxytocinergic 
neurons (Fig. 4.8C), highly expressed in this brain area. The increased oxy mRNA 
levels observed in R+S rats treated with OEA is in accordance with this hypothesis and 
is in line with our previous studies indicating that the behavioural effect of OEA on 
food intake is linked to the activation of the central oxytocinergic system 47,58. 
Brain DA signaling is essential for the reinforcing/rewarding properties of several 
stimuli, such as drug of abuse and food; additionally a large body of evidence suggests 
that brain DA regulates the entire body energy homeostasis 92–94. Two are the brain 
dopaminergic pathways involved in hedonic feeding: 1) the nigrostriatal circuit, which 
maintains constant levels of fat ingestion by regulating the food consumption phase, and 
2) the mesolimbic dopaminergic circuit, which plays a pivotal role in the drive towards 
high caloric palatable food (motivation to consume food, particularly energy-dense 
food) and is also associated to stress- and cue-induced feeding 95. Previous studies from 
Tellez and collaborators 59 have linked the anorexigenic effect of OEA to its ability to 
restore a dorsal striatal DA release in diet-induced obese (DIO) mice displaying a deficit 
in nigrostriatal DA signalling in response to fat ingestion. Tellez’s study suggested for 
the first time that OEA might regulate the reward value of fat by establishing a link 
between caloric-homeostatic and hedonic-homeostatic control of eating. In the present 
work we focused our attention at the AcbSh level, where the DA release is promoted by 
addictive drugs, palatable food and by acute stress challenge 96–99.  
We observed that restricted and non restricted rats were characterized by similar DA 
baseline levels and similarly responded to stress, with a small pick increase of 
extracellular DA concentrations. Moreover, in both groups, HPF consumption was 
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unable to evoke DA release in accordance with previous observations showing that 
AcbSh DA responds only when the palatable food is consumed for the first time, 
differently from the core of the Acb (AcbC) where DA levels increase whenever the 
food is ingested and such increase is not related to the palatability or to the novelty 100. 
We found that OEA treatment was able to significantly dampen DA release evoked by 
frustration stress within the AcbSh of both non-restricted and restricted rats. 
This result is supported by previous observations suggesting that the activation of 
PPAR-α receptors (through OEA or the synthetic PPAR-α agonist WY14643 
administration) dampens the activity of DA neurons within the VTA and decreases the 
nicotine-inducing DA release in the Acb 85,101. At the basis of this response the authors 
hypothesize a rapid and non-genomic activity of PPAR-α receptors which consists in a 
phosphorylation of nicotinic receptors present on dopaminergic neurons of the VTA, by 
promoting their internalization and by abolishing the response of DA neurons to 
nicotine 102. Additionally, we observed that peripheral OEA is able to revert also the 
effect of amphetamine in both restricted and non-restricted animals. In fact, we found 
that OEA significantly reduced DA release evoked by the subcutaneous challenge of 
amphetamine. Amphetamine promotes monoaminergic transmission by recruiting 
several mechanisms including the blocking of the DA, NA and 5-HT transporters 
(DAT, NET, and SERT respectively). Moreover, amphetamine acts as substrate of the 
monoamine transporters, competes with the neurotransmitter substrate and enter the 
presynaptic neurons. Inside the nerve terminals, amphetamine inhibits the vesicular 
monoamine transporter 2 (VMAT2). As result of these latter mechanism, amphetamine 
reverses the transport of monoamines by pumping them into the synapse 103. This is not 
the first time that OEA has been associated to the effect induced by amphetamine-like 
compounds; for instance it has been demonstrated that OEA prevents MDMA-induced 
cognitive deficits in mice 104. Moreover, the same authors demonstrated that OEA is 
also able to prevent MDMA-induced DAT loss; similarly, in the present work, we 
suggest that peripheral administration of OEA might prevent the reduction of DAT 
induced by amphetamine, and this effect might contribute to a restoration of a 
physiologic DA release. OEA might therefore have a protective role against the 
abnormalities evoked by psychostimulant drugs such as amphetamine, at least regarding 
tonic dopaminergic neuronal activity, which is possible to measure through brain 
microdialysis experiment 105. In keeping with results obtained by brain microdialysis 
experiment, we found that OEA also reduces DA tissue levels within the Acb of 
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bingeing rats; interestingly opposite results were observed at the level of the VTA, 
where OEA induces a significant increase of DA tissue concentration in both restricted 
and non restricted animals without altering DA turnover. We think that these latter 
results might occur in virtue of OEA capability to activate the PP which, as previously 
mentioned in the text, sends excitatory glutamatergic inputs to the VTA where it 
mediates DA burst firing (phasic DA release) (Fig. 4.8A) 73. 
The observation that the increase in DA VTA concentration induced by OEA does not 
produce a discernible increase in DA levels within the Acb was surprising for us, since 
burst firing is the main mechanism by which DA is released. However, we hypothesize 
that OEA-induced PP activation produces a massive DA release that will be highly 
located at the synaptic cleft level; this huge amount of DA stimulates reuptake 
mechanisms and the activation of presynaptic DA type 2 receptors (D2R), which would 
then result in a rapid downregulation of the dopaminergic tone (Fig. 4.8A). As far as the 
DA turnover, which is an index of neurotransmitter activity 106,107, we found that OEA 
dampens the DA turnover induced by frustration stress exposure in bingeing rats in both 
mPFC and AMY. On this regard it has been demonstrated that DA type 1 receptors 
(D1R), highly expressed within the mPFC, play a crucial role in food-related behaviour 
108 by activating a population of glutamatergic neurons within the AMY 109, which, in 
turn, project to the Acb and modulate the appetitive drive motivation 110. The increase 
of DA turnover that we observe in bingeing rats treated with veh is in line with previous 
study suggesting that the activation of D1 family receptors in the mPFC is involved in 
the stress-induced drug seeking, and in yohimbine-induced of food seeking 111. We 
therefore hypothesize that OEA might dampen the hyperactivity of the dopaminergic 
system in the mPFC which, in turn, reflects a decrease in DA activity also within the 
AMY by restoring a physiological dopaminergic transmission. This is supported by the 
values of the turnover measured in bingeing rats treated with OEA, which are 
comparable to those of control animals (no restricted animals). As far as the 
serotonergic system, we found that OEA is able to enhance 5-HT transmission in most 
of the brain areas analysed selectively in bingeing rats. We think that the increase of 5-
HT observed within the HYPO is consistent with its role in the control of appetite 112; in 
fact drugs like d-fenfluramine, sibutramine, fluoxetine (selective serotoninergic 
reuptake inhibitor) (SSRIs)) and 5-HT2C receptor agonists significantly induce 
hypophagia in laboratory rodent and reduce caloric intake in both lean and obese 
humans 113. We therefore hypothesize that the anti-binge effect induced by OEA in 
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bingeing rats might occur, at least in part, because of its effect in promoting a high 
serotonergic tone. Moreover, our previous study demonstrated that both Sibutramine 
and Fluoexetine are efficient in reducing HPF intake in this rat model of BED 66, further 
supporting that an increase of 5-HT tone might be a valid approach for the treatment of 
this pathology. Importantly, differently from sibutramine and fluoexetine, which are 
able to reduce HPF intake also in the other experimental groups (NR+NS, R+NS and 
NR+S), the effect induced by OEA is selective in reducing HPF intake in bingeing rats, 
without modifying HPF intake in control animals (NR+NS) or in animal that 
experienced food restriction or stress separately (R+NS and NR+S). Additionally, 5-
HT2c receptors are located not only within the HYPO, where they modulate homeostatic 
feeding, but also within the VTA, Acb and mPFC where they regulate DA cell activity 
associated with several behaviours, including reward and impulse control 114–116; such 
effect is supported by the finding that lorcaserin (a selective 5-HT22c receptor agonist) 
reduces binge eating in mice by stimulating dopaminergic transmission 30. Moreover, 
since the increase of serotonergic tone is also able to alleviate depressive-like symptoms 
117, in keeping with very recent findings obtained by Costa and collaborators 60 we think 
that the high levels of 5-HT induced by OEA might also counteract the depressive-like 
state that often occurs in subject suffering from BED. Finally, we also found that OEA 
increases the noradrenergic tone in most of the brain region analysed. We hypothesize 
that the increase observed within the LC might reflect an increase in the NA synthesis 
exerted by OEA, since this is the brain area in which reside the cell bodies of 
noradrenergic neurons. Moreover, the OEA-induced NA increase within the HYPO is 
consistent with our previous study demonstrating that the behavioural effects of OEA 
are strictly dependent from the activation of a noradrenergic pathway connecting the 
brainstem to the HYPO 51. Finally, our results are in keeping with previous study from 
others 53 demonstrating that i.p. OEA induces a dose-dependent increase in the levels of 
hypothalamic NA. NA, in fact, is released within the HYPO during consumption of a 
meal and correlates with the meal size thus suppressing food intake 118. 
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Fig. 4.8: Schematic drawing illustrating the putative interactions between OEA and the central 
dopaminergic system (panel A), the hypothalamic-pituitary-adrenal (HPA) axis (panel B) and the 
central oxytocinergic system (panel C).  
Panel A: the OEA-induced Fos increase in the pedunculopontine nucleus (PP) produces a massive 
dopamine (DA) release at the level of the ventral tegmental area (VTA), this huge amount of DA 
activates presynaptic DA type 2 receptors (D2R) thus resulting in a rapid downregulation of the 
dopaminergic tone and leading to a lower release of DA in the shell of the nucleus accumbens (AcbSh) of 
both NR+S (non restricted – stressed) and R+S (restricted – stressed) rats as we observed by the 
microdialysis study. In accordance with this hypothesis, OEA does not induce an activation of the ventral 
pallidum (VP, in terms of Fos activation), which sends gabaergic projections to the VTA.  
Panel B: The stress response is associated to a stimulation of the HPA axis. OEA is able to decrease Fos 
expression and CRF mRNA levels within the amygdala (AMY) in R+S rats, thus suggesting the ability of 
this lipid to counteract the neurological mechanism related to stress. No significant differences were 
observed in CRF mRNA levels within the PVN, thus suggesting that that hypothalamic CRF system is 
not sufficient to account for binge-like HPF consumption in our BED model. 
Panel C: After being intraperitoneally administered, OEA activates noradrenergic neurons of the area 
postrema (AP), which in turn project to the nucleus of the solitary tract (NST). Noradrenergic neurons 
within the NST could then mediate OEA ability to increase Fos expression within the PVN of R+S rats. 
This effect is linked to the increased oxy mRNA levels observed in R+S rats after OEA treatment. 
 
 
4.5. Conclusions  
In conclusion, in the current study we provide evidence for the first time that the 
endogenous fatty-gut lipid OEA exerts a selective inhibitory effect on binge-like eating 
behaviour in female rats, by modulating key mechanism of the hedonic-homeostatic 
brain circuits. These conclusions broaden our current knowledge on the role played by 
OEA in the caloric-homeostatic control system and support the hypothesis that OEA 
might represent a novel potential pharmacological target for the treatment of aberrant 
eating patterns.  
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5.1. Conclusions 
Although further studies are necessary, the results collected in almost 20 years of both 
preclinical and clinical studies strongly support OEA as a promising candidate for the 
development of more effective and safe anti-obesity therapies.  
The results of the present work represent a major advance in understanding the complex 
circuitry underlying OEA pro-satiety effect. In particular, through my thesis project we 
demonstrated, for the first time, that OEA is able to reach and permeate the brain 
parenchyma within few minutes after its peripheral administration, and we showed a 
crucial role of the AP as receptive brain region for circulating OEA. Moreover, we here 
demonstrated that OEA exerts a selective inhibitory effect on binge-like eating 
behaviour in female rats, by modulating key mechanism of the hedonic-homeostatic 
brain circuits and therefore it might represent a novel potential pharmacological target 
for the treatment of aberrant eating patterns.  
Interestingly in the last few years, several clinical studies have been conducted to clarify 
the role of this lipid compound in the regulation not only of the satiety but also of the 
body weight and body fat. The majority of OEA studies in humans have been focusing 
on the effect of diet manipulation on endogenous OEA tone or on the correlation 
between OEA plasma levels and a variety of pathophysiological parameters such as 
body fat, exercise, BMI and satiety1–6.  
In virtue of its oral availability and its property in reducing body weight, OEA has been 
introduced into the weight loss supplement market in USA, under the name of 
RiduZone (OEA [200 mg]/capsule- the only FDA-acknowledged OEA supplement on 
the market). Indeed encouraging data collected from a retrospective analysis performed 
on 42 patients (14 male, 28 female) who took RiduZone 2–3 times/day for 4–12 weeks 
demonstrated that RiduZone induces an average of 7–8% decrease in BMI after 10 
weeks of treatment 7.  
Very recently, Payahoo and colleagues conducted a randomized, double-blind, placebo-
controlled clinical trial to evaluate the effects of OEA supplementation on 60 healthy 
obese subjects.  
The eligible patients assigned to the intervention group received two capsules of OEA 
([125 mg]/capsule) a day for 60 days whereas the placebo group received the same 
amount of starch 8.  
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Beyond collecting anthropometric measurements, body fat and appetite sensations 
(hunger, fullness, the desire to consume food, and the desire to eat sweet/salty/fatty 
foods), PPAR-α gene expression was also measured during the present study.  
The authors showed a significant reduction of body weight, BMI, waist circumference, 
and fat percent after 8 weeks of OEA treatment in the intervention group compared to 
the placebo group without showing any adverse events. These effects have been shown 
to be paralleled to the OEA-induced PPAR-α increase observed in the group of patients 
treated with OEA 8. Interestingly, in this study OEA was also able to significantly 
decrease hunger and sweet food craving selectively in the intervention group. This latter 
results we think is in line with our study, further confirming the selective anti-binge 
property of OEA 8.  
The same research group performed an additional clinical trial on obese individuals by 
using the same above-described experimental design showing OEA ability to improve 
obesity-related conditions such as inflammation and oxidative stress 9.  
Finally it is noteworthy that both preclinical and clinical studies revealed that OEA does 
not induce any signs of anxiety nor does it change CORT levels; moreover, hypophagic 
effects of OEA are not accompanied by, malaise, visceral illness, changes of body 
temperature or nausea 10.  
Taking together, the results of the above-cited human studies further support the 
relevance of our findings, thus opening novel perspectives for OEA potential clinical 
use for eating-related disorders. 
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